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 Cells undergo distinct morphological changes during cellular division, 
differentiation and migration, elicited mainly by the intricate network of activation and 
inactivation of Rho family small GTPases which function as molecular switches linking 
their immediate upstream regulators and downstream effectors. The BCH domain is a 
novel protein module first identified and characterized in this laboratory. This unique 
protein domain is about 145 amino acids in length and was initially known to be conserved 
in two proteins: BCL2/adenovirus E1B 19kDa interacting protein 2 (BNIP-2) and p50-
RhoGAP. BNIP-2 is a potent inducer of membrane protrusions and exerts its function as a 
novel regulator of cell morphogenesis by specifically targeting Cdc42, a member of Rho 
GTPases via its BCH domain. In addition, it can form homo- and heterophilic complexes 
with itself or others via this domain.  
 To elucidate the functional significance of such a domain, we have identified and 
cloned the novel BCH-domain containing BNIPXL (for BNIP-2 Extra-Long) cDNAs from 
the human brain and kidney libraries. BNIPXL encompasses most of the prototypic BNIP-
2 sequence at its distal carboxyl terminus with ~65% amino acid identity to the BCH 
domain of BNIP-2. BNIPXL exists as two alternatively spliced isoforms: BNIPXLα and 
BNIPXLβ. BNIPXLα is 769 amino-acid residues in length and is encoded by a 13-exon 
gene mapped to the human chromosome 9q21.2. Exon skipping results in the removal of 
exons 11 and 12 and introduces a premature stop codon in BNIPXLβ. This corresponds to 
a deletion of the last 36 amino acids of its BCH domain. Both isoforms are ubiquitously 
   xi
expressed in most human tissues and cell lines examined, except for the HEK293T 
embryonic kidney epithelial cells which showed exclusive expression of the β-isoform. 
Interestingly, the expression profile of murine BNIPXL closely resembles that of BNIP-
H/Caytaxin, whose loss-of-function is responsible for Cayman ataxia, a form of 
neurological disorder. Through the BCH domain, BNIPXL associates with itself and other 
BCH-domain containing proteins. However, unlike BNIP-2, the BCH domain of BNIPXL 
associates specifically with RhoA but not Cdc42 or Rac1. This is similar to that of BNIP-
Sα, another BCH-domain containing homolog which targets RhoA for its activation in cell 
rounding during apoptosis. 
 Intriguingly, immunofluorescence microscopy indicates that the BNIPXL BCH 
domain is sufficient to elicit filopodia-like protrusions that is potentiated only by co-
expression of the dominant negative RhoA(T19N), but inhibited by co-expression of the 
PAK-CRIB domain which sequesters endogenous active Cdc42. This indicates that 
BNIPXL promotes cell protrusions that involve inactivation of the RhoA pathway 
concomitant with the activation of the Cdc42/Rac pathways. Removal of the proximal 
region of the its BCH domain (residues 615-644), which resembles the Class I Rho-
binding motifs (found in the RhoA effectors PKN, rhophilin and rhotekin) and other 
neighboring regions abolished both RhoA binding and cell protrusions. This suggests that, 
unlike BNIP-S, a full composite of the BCH domain, probably in a conformation-
dependent manner, is required for both RhoA binding and cell morphological changes. 
These results suggest that the unique structural motifs in the BNIPXL BCH domain target 
different small GTPases to confer distinct mechanisms in cell morphogenesis.  
   xii
 Our present study indicates that BNIPXL functions differently from BNIP-2 and 
BNIP-S in mediating cell shape changes by directly promoting RhoA inactivation via its 
direct binding with the BCH domain while it indirectly activates Cdc42/Rac effector 
pathways necessary for the membrane protrusions. These findings highlight the plasticity 
of the BCH domain amidst increasing evidence supporting an emerging notion that the 
BCH domain is an important signaling module integrating diverse small GTPase pathways 
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1.1. The machinery of signal transduction 
1.1.1. Molecular basis of signal transduction 
Signal transduction is the transmission of extracellular signals via a network of 
intracellular protein cascades and allows the cell to elicit a specific response necessary for 
adaptation to changing physiological conditions. Cells respond to a diverse range of 
external stimuli such as light, hormones, neurotransmitters, growth factors and cytokines. 
This process is initiated when a signaling molecule or ligand is recognized by its cognate 
membrane-bound receptor which triggers a series of consecutive events that serve to 
amplify the initial signal within the cell interior. A subset of these signals is transmitted 
into the nucleus which results in changes in gene expression while others direct 
biochemical modifications of cytosolic proteins, formation of subcellular ternary signaling 
complexes or cytoskeletal rearrangements (Figure 1.1). 
Signals can be propagated via multiple signaling pathways within the cytosol and 
beyond. While some are direct, others follow more complex routes which provide greater 
opportunities for cross-talk, diversification and modulation of the cellular response via a 
whole plethora of second messengers, accessory proteins and lipid complexes. This 
scheme allows for selective activation of several pathways downstream of receptor 
activation in both quantitative and qualitative terms. Furthermore, simultaneous activation 
of various linear pathways may result in the formation of molecular complexes comprising 
distinct combinations of proteins and/or lipids adding to signaling complexity and 
plasticity. Conversely, a single signaling complex may coordinate several diverse 
biochemical activities simultaneously. Such scaffold proteins are essential for recruitment  






Figure 1.1. Signaling molecules can transmit signals to cells in a variety of ways. Growth 
factor receptors have tyrosine kinase activities whilst hormones interact with GPCRs to 
increase second messenger levels that serve to propagate the signals further. Cytosolic 
steroid hormone receptors translocate into the nucleus upon activation to direct gene 
transcription. Neurotransmitters bind to receptors that function as ion channels and may 
also direct second messenger production via GPCR coupling. Ras and Rho are small, 
monomeric G proteins that couple RTK and GPCR activation to cell growth and cell 
dynamics control. More detailed description on the involvement of Rho GTPases is given 
under section 1.26, Figure 1.18. 
 
   3
of a diverse repertoire of proteins allowing greater signaling specificity possibly, in a 
spatio-temporal manner. Taken together, these concerted events help mediate a coherent 
cell response in the face of multiple synergistic and/or antagonistic stimuli (reviewed in 
Pawson and Saxton, 1999).  
 
1.1.2. Components and mechanisms of signaling networks 
There are generally two types of signals: hydrophobic compounds like steroid 
hormones and metabolites that pass through the plasma membrane by diffusion or through 
specific membrane channels and hydrophilic molecules such as growth factors and 
hormones that cannot pass through the membrane, but instead bind to membrane receptors 
to activate signal transduction. Thus, the induction of a cellular response is dependent on 
ligand recognition by its cognate membrane bound receptors in target cells thereby 
defining downstream intracellular events in a cell-type specific manner.  
There are several receptor families classified based on their structure and 
biochemical activities. Amongst them are the receptor tyrosine kinases (RTKs), the seven 
transmembrane G-protein coupled receptors (GPCRs) and the multi-chain cytokine 
receptors (reviewed in Hunter, 2000). Although varied in structure and function, all 
receptors operate via fundamentally similar mechanisms. Generally, receptor activation 
results in the generation of a variety of second messengers and effector proteins which 
serve to propagate and amplify the initial signal, causing changes in biochemical activities 
within the cell. At the core of these events, distinctive mechanisms provide coordinated 
response. The Ras superfamily of small, monomeric G proteins represents a point of 
convergence coupling RTK and GPCRs to a variety of cellular events like cell growth, cell 
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dynamics control, endocytosis and vesicular trafficking. Detailed description on the 
involvement of Rho GTPases is given under section 1.26, Figure 1.18.  
The transmembrane segments of RTKs contain intrinsic protein kinase activity 
which participates in receptor autophophorylation thereby creating docking sites for 
downstream signaling molecules and the trans-activation of intracellular substrates (Figure 
1.2). RTKs work in concert with adaptor proteins which participate in the recruitment of 
protein complexes required for specific pathways (reviewed in Pawson and Scott, 1997). 
Further information on their mode of action is discussed in section 1.1.3. Ligand 
stimulation results in RTK dimerization and activation, leading to phosphorylation of 
protein components in distinct mitogen-activated protein (MAP) kinase pathways leading 
to modulations in gene expression, cell proliferation, differentiation and survival (Furnari 
et al., 1998). 
GPCRs function as guanine nucleotide exchange factors (GEFs) that coordinate 
ligand stimulation at the membrane with intracellular activation of heterotrimeric G-
proteins (reviewed in Cabrera-Vera et al., 2003). Ligand binding results in conformational 
changes that promote GPCR-mediated GDP to GTP exchange on the G-protein α subunit. 
The subsequent dissociation of the Gα/Gβγ complex results in signal propagation through 
various downstream effectors and secondary messengers such as cyclic adenosine 
monophosphate (cAMP) and Ca2+ (Figure 1.2). There is also increasing evidence for 
extensive cross-talk between the different signaling pathways. For example, GPCR 
signaling has been linked to activation of the Ras superfamily of small GTPases (Sah et al., 
2000; Marinissen and Gutkind, 2001). This may be via the classical second messenger-
dependent protein kinases (reviewed in Takai et al., 2001) or through the transactivation  









Figure 1.2. Schematic diagrams of cell signaling at the plasma membrane. (a) Ligand 
binding results in receptor dimerization and autophophorylation on tyrosine residues 
within the intracellular kinase domain which in turn phosphorylates cytosolic adaptors to 
turn on several MAPK phosphorylation cascades downstream. (b) Ligand binding to 
GPCRs result in the dissociation of the Gα subunit from the Gβγ subunits of the 
heterotrimeric G-protein complex enabling it to function as a molecular switch binding to 
effector proteins in a nucleotide dependent manner.  
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of receptor and non-receptor tyrosine kinases (Luttrell, 2002). Furthermore, GPCRs can 
influence actin cytoskeleton reorganization by mediating Rho activation through the Gαq/11 
and Gα12/13 families of heterotrimeric G-proteins (Figure 1.3). The Gαq/11 and Gα12/13 
families couple GPCR activation to small monomeric G-proteins via direct interactions 
with the RhoGEFs, lymphoid blast crisis (Lbc) (Sagi et al., 2001) and p115-RhoGEF, 
respectively. Detailed descriptions of which are provided under section 1.2.3.1.2, Figure 
1.10. Conversely, the Arf and Rab subfamilies have been implicated in the modulation of 
GPCR signaling by regulating membrane trafficking events associated with receptor 
endocytosis and recycling (reviewed in Bhattacharya et al., 2004; Moolenaar et al., 2004). 
 
1.1.3. Protein domains in signal transduction networks 
Ligand stimulation and subsequent activation of membrane bound receptors result 
in activation of downstream signaling cascades. Signal transduction along these networks 
is dependent on faithful activation and amplification through post-translational 
modification, structural and biochemical activation of protein components (Pawson and 
Nash, 2000). Deregulated signaling could have potentially lethal effects and thus, several 
checks are in place in the cell to ensure spatial and temporal regulation. Cytosolic proteins 
are key players which orchestrate diverse cellular events and are thus candidates for 
regulation. Discrete polypeptide modules within these proteins serve as recognition sites 
which mediate specific protein–protein and protein–phospholipid interactions through 
tertiary folds. Signaling complexity is increased through homo- and heterodimerization or 
cooperation with different protein domains acting in cis or trans (reviewed in Pawson et 
al., 2002; Pawson and Nash, 2003). These signaling modules can be subdivided into  
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Figure 1.3. Ligand binding to the GPCR promotes GDP to GTP exchange on the Gα 
subunit resulting in the dissociation of the Gα/Gβγ complex and activation of second 
messengers. In addition, GPCRs can also signal to Ras and Rho GTPases via Gβγ and 
G12/G13, respectively. Gβγ proteins also stimulate Src-dependent activation of 
metalloproteinases (MMPs) that release heparin-binding EGF (HB-EGF) for RTK and Ras 
activation. (Adapted from Bhattacharya et al., 2004). 
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different families based on structure-function relationships in which closely related 
members may participate in complementary pathways with specific targets. For example, 
the Src-homology 2 (SH2) domain recognizes phosphorylated tyrosines on their cognate 
binding partners which effectively limits their participation to RTK signaling (reviewed in 
Pawson, 2004). Alternatively, protein domains may also direct context-dependent 
interactions which increase signaling plasticity as in the case of the SH3 domain which 
directs proline-rich motif-dependent protein-protein interactions and are thus implicated in 
diverse cellular processes (reviewed in Zarrinpar et al., 2003).  
 Generally, protein domains contain recognition motifs made up of a core group of 
consensus residues with conserved flanking sequences that aid its function. The presence 
of multiple recognition motifs in tandem allows protein domains to modulate affinities and 
response to different targets. In addition, these motifs may bring different proteins together 
in a scaffold-complex thus exerting spatial control.  Post-translational modifications are an 
integral part of protein-protein interactions. These covalent modifications include 
prenylation, acetylation, methylation, phosphorylation and ubiquitination. They enhance 
candidate recognition by protein domains by mediating structural changes that expose the 
complementary residues or subcellular localization.  Furthermore, these modifications are 
often reversible, allowing temporal control over the signaling. Propagation of intracellular 
signals is thus the result of multiple sequential steps involving protein modification, 
recognition and activation. Multiple linear activation events often intersect one another 
with common components participating in different pathways and providing feedback and 
crosstalk mechanisms. 
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1.2 Signaling networks of small monomeric G proteins 
1.2.1 The Ras superfamily of small G proteins 
The extensive Ras superfamily of guanine nucleotide binding proteins comprises 
more than 100 individual eukaryotic proteins that are divided into 5 sub-families: Ras, 
Rho, Rab, Sar1/Arf and Ran (reviewed in Takai et al., 2001; Ridley et al., 2001; 
Aspenstrom, 2004) (Figure 1.4). Generally, these proteins have molecular masses of 20-
40kDa and function as molecular switches cycling between an inactive GDP- and an active 
GTP-bound state. They posses an intrinsic GTP hydrolyzing activity and are thereby also 
referred to as GTPases. Structurally, these proteins share ~30% to 50% amino acid identity 
with conserved regions adopting similar conformations that present the switch I and II 
regions to different binding partners (Figure 1.5). In addition, a subset of the Ras 
superfamily (Ras, Rho, Rab and Arf) also undergoes post-translational modifications 
which are crucial for subcellular distribution and function.  
Despite their structural and biochemical similarities, these small GTPase 
orchestrate a diverse range of signaling events. Typically, the Ras subfamily regulates gene 
expression while the Rho subfamily is involved in actin cytoskeleton organization and 
gene expression. The Rab and Sar1/Arf subfamilies regulate intracellular vesicle 
trafficking and the Ran subfamily is involved in nucleocytoplasmic transport crucial for 
cell cycle progression. These proteins direct different cellular activities through integration 
of upstream activating signals with the concomitant activation of downstream pathways via 
complex signaling cascades involving several families of effector proteins.
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Figure 1.4. Dendrogram of the small G protein superfamily. (Adapted from Takai et al., 2001). 









                       
Figure 1.5. Small G proteins are made up of five α-helices and six β-strands joined by five 
highly conserved polypeptide loops (G1-G5). Consensus sequences indicate conserved 
regions amongst small G proteins for nucleotide binding, recognition and catalytic 
activities. The switch I region corresponds to the G2 loop and is the site for effector and 
GAP binding while switch II is formed by the G3 loop. The G1 or P-loop (phosphate-
binding loop) binds to the α- and β-phosphate groups while the G2 (effector) loop provides 
a conserved Thr residue responsible for Mg2+ binding. The G3 loop contains a Gly residue 
in the DXXG sequence essential for orientation and folding of the switch II region. The 
consensus motifs in G4 and G5 loops provide residues that participate in nucleotide 
recognition and association. (Modified from Takai et al., 2001; Paduch et al., 2001). 
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1.2.2. The Rho subfamily of small G proteins  
First identified as a homolog of the Ras gene in Aplysia (Madaule and Axel, 1985), 
the mammalian Rho family currently consists of 23 members, which can be further 
subdivided into 8 subgroups: Cdc42 (Cdc42, TC10, TCl, Chp, Wrch1), Rac (Rac1-3, 
RhoG), Rho (Rho A-C), Rnd (Rnd1-3), RhoD (RhoD and Rif), RhoH/TTF. RhoBTB 
(RhoBTB1-3) and Miro (Miro1-2) (Aspenstrom, 2004). RhoA, Rac and Cdc42 are the best 
characterized members and like their counterparts in other subfamilies, these Rho members 
carry out their physiological functions by cycling between the two interconvertible forms 
under the influence of three distinct classes of regulatory proteins that provide spatial and 
temporal regulation of RhoGTPases in a nucleotide-dependent manner (Figure 1.6). 
 The GEFs are positive regulators promoting GDP to GTP exchange. There are two 
classes of negative regulators: GTPase activating proteins (GAPs), which stimulate 
intrinsic GTPase activity by catalyzing the hydrolysis of GTP to GDP and guanine 
nucleotide dissociation inhibitors (GDIs), which prevent nucleotide exchange and 
sequester Rho from membranes. The GDIs represent a class of regulatory proteins found in 
the Rho and Rab subfamilies (reviewed in Pfeffer and Aivazian, 2004). While some 
regulatory proteins are specific for certain members of the Rho subfamily of G proteins, 
others have a larger substrate repertoire (Settleman et al., 1992). Active GTP-bound Rho 
GTPases adopt complementary conformations that promote effector binding enabling the 
propagation of signals to downstream signaling pathways. Rho GTPases can activate a 
common pool of effectors allowing for crosstalks necessary for coordination of signaling 
events (reviewed in Schwartz, 2004). 
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Figure 1.6. Rho GTPases are molecular switches, shuttling between the inactive GDP-
bound and the active GTP-bound states. Activation is supported by guanine nucleotide 
exchange factors (GEFs) which promote GDP to GTP exchange. Downregulation is 
mediated by the GTPase activating proteins (GAPs) and guanine nucleotide dissociation 
inhibitors (GDIs). GAPs stimulate intrinsic GTPase activity resulting in hydrolysis of GTP 
to GDP while GDIs prevent nucleotide exchange and sequester Rho from membranes. 
Activated GTP-bound Rho binds to effectors (E) which mediate downstream signal 
propagation. Different Rho GTPases may regulate a common pool of effectors downstream 
of activating signals. Some examples of the regulators are indicated. (Modified from 
Karnoub and Der, 2004). 
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In addition to these classes of regulatory proteins, the subcellular distribution of 
GTP-binding proteins also determine their functions. Members of the Rho and Rab 
subfamilies translocate between the cell membrane and the cytosol while Ras proteins are 
found associated with the cytoplasmic side of the plasma membrane. Generally, these 
subfamilies undergo posttranslational modifications at their C-terminus CAAX (C, 
cysteine; A, aliphatic; X, any residue) motifs which facilitate membrane association. In 
Rho proteins, this involves the addition of geranylgeranyl and methyl moieties. The lipid 
moieties are expected to interact with the acyl moieties of the membrane phospholipids. In 
addition, a stretch of polybasic amino acids upstream of the CAAX motif contributes to 
membrane association by interacting with the polar head groups of the phospholipids. 
These regions have been classified into four groups: Cys-A-A-X, Cys-A-A-Leu/Phe, Cys-
X-Cys and Cys-Cys based on amino acid composition (reviewed in Takai et al., 2001).  
Recent work however suggests that post-prenylation C-terminus processing of Ras 
but not Rho proteins is required for membrane localization (Michaelson et al., 2005). 
These reactions are catalyzed by several enzymes including the 
geranylgeranylytransferases which catalyze the transfer of lipid moieties to the C-terminus 
CAAX motifs, a prenyl-CAAX-specific protease, Rce1 which mediates the subsequent 
proteolytic cleavage of the –AAX motif (Boyartchuk et al., 1997; Schmidt et al., 1998) 
and isoprenylcysteine-directed carboxyl methyltransferase which adds a methyl group to 
the cysteine residue (Dai et al.,, 1998). Further investigations should provide deeper 
insights into the roles of posttranslational modifications in Rho GTPase function.  
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1.2.3. Regulators of Rho GTPase signaling 
1.2.3.1. Rho family Guanine Nucleotide Exchange Factors (RhoGEFs) 
 The prototypic mammalian GEF is the proto-oncogene diffuse B-cell lymphoma 
(Dbl) that was first isolated in foci formation assays (Eva and Aaronson, 1985). 
Interestingly, Dbl was found to share significant similarity to CDC24, a RhoGEF with 
activity toward Cdc42p, the yeast ortholog of Cdc42 (Bender and Pringle, 1989; Ron et al., 
1991). Further investigations revealed that the conserved region in Dbl was responsible for 
nucleotide exchange activity on human Cdc42 (Hart et al., 1991; Hart et al., 1994). 
Subsequently, an increasing number of Dbl homology (DH) domain-containing proteins 
were isolated. In addition to the DH domain, these proteins also possessed a pleckstrin 
homology (PH) domain found in tandem and C-terminal to the DH domain. Generally, the 
DH/PH domain pair is considered the minimal module for nucleotide exchange activity.  
To date, the RhoGEF protein family is estimated to contain forty-six members in 
eukaryotes sharing low homology limited to the tandem DH/PH domains (Venter et al., 
2001). Although structurally diverse beyond the DH/PH domains, RhoGEFs have similar 
activities toward Rho GTPases. Biochemically, GEFs bind to the GDP-bound small 
GTPase destabilizing it in favor of a nucleotide-free reaction intermediate (Cherfils and 
Chardin, 1999). The released GDP is subsequently replaced with GTP due to high 
intracellular ratio of GTP to GDP. This effectively promotes effector recognition of the 
active small GTPase (reviewed in Schmidt and Hall, 2002; Rossman et al., 2005). Recent 
work suggests that GEFs may also stimulate GDP dissociation with the formation of a two 
nucleotide-one G-protein intermediate indicating that GEF activity may occur via 
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competitive displacement of GDP by GTP through this intermediate (Zhang et al.,  2005). 
Mammalian GEFs can be identified by their ability to stimulate nucleotide exchange in 
vitro in GEF activity assays or by examining effects of overexpresion in vivo. Interestingly, 
some GEFs appear specific toward a single GTPase target like the p115RhoGEF for RhoA 
(Hart et al., 1996; Zheng et al., 1996) while others like Dbl and Vav1 have promiscuous 
affinities for multiple Rho proteins (Hart et al., 1994; Olson et, al., 1996).  
More recently, there has been increasing evidence suggesting the existence of non-
conventional RhoGEFs that utilize a novel DH-independent domain for catalysis (reviewed 
in Meller et al., 2005; Rossman et al., 2005). These atypical RhoGEFs are members of the 
Ced-5, DOCK180, Myoblast city (CDM)-zizimin homology (CZH) protein superfamily 
that are conserved throughout evolution with representatives from Saccharomyces 
cerevisiae, Dictyostelium discoideum, Caenorhabditis elegans, Drosophila melanogaster, 
Arabidopsis thaliana and Homo sapiens (Meller et al., 2005). CZH proteins share two 
conserved domains namely, CZH1 and CZH2. To date, the latter is known to confer GEF 
activity while the role of former remains elusive (Cote and Vuori, 2002; Brugnera et al., 
2002). CZH proteins can be further classified into the CDM protein and zizimin1 sub-
families based on their ability to activate Rac and Cdc42, respectively (Meller et al., 2005; 
Wu and Horvitz, 1998; Cote and Vuori, 2002; Brugnera et al., 2002).  
 
1.2.3.1.1. Structure of RhoGEFs 
 All members of this protein family share a region of similarity spanning ~300 
residues. This region can be further classified into two smaller domains, a ~200 residue 
DH domain and a ~100 residue PH domain. The DH domain contains three conserved 
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regions (CR1, CR2 and CR3) about ten to thirty residues in length. While the DH domain 
is specific to members of the RhoGEF family, the PH domain is a general protein domain 
that binds to phospholipids and is found in other signaling molecules (Rebecchi and 
Scarlata; 1998; Lemmon and Ferguson, 2000). In addition, RhoGEFs may also contain 
additional signaling modules like the SH2, SH3, kinase, PDZ RhoGAP, RasGEF and 
Regulator of G protein signaling (RGS) domains.  
Structurally, the DH domain is folded into a flattened, elongated bundle of eleven 
α-helices (Aghazadeh et al., 1998; Liu et al., 1998; Soisson et al., 1998; Worthylake et al., 
2000) and forms extensive interactions with the switch regions of Rho GTPases. Switch I 
interacts with the DH domain via the exposed CR1 and CR3 helices while the Switch II 
region contacts the CR3 and a C-terminal helix (α6). A conserved glutamate in CR1 and 
two other residues in CR3 mediate complex formation and nucleotide-exchange potential. 
Structural elements (β2 and β3 strands) between the switch regions mediate additional 
contacts with the DH domain that determine specificity for different Rho targets (Figure 
1.7).  
 
1.2.3.1.2. Regulation of RhoGEFs 
 Regulation of GEF activity is mediated via different interactions which modulate 
the conformation of the RhoGEF. Inactive RhoGEFs exist in a conformation in which the 
DH domain contacts the adjacent PH domain or distal regulatory sequences and blocks 
GEF activity through intramolecular interactions (Ron et al., 1989; Katzav et al., 1991; van 
Leeuwen et al., 1995; Bi et al., 2001). The PH domain can participate in the GTPase-
binding interface and facilitate nucleotide exchange in concert with the DH domain  
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Figure 1.7. Ribbon plot of the DH domain (yellow) and PH domain (blue) of Dbs bound to 
Cdc42 (green) (available from http://www.rcsb.org/pdb/ under the PDB ID 1KZ7). CR1, 
CR3 (magenta) and α6 helix of the DH domain are primary contact sites with the switch I 
and II (S1 and S2, respectively) regions of Cdc42 (red). The β3-β4 loop of the Dbs PH 
domain makes contacts with switch II of Cdc42, essential for catalysis of nucleotide 
exchange. The 'seat back' region (grey outline) of the Dbs DH domain forms a 
complementary interface with β1-β3 strands of Rho GTPases. (Adapted from Rossman et 
al., 2002). PIP2 to PIP3  results in exposure of the Rac binding site (Das et al., 2000) which 
is necessary for phosphorylation (Hart et al., 1998). 
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(Rossman et al., 2002). Alternatively, they could help target GEFs to the appropriate 
intracellular location through associations with phosphoinositides (PIPs) (Rebecchi and 
Scarlata; 1998; Lemmon and Ferguson, 2000; Bi et al., 2001). Recent work indicate that 
PH domains provide docking sites for proteins associated with a common Rho signaling 
pathway as seen in the Dbl PH domain with ezrin (Vanni et al., 2004). Collectively, these 
activities suggest that the PH domain plays crucial roles in regulating GEF activity.  
 In addition, the diversity of domain combinations found in RhoGEFs provides the 
basis for modulating GEF activity through synergistic activities of different signaling 
molecules. These include phosphoinositides, protein kinases, heterotrimeric G proteins and 
small GTPases. In Vav, autoinhibitory constraints imposed by the DH/PH domain can be 
relieved by activation of phosphatidylinositol 3-kinase (PI3K) and tyrosine 
phosphorylation (Bustelo, 2000; Crespo et al., 1997). The subsequent conversion of PIP2 to 
PIP3  results in exposure of the Rac binding site (Das et al., 2000) which is necessary for 
phosphorylation (Hart et al., 1998). 
 Members of the RhoGEF family have been known to regulate several small 
GTPase targets via coordinating GEF activities toward two targets. For example, the 
RasGEF Son of Sevenless 1 (Sos1) can stimulate guanine nucleotide exchange on Ras and 
Rho proteins, thus providing a mechanism for sequential activation of GTPase signaling 
pathways. Investigations reveal that Sos1 stimulates guanine nucleotide exchange on Rac1 
in a PI3K-dependent manner. Activation of PI3K is associated with upstream activation of 
Ras which is mediated through Sos1 (Nimnual et al., 1998). Thus, Sos1 utilizes 
structurally distinct domains to mediate its biochemical activities on Ras and Rac which 
can be regulated by PIP3 binding to the PH domain (Das et al., 2000). A schematic diagram 
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of coordinated regulation of Ras and Rac by Sos1 is illustrated (Figure 1.8). Upon ligand 
binding and receptor activation, Sos1 is recruited to the membrane resulting in Ras 
activation through the Sos1 RasGRF domain. This in turns activates PI3K which promotes 
conversion of PIP2 to PIP3 through phosphorylation, leading to conformational changes that 
relieve the Sos1 DH domain from intramolecular interactions, thus promoting guanine 
nucleotide exchange on Rac.  
 Regulation of GEF activity by regions other than the conserved DH/PH domains 
are likely to involve upstream receptors and signaling molecules like the heterotrimeric G 
proteins which coordinate conversion of extracellular stimuli and intracellular events 
(Whitehead et al., 2001).  p115RhoGEF, PDZ-RhoGEF and leukemia-associated Rho GEF 
(LARG) form a subgroup of RhoGEFs containing the RGS domain which may serve to 
couple cellular changes accompanying heterotrimeric G protein activation with small 
GTPase signaling. Almost all RGS domain-containing proteins can function as GAPs for 
Gα subunits by accelerating GTP hydrolysis on the Gα (Hollinger and Hepler, 2002). 
p115RhoGEF is a RhoA-specific exchange factor (Hart et al., 1996; Kozasa et al., 1998) 
(Figure 1.9). Interestingly, the recruitment of Gα13 but not Gα12 to the p115RhoGEF RGS 
domain allows coupling of Gα13 deactivation with Gα13-induced RhoA activation, thus 
allowing tight control of G protein signaling through an in-built feedback mechanism (Hart 
et al., 1998; Mao et al., 1998). Recent work indicates distinct residues within the RGS 
domain may be responsible for the dual activities of Gα13/p115RhoGEF complex 
(Grabocka and Wedegaertner, 2005). In addition to temporal regulation of GEF activity, 
subcellular sequestration of Dbl proteins provide spatial regulation of Rho GTPase 
activation in response to different stimuli as evidenced by T-cell lymphoma invasion and  
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Figure 1.8. Coordinate regulation of Ras and Rac1 by Sos1. Recrutiment of the Grb/Sos1 
complex to the membrane following ligand stimulation of RTK results in activation of 
membrane-bound Ras which in turn interacts with PI3K which converts PH-domain bound 
PIP2 to PIP3. Conformational changes allow Rac1 access to the catalytic DH domain.   
 












Figure 1.9. A model for Gα-subunit mediated RhoA activation. Ligand binding to the 
GPCR results in a sequential cascade that activates RhoA through the conversion of Gα-
subunit to the GTP-bound state, its dissociation from the Gβγ dimer and binding to the N-
terminus RGS domain of p115RhoGEF. Subsequent conformational changes provide the 
mechanism for coordinate regulation of small GTPase activation via GPCRs. 
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metastasis 1 (Tiam1)-dependent Rac activation, where redistribution of Tiam1 from the 
cytoplasm to the membrane follows serum (Michiels et al., 1997) or platelet-derived 
growth factor (PDGF) (Buchanan et al., 2000) stimulation. 
 
1.2.3.1.3. Physiological roles of RhoGEFs 
GEF participation in diverse physiological processes is associated with actin 
cytoskeleton remodeling. The ability to influence the guanine nucleotide binding status of 
small GTPases implicates RhoGEFs in diverse Rho-mediated cellular events including 
regulation of transcription and cell cycle progression.  Interestingly, a recent survey of the 
human genome indicates that RhoGEFs far exceed the number of Rho GTPases (Venter et 
al., 2001). It is possible that multiple GEFs increases signaling plasticity linking several 
receptor classes to downstream Rho activation (Bustelo, 2000).  
The most well-known RhoGEF function is its role in oncogenic transformation as 
most GEFs were first identified in NIH3T3 foci formation assays. Overexpression of 
RhoGEFs result in distinct phenotypes such as anchorage independent cell growth and 
tumorigenesis in animal models (Whitehead et al., 1997; Cerione and Zheng, 1996). The 
transforming effects of RhoGEFs are mainly attributed to truncation mutants that relieve 
intramolecular interactions leading to constitutive GEF activity and chronic stimulation of 
GTPase targets. Several reports confirm the absolute requirement of the DH domain for 
transformation (Ron et al., 1991; Horii et al., 1994; Whitehead et al., 1995). However, 
other lines of evidence indicate a requirement for the PH domain for full transforming 
potential (Hart et al., 1994; Whitehead et al., 1999; Ron et al., 1991). Thus, transformation 
appears to require concerted coordination of catalytic GEF activity and subcellular 
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localization conferred by the DH and PH domains, respectively. Many RhoA effector 
proteins like protein kinase N (PKN) and Rho kinase (ROCK) have been implicated in the 
propagation of signals for deregulated growth as the GEF mutant phenotypes closely 
resemble those exhibited by constitutive active GTPase mutants (Marinissen et al., 2001; 
Sahai et al., 1999; Tran et al., 2000). In addition, mutations and chromosomal 
rearrangements that affect RhoGEF gene expression have been associated with leukemias 
and human developmental disorders linking these clinical etiologies to deregulated Rho 
GTPase signaling.  
  
1.2.3.2. Rho family GTPase-Activating Proteins (RhoGAPs) 
 The first GAP to be identified was the p50-RhoGAP which was isolated from 
human spleen extracts and was found to have intrinsic activity toward Rho, Rac and Cdc42 
(Garrett et al., 1989). Sequence analyses indicate that p50-RhoGAP shares a region of 
homology with the breakpoint cluster region (BCR) and N-chimaerin which have GAP 
activity towards Rac1 and Cdc42 (Diekmann et al., 1991). Subsequent investigations 
determined that the conserved ~140 residue region was responsible for the catalytic 
activity of these proteins and was designated the RhoGAP domain (Zheng et al., 1993).  
Generally, members of the RhoGAP family possess a catalytic RhoGAP domain 
with at least 20% amino acid identity while retaining the ability to catalyze the conversion 
of GTP to GDP by stimulating the intrinsic GTPase activity of their cognate targets. To 
date, the RhoGAP family is estimated to consist of 40 distinct proteins from prokaryotes 
and eukaryotes. In addition, in silico analyses by SMART (Simple Modular Architecture 
Research Tool) has identified another ~220 potential members in the non-redundant 
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protein database (Ponting et al., 1999). Sequence alignment of the various RhoGAP 
domains provide insights into the phylogenetic relationships of the different members, 
suggesting that this domain has undergone frequent duplication with entire genes coding 
these domains (Peck et al., 2002).  
Although the RhoGEF and RhoGAP families have essentially antagonistic 
biochemical functions, several common themes exist between them. It is evident that the 
number of RhoGEFs and RhoGAPs far outnumber the current 23 members of the Rho 
GTPase family. The large repertoire of regulatory proteins provides a means for regulating 
common substrates through substrate specificity in different signaling complexes (Ahmed 
et al., 1990; Ahmed et al., 1991; Ahmed et al., 1993; McGlade et al., 1993); Ren et al., 
2001; Jenna et al., 2002). Conversely, both GEFs and GAPs can show specificity towards 
multiple targets within a branch of the Ras superfamily providing plasticity to Rho 
signaling networks. For example, the human active BCR related (ABR) and BCR proteins 
are known to stimulate GTPase activity of Rac1, Rac2 and Cdc42 but not RhoA (Chuang 
et al., 1995). 
 
1.2.3.2.1. Structure of RhoGAPs 
 Much of the structural information on RhoGAPs is derived from p50-RhoGAP, the 
smallest member (499 residues) of the RhoGAP family. This protein contains an N-
terminus Sec14-like domain which we previously identified as the BNIP-2 and Cdc42GAP 
Homology (BCH) domain (Low et al., 2000a) and a C-terminus RhoGAP domain which 
has activity toward RhoA and Cdc42 (Ridley et al., 1993; Barfod et al., 1993; Lancaster et 
al., 1994). The Sec14 domain is speculated to bind PIP3  providing a mode of regulation for 
   26
GAP activity via recruitment to the plasmas membrane and/or conformational changes 
(Krugmann et al., 2002). Interestingly, recent work implicates the Sec14-like domain of 
p50-RhoGAP in mediating auto-inhibitory conformations that block access to its catalytic 
GAP domain which may be relieved by lipid modification of its Rho targets (Moskwa et 
al., 2005). 
Sequence analysis of the RhoGAP domain indicates the presence of three blocks of 
conserved residues (Zheng et al., 1993; Mussacchio et al., 1996) while crystal structures of 
the human p50-RhoGAP and p85α subunit of PI3K reveal that RhoGAP domains share 
similar tertiary folds and GTPase-activating mechanisms with that of RasGAP (Bax, 1998; 
Rittinger et al., 1998) even though their primary sequence may vary. Structural 
information from GAP domain complexes with RhoA (Rittinger et al., 1997b) and Cdc42 
(Nassar et al., 1998; Rittinger et al., 1997a) provide greater insights into the mechanisms 
underlying RhoGAP-mediated GTP hydrolysis. The RhoGAP domain is composed of 9 α-
helices and a highly conserved arginine residue presented in a loop structure (Gamblin and 
Smerdon, 1998). It interacts with the switch regions and the P-loop of Rho GTPases and 
participates in GTP hydrolysis by contributing an arginine residue (Arg85) to the active 
site of the Rho GTPase. During hydrolysis, a glutamine residue (Gln63 in RhoA) positions 
a water molecule necessary for the reaction. Thus, stabilizing this residue with the GAP 
domain arginine finger motif restricts the water molecule and reduces energy barrier for 
GTP hydrolysis (Nassar et al., 1998).  
Substrate specificity of RhoGAPs is mediated by interactions with residues that lie 
outside the P-loop and switch regions of Rho GTPases (Li et al., 1997; Longenecker et al., 
2000; Dvorsky and Ahmadian, 2004). Interestingly, although the RhoGAP domain is 
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distinguishable from the GAP modules of other GTPase classes (Ras, Ran or ARF), the 
involvement of multiple residues for RhoGAP specificity prevents clear distinction of 
structure-function relationships amongst the Rho subfamily members. Consistent with 
these observations, site-directed mutational analyses indicate that RhoGAP association 
with their cognate targets is independent of GAP activity thus, providing an additional 
level of complexity in RhoGAP-mediated regulation (Ahmed et al., 1994). The RhoGAP 
domain of the p85 regulatory subunit of PI3K is one such example, having the ability to 
associate with Rho GTPases even though it lacks GAP activity (Lamarche and Hall, 1994; 
Musacchio et al., 1996; Barrett et al., 1997).  
 
1.2.3.2.2. Regulation of RhoGAPs 
Like the RhoGEF family, a number of RhoGAPs have multiple Rho substrates. The 
multi-domain architecture of many RhoGAPs provides additional regulatory motifs for 
tight regulation preventing spurious activity of their cellular substrates (reviewed in 
Bernards, 2003; Bernards and Settleman, 2004) (Figure 1.10). These motifs may facilitate 
RhoGAP recruitment to protein complexes in a spatio-temporal manner (Lamarche and 
Hall, 1994). For example, RhoA inactivation by the p190A-RhoGAP occurs in a spatio-
temporal manner in fibroblasts upon integrin engagement which promotes cell movement 
(Arthur et al., 2000).  
Interestingly, a common repertoire of protein or lipid-binding domains directs 
conformational changes and localization in RhoGEF and RhoGAP proteins. 
Phosphorylation by protein kinases provides a mode of RhoGAP regulation as evidenced 
by Src-mediated p190 RhoGAP activity (Roof et al., 1998; Hu and Settleman, 1997). Src 
activation results in phosphorylation of p190RhoGAP. This promotes p120RasGAP  
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Figure 1.10. Domain distribution of the RhoGAP family. A recent survey of the RhoGAP 
proteins indicates an increasingly diverse combinations of protein domain(s) exist with the 
canonical RhoGAP domains. Abbreviations: Actin bs, actin filament binding site; C2, 
calcium-dependent lipid binding; CC, coiled coil; CR, cysteine rich, zinc butterfly motif, 
binds diacylglycerol and phorbol ester; DH, Dbl homology; Endophilin, Endophilin 
homology domain; FCH, Fes/CIP4 homology domain; IQ, calmodulin binding; PH, 
pleckstrin homology; P, proline-rich SH3 binding motif; PEST, amino acids P-, E-, S- and 
T-rich degradation motif; RA, Ras-associating (also known as ralGDS/AF-6) domain; Ral 
BR, Ral GTPase binding region; Rho GAP, Rho GTPase-activating protein motif; 
Sec14/BCH, Sec14 homology/BNIP2 and Cdc42 GAP homology; SH2, Src homology 2; 
SH3, Src homology 3; S/T kinase, serine and threonine kinase; START; Star-related lipid 
transport domain; Z, PDZ binding region. (Adapted from Moon and Zheng, 2003). 
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 recruitment to the p190RhoGAP complex via a SH2 domain-phosphotyrosine interaction 
leading to subsequent activation of Rho-specific p190RhoGAP activity. In addition, auto-
inhibitory intra- or intermolecular interactions is another common mechanism that 
contributes to GAP regulation as evidenced in p190 RhoGAP and p50-RhoGAP (Tatsis et 
al., 1998; Moskwa et al., 2005). A variation of this mechanism is observed in the RacGAP 
chimaerin, whose activity is regulated by a cysteine-rich CR domain. The CR domain has 
been speculated to mediate spatial regulation of chimaerin through association with 
membrane components (Caloca et al., 1997). In addition, GEFs can coordinately down-
regulate GAPs and promote activation of nucleotide exchange.  The scaffold protein 
intersectin, is a Cdc42-specific GEF that can regulate the RhoGAP activity of CdGAP 
through SH3 domain interactions with the proline-rich C-terminus of CdGAP. This 
promotes an unfavorable conformation that reduces its intrinsic RhoGAP activity (Jenna et 
al., 2002). Recruitment of additional factors to this complex mediates concerted regulation 
of the actin cytoskeleton (O’Bryan et al., 2001). Collectively, these observations 
demonstrate that GAP regulation is mediated by diverse mechanisms orchestrated by the 
various resident domains acting in cis- and trans (Figure 1.11).   
 Although RhoGAPs are known to be specific for Rho family GTPases, a subset can 
interact with targets outside the Rho subfamily. The human IQGAP1 and IQGAP2 
interacts with Cdc42 and Rac1 via their RasGAP-related domains resulting in the 
inhibition of intrinsic and RhoGAP-stimulated GTPase activity (Hart et al., 1996; Brill et 
al. 1996). Similarly, the RhoGAP domain of the p85α regulatory subunit of PI3K may 
structurally resemble the p50-RhoGAP (Musacchio et al., 1996) and interact with activated 
Cdc42 and Rac1 but it does not exhibit any GAP activity towards Rho family members  









Figure 1.11. Models for RhoGAP regulation. (a) Phosphorylation of p190 RhoGAP by Src 
family tyrosine kinases downstream of PDGF receptor activation initiates association with 
p120 RasGAP, membrane translocation and activation of GAP activity. (b) Proposed lipid 
mediated regulation of n-chimaerin. (c) Regulation of CdGAP via protein complex 
formation with intersectin. (Adapted from Moon and Zheng, 2003). 
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(Zheng et al., 1994). Recently, our group identified that the BCL2/adenovirus E1B 19kDa 
interacting protein 2 (BNIP-2) can function as a non-canonical RhoGAP via its 
BCH/Sec14-like domain which resembles the noncatalytic domain of p50-RhoGAP (Low 
et al., 2000a, Low et al., 2000b). We also showed that the BCH domain of the BCH 
domain-containing, Proline-rich and Cdc42GAP-like protein subtype-1 (BPGAP1) 
regulates cell protrusion necessary for migration (Shang et al., 2003) and Erk1/2 activation 
(Lua and Low, 2005b). It remains to be seen how the BCH domain coordinates the 
activities of the GAP domain. 
 
1.2.3.2.3. Roles of RhoGAPs in whole animal physiology 
Insights into the normal in vivo functions of RhoGAP domain-containing proteins 
has been obtained using knockout mouse models of p190A RhoGAP (Billuart et al., 2001) 
and p190B RhoGAP (Sordella et al., 2002). The null mice for p190B RhoGAP exhibited 
reduced body size and developmental defects. Embryonic fibroblasts had high levels of 
RhoA activity and defective insulin signaling pathways indicating that p190B RhoGAP 
functions in glucose metabolism, cell growth and animal size determination during 
embryogenesis. Chromosomal rearrangements that affect the RhoGAP oligophrenin-1 has 
been implicated in X-linked mental retardation (Billuart et al., 1998). Further 
investigations using RNA interference assays and targeted knock-ins will aid the 
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1.2.3.3. The Rho Guanine Nucleotide Dissociation Inhibitors (RhoGDIs) 
The third class of Rho GTPase regulatory proteins is the RhoGDI proteins. As the 
name suggests, these proteins have a negative regulatory effect on Rho GTPase signaling 
pathways (reviewed in Sasaki and Takai, 1998; Olofsson, 1999; Hoffman and Cerione, 
2004). The GDI proteins were first isolated based on their ability to block RhoGEF 
mediated nucleotide exchange by associating with the inactive GDP-bound form of Rho 
GTPases (Ueda et al., 1990; Leonard et al., 1992; Fukumoto et al., 1990). Subsequent 
investigations demonstrate that the RhoGDI could also bind to the GTP-bound form of 
Cdc42, inhibiting its intrinsic and RhoGAP-mediated GTP hydrolysis (Hart et al., 1992). 
In addition, it could also extract Cdc42 from cellular membranes, retaining it in cytosolic 
RhoGDI-Cdc42 complexes (Isomura et al., 1991; Nomanbhoy et al., 1999). The RhoGDI 
family represents a unique class of proteins with the ability to mediate both spatial and 
temporal regulation of Rho proteins by influencing the cellular localization and nucleotide 
binding states of their cognate targets, respectively. To date, only three members of the 
RhoGDI family have been identified unlike the extensive RhoGEF and RhoGAP protein 
families 
The first Rho-specific GDI was isolated from bovine brain cytosol extracts and 
designated RhoGDI (also known as GDI1 or αGDI) (Ueda et al., 1990; Leonard et al., 
1992; Fukumoto et al., 1990) and is involved in Cdc42-mediated cellular transformation 
(Lin et al., 2003) as well as Rac1-mediated regulation of the NADPH oxidase system in 
neutrophils (Di-Poi et al., 2001). Subsequently, another member of this family with 75% 
sequence identity to RhoGDI was identified by two groups (Adra et al., 1993; Lelias et al., 
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1993; Scherle et al., 1993). The Ly- or D4-GDI (also known as GDI2 or βGDI) is 
preferentially expressed in hematopoietic cells and has a lower affinity for Cdc42 than 
RhoGDI. The third RhoGDI designated GDI3 (or γGDI), was found to be enriched in the 
brain and has high affinities for RhoB- and RhoG binding, weakly to Cdc42 and RhoA, but 
not Rac (Adra et al., 1997; Zalcman et al., 1996). Interestingly, GDI3 has a different 
subcellular distribution compared to the other cytosolic members. The N-terminus 
amphipathic alpha-helix appears to mediate its association with vesicular structures in the 
vicinity of the endoplasmic recticulum (ER). Functionally, RhoGDI3 specifically 
sequesters RhoG at the Golgi (Brunet et al., 2002), inhibiting translocation to cell 
periphery and induction of lamellipodia and membrane ruffles (Gauthier-Rouviere et al., 
1998; Blangy et al., 2000). Regardless of structural differences and biochemical affinities, 
the conserved primary sequences of the RhoGDIs suggest that a common mode of 
interaction exists amongst members of this family (Figure 1.12).  
 
1.2.3.3.1. Structural insights of GDI function 
  Understanding the structural basis of RhoGDI-GTPase interactions has provided 
insights into the mechanisms underlying its biochemical activities and cellular functions. 
Rho proteins can stably associate with the plasma membrane via a series of post-
translational modifications at their C-terminus CAAX motif (Clarke, 1992). RhoGDIs bind 
specifically to the prenylated forms of Rho, thereby sequestering it from the membrane to 
form soluble cytosolic GDI-GTPase complexes. Mechanisms underlying RhoGDI 
functions are based on Cdc42/RhoGDI (Hoffman et al., 2000), Rac1/GDI2 (Scheffzek et 
al., 2000) and Rac2/RhoGDI (Grizot et al., 2001; Di-Poi et al., 2001) complexes. RhoGDI  












Figure 1.12. Domain layout of the three members of the RhoGDI family. Each member 
shares high level of amino acid identity (values indicated as percentage identity). 
Generally, members are composed of an N-terminus regulatory domain and a C-terminus 
immunoglobulin-like domain with the exception of GDI3, which contains a unique 
amphipathic helix. (Adapted from Hoffman and Cerione, 2004).  
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is composed of two distinct domains: a well-ordered C-terminus and a more flexible N-
terminus. The former adopts a conformation comprising two anti-parallel β-sheets forming 
a β-sandwich (Gosser et al., 1997; Keep et al., 1997) which provides a hydrophobic 
immunoglobulin-like fold for binding the geranylgeranyl moiety while the latter has a 
well-ordered helix-loop-helix conformation. In the absence of Cdc42, the binding pocket is 
too small to accommodate the lipid but RhoGDI-Cdc42 complex formation results in 
expansion that permits insertion of the lipid moiety. Sequestration of this moiety within the 
hydrophobic cavity results in the release of the GTPase from the plasma membranes. 
Analysis of the Rac1/GDI2 complex demonstrate that a hydrophobic isoleucine residues at 
position 177 stabilizes lipid sequestration and its substitution to a polar asparagine residue 
explains the differential affinities of RhoGDI and GDI2 for Cdc42 (Platko et al., 1995). 
The N-terminus regulatory arm of RhoGDI is responsible for mediating 
interactions with the switch I and II regions of Rho proteins. RhoGDIs exist in two 
conformations in which the N-terminus exists either in a random coil or a helical structure 
(Lian et al., 2000; Nomanbhoy and Cerione, 1996; Golovanov et al., 2001a). The latter is 
stabilized against the immunoglobulin-like domain (Hoffman et al., 2000) by an invariant 
arginine residue in the switch II (Arg66 in Cdc42) region. In this conformation, residues 
45-60 mediate GTPase binding and inhibit guanine nucleotide dissociation and hydrolysis 
(Nomanbhoy and Cerione, 1996; Golovanov et al., 2001b) while residues 10-15 participate 
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1.2.3.3.2. Mechanisms of GDI activity 
A proposed model for GDI-mediated membrane release involves the acidic 
residues of the C-terminus binding pocket and the phospholipid headgroups of the 
membrane bilayer. Competition for the lipid moiety at the polybasic tail of the Rho protein 
results in its extraction from the membrane. In addition, extensive contacts between the 
RhoGDI N-terminus regulatory arm and the switch II region enable the GDI to bind 
GTPases regardless of their nucleotide states (Nomanbhoy et al., 1996). GDIs inhibit GEF 
and GAP activities by competing for a common set of residues necessary for Rho GTPase 
interaction. High affinity nucleotide associations with the switch regions are stabilized by a 
Mg2+ ion which neutralizes the negative charge on the phosphate groups.  Generally, GEFs 
and GDIs regulate nucleotide binding by influencing Mg2+ ion coordination (Wei et al., 
1997). While GEFs form favorable interactions that promote the release of the bound 
nucleotide, GDIs achieve an opposite effect by stabilizing Mg2+ ion coordination to 
promote a switch II conformation that locks the nucleotide in the binding pocket. GAP 
proteins on the other hand, contribute an arginine finger motif to the active site to stabilize 
the conformation of the invariant glutamine (Gln63 in RhoA) residue to facilitate GTP 
hydrolysis through the formation of a catalytically active transition state. As no structural 
data is currently available, GDI binding is proposed to maintain the Rho-GTP bound 
conformation by influencing the formation of this transition state based on structural 
insights from RhoGAPs in complex with active small GTPases (Hoffman and Cerione, 
2004).  
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1.2.3.4. Intracellular targeting of the Rho family GTPases 
The diversity of cellular distribution of Rho family members may aid Rho 
involvement in different cellular events. As described previously, nascent cytosolic Rho 
proteins undergo a series of posttranslational modifications which attach a hydrophobic 
group to the C-terminus CAAX motif, necessary for its subcellular localization. However, 
this modification is only sufficient for targeting to endomembranes (Choy et al., 1999). 
The distribution of Rho proteins to different cellular compartments including the cytosol 
(Abo et al., 1991), plasma membranes (Boivin and Beliveau, 1995), Golgi (Erickson et al., 
1996), endosomes (Murphy et al., 1996) and the nucleus (Baldassare et al., 1997) involves 
a second signal provided by the 20-amino acid hypervariable region found upstream of the 
CAAX motif.  However, recent works demonstrate a contradicting view suggesting that 
post-prenylation CAAX motif processing is not essential for Rho GTPase localization and 
function unlike the farnesylated Ras proteins (Michaelson et al., 2005). The hypervariable 
region consists of a series of basic amino acids or cysteine residues that are sites for 
palmitoylation (Hancock et al., 1990; Choy et al., 1999; Michaelson et al., 2001). Previous 
work indicates that Rho proteins lacking this second motif are retained in the 
endomembrane and exhibit defective subcelluar localization (Michaelson et al., 2001). 
Thus, RhoGDI-mediated intracellular targeting involves coordinate regulation by the 
CAAX motif and the hypervariable region. This enables cytosolic sequestration of Rho in 
the absence of stimuli and the translocation of Rho proteins to suitable compartments upon 
activation. Sequence comparisons of the hypervariable regions of Rho and Ras proteins 
demonstrate the existence of 4 different classes based on the number of positively charged 
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residues corresponding to distinct intracellular compartmentalization (Michaelson et al., 
2005). 
 
1.2.4. Structural aspects of Rho GTPase signaling: effector and regulator 
recognition motifs  
The complexities of Rho signaling cascades can be attributed to its ability to 
interact with a diverse repertoire of protein targets. These include the different classes of 
regulatory proteins previously discussed as well as downstream effectors which serve to 
direct distinct cellular response. The cross-utilization of common effectors by the Rho 
GTPases contribute to increasingly complex signaling cascades. Emerging data on the 
structural characteristics of these interactions provide further insights into the underlying 
mechanisms that direct the biochemical activities of these molecular switches (Vetter and 
Wittinghofer, 2001; Corbett and Alber, 2001).  
Interestingly, the monomeric small G proteins share common mechanisms that 
direct protein-protein interaction with diverse auxiliary proteins. Generally, these protein 
targets bind the small GTPase in a nucleotide-dependent manner. Discrimination of the 
GTP- or GDP-bound state is mediated by three segments that border the nucleotide-
binding site. The switch I and II regions undergo conformational changes in response to 
the GTP binding while the P-loop motif (GXXXXGK[S/T]) commonly found in adenine 
and guanine nucleotide-binding proteins makes contact with a phosphate group of the 
bound nucleotide and coordinates a Mg2+ ion for stabilizing nucleotide binding (Saraste et 
al., 1990; Wittinghofer, 2000). Recent analyses of the Rho family GTPase-protein complex 
interface indicates that the consensus binding site responsible for mediating interactions 
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with various effectors, activators and inhibitors in RhoA correspond to residues 29-42 
(switch I) and 62-68 (switch II) (Dvorsky and Ahmadian, 2004) (Figure 1.13). 
 
1.2.4.1. Interaction with RhoGDIs 
RhoGDIs sequester the prenyl moiety at the COOH-terminus of the small GTPase 
inside an immunogloubulin-like domain (Hoffman et al., 2000). This effectively blocks the 
hydrophobic tail from the aqueous environment and extracts the Rho GTPase from 
membrane compartments. Structural data also indicate that GDIs form extensive contacts 
with their cognate Rho targets involving residues beyond the switch I and II regions which 
results in high-affinity interactions that inhibit GDP dissociation and GTP hydrolysis 
(Hoffman et al., 2000; Scheffzek et al., 2000) 
  
1.2.4.2. Interaction with RhoGEFs 
The Dbl family of RhoGEFs catalyze nucleotide exchange by disrupting Mg2+-ion 
coordination and favourable interactions for high affinity nucleotide binding (Worthylake 
et al., 2000; Buchwald et al., 2002; Rossman et al., 2002; Snyder et al., 2002). This is 
achieved through the DH domain which promotes conformational changes in the switch 
regions by insertion of residues in close proximity to the P-loop and the Mg2+-binding area 










Figure 1.13. Ribbon plots of GDP- and GTPγS-bound RhoA (upper and lower panels, 
respectively) with the switch region coloured from yellow (corresponding to one contact) 
to red (corresponding to a maximal number of 24 contacts). Grey indicates the residues 
that are not involved in any interactions. Conserved residues frequently used for 
interactions with GDIs, GEFs, GAPs and effectors are depicted in a ball-and-stick 
configuration. (Adapted from Dvorsky and Ahmadian, 2004). 
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1.2.4.3. Interaction with RhoGAPs 
 The canonical GAP domain found in RhoGAPs catalyzes GTPase binding and GTP 
hydrolysis (Moon and Zheng, 2003). Interestingly, these RhoGAP activities have been 
found to be independent of one another (Ahmadian et al., 1997; Leonard et al., 1998; 
Graham et al., 1999). Structurally, RhoGAPs serve to promote the transistion state of GTP-
hydrolysis reaction by insertion of an arginine residue into the active site and by stabilizing 
the glutamine residue (Gln63) in the switch II region in a conformation promoting 
nucleophilic attack crucial for GTP hydrolysis (Gamblin and Smerdon, 1998; Scheffzek et 
al., 1998; Kosloff and Selinger, 2001; Vetter and Wittinghofer, 2001).  
 
1.2.4.4. Effector-recognition sites 
Effector proteins are molecules that associate with small GTPases in a 
conformation-dependent manner but unlike the regulatory proteins, they act downstream of 
GTPase activation. Generally, effector activation involves the relief of intramolecular auto-
inhibitory conformations that allow greater access to its functional domains. Although little 
is known about the mechanisms underlying effector activation, the conserved leucine 
residues (Leu69 and Leu72) in RhoA switch II region have been suggested to mediate 
hydrophobic contacts necessary for activation of Cdc42/Rac-interactive binding (CRIB)-
motif-containing proteins including activated Cdc42-associated kinase (ACK) and p21-
activated kinase (PAK) (Morreale et al., 2000). In addition, Cdc42-effector complexes 
demonstrate that CRIB-motif-containing proteins make extensive contacts around the 
small GTPase (Hoffman and Cerione, 2000). Structural data on the GTPase-binding 
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domains (GBDs) of a subset of RhoA effectors including PKN and ROCK indicate that 
these effectors form multiple contact points with regions outside the classical RhoA switch 
domains (Blumenstein and Ahmadian, 2004). Thus, despite their structural differences and 
affinities, these groups of Rho effectors employ a strategy that utilizes a core binding 
interface with additional associations that provide target specificity.  
Current reviews provide insights into the structural basis underlying versatility in 
Rho GTPase signaling pathways and provide greater understanding of the dynamics of 
RhoGTPase interactions.  In summary, two invariant leucines in the α2-helix and twelve 
residues in the switch regions mediate GTPase interactions with all binding partners in a 
nucleotide-independent manner. In addition, different partners also interact with additional 
regions on the small GTPase to enhance recognition specificity. For example, all 
regulatory proteins associate with the α3-helix while the GDIs sequester the hydrophobic 
C-terminus and the GAPs make contact with the insert region of Rho GTPases. Effector 
proteins on the other hand bind to the N-terminus of the small GTPase or the α5-helix 

















Figure 1.14. Structural motifs and intermolecular contact sites of RhoA. Structural 
elements (α-helices are represented as cylinders and β-strands as arrows), the guanine 
nucleotide-binding peptide loops (G1−G5), the conserved sequence motifs and the 
isoprenylation site at the C-terminus of RhoA are highlighted on the top according to Ihara 
et al (1998). The frequencies of intermolecular contacts of interacting partners with Rho 




1.2.5. Deregulated Rho GTPase mutants: tools for functional studies 
Structural data presented here demonstrate the importance of conformational folds 
in mediating Rho GTPase interactions and has helped identify a series of residues that are 
crucial for these associations. Thus, it is not surprising that alteration of these specific 
residues through mutations occurring naturally or by molecular manipulations in vitro can 
lead to development of aberrant signaling and mutant phenotypes in vivo. Substitution of 
crucial residues within the switch regions and the C-terminus usually result in the gain of 
transforming activity and oncogenesis. Nevertheless, these mutants provide an opportunity 
for the genetic manipulation of Rho binding with its plethora of protein targets and the 
dissection of small GTPase signaling networks. Depending on the residue, different mutant 
forms of a small GTPase can be generated. Generally, these mutants are classified into 
three functional classes: dominant active, dominant negative or inactive. Amongst these, 
the dominant active and negative mutants have proven to be useful in evaluating the 
different biological functions of Rho GTPases (Figure 1.15).  
 
1.2.5.1. Constitutively active mutants  
The constitutively active (G12V, Q63L) mutants have amino acid substitutions that 
interefere with the intrinsic GTP hydrolysis resulting in a GAP-insensistive mutant protein 
that is always in the GTP-bound active conformation (Rittinger et al., 1997a; Ihara et al., 
1998). Another subset of activated mutants are the ‘fast-cycling’ variants based on the 
Ras(F28L) mutant. The corresponding versions in the Rho proteins are spontaneously 




    
 
 
Figure 1.15. Strategies for dissecting Rho GTPase function. The RhoA constitutive active 
(G14V, Q63L) mutant is GAP-insensistive and is used to characterize different cellular 
functions of wild-type Rho proteins. The dominant negative (T19N) mutant inhibits 
RhoGEF function via sequestration and has been used to assess Rho involvement in 
various signaling pathways. The T19N mutants can sequester several GEFs and thus, have 
broader inhibitory effects on other Rho GTPases. In addition, peptide fragments consisting 
of the GTP-dependent Rho binding domain (RBDs) or p21 binding domains (PBDs) of 
specific effectors have been used as selective dominant negative versions of specific Rho 
proteins. (Adapted from Karnoub and Channing, 2004). 
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(Reinstein et al., 1991). 
 
1.2.5.2. Dominant negative mutants 
 These mutants have helped establish the roles of Rho GTPases in oncogenesis 
(Feig, 1999). Introduction of an aspargine at position 19 in RhoA (T19N) results in 
increased affinity for RhoGEFs, corresponding to impaired nucleotide exchange and 
decreased affinity for GTP (Seasholtz et al., 1999). Thus, when introduced into cells, this 
mutant exerts its effects through RhoGEF sequestration which in turn affects GEF turnover 
and the subsequent inhibition of endogenous GTPase activation. 
  
1.2.5.3. Defective effector-binding mutants 
 The third functional class of GTPase mutants have impaired effector recognition 
and activation. Most effector interactions involve the switch I and II regions. Selected 
mutations in these regions can affect effector binding and thus aid assessment of the 
effector function downstream of a specific Rho GTPase pathway (Westwick et al., 1997; 
















   
 
 
Figure 1.16. Schematic diagram of dominant active (G14V, F30L, Q63L) and dominant 
negative (T19N) RhoA mutants. Site directed mutagenesis and effector domain swap 
studies have delineated functionally important residues within the effector domain. 
Mutations in the CAAX motif result in defective GTPase membrane targeting due to lack 
of prenyl group addition during post-translational modifications. The insert regions have 




1.2.6. Functions of the Rho family GTPases 
Earlier studies demonstrate that impaired Rho expression resulted in defective 
budding in S. cerevisiae, indicating that they may mediate actin reorganization during 
division (Lelias et al., 1993; Yamochi et al., 1994). Further insights into the cellular 
functions of the Rho subfamily have been derived from studies utilizing the C3 exoenzyme 
of Clostridium botulinum. The C3 exoenzyme modifies specific residues within the 
effector binding region in Rho proteins by ADP-ribosylation, thus inhibiting Rho-effector 
interactions and subsequent propagation of downstream signaling pathways (reviewed in 
Bishop and Hall, 2000).  
These studies indicate that Rho proteins are the main regulators of actin 
cytoskeleton remodeling that forms the basis of various cellular events such as cell shape 
change, cell motility and cell adhesion. This in turn influences basic developmental 
processes such as cell migration, cytokinesis and axon guidance. In addition, Rho proteins 
also participate in other cellular events such as gene transcription, cell proliferation and 
cell cycle progression and vesicular transport (reviewed in Ridley, 2001; Symons and 
Settleman, 2000; Takai et al., 2001) (Figure 1.17). Recent reviews indicate that several 
major families of effector proteins and feedback regulatory proteins act downstream of 
activated Rho GTPase (reviewed in Schwartz, 2004) (Figure 1.18). A subset of these 
effectors will be reviewed with respect to their functions in cell motility, phagocytosis and 







        







Figure 1.17. Rho GTPases participate in a plethora of cellular events and represent a point 




                     
 
Figure 1.18. Rho GTPase effector pathways. (Adapted from Schwartz, 2004). 
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1.2.6.1. Reorganization of the actin cytoskeleton  
In addition to its primary role in cell shape maintenance, the actin cytoskeleton 
provides an environment in which various biochemical and cellular activities take place. 
The cytoskeleton is composed of a network of different protein filaments namely actin, 
microtubule and intermediate filaments (reviewed in Chang and Goldman, 2004). Actin 
filaments are made up of filamentous actin bound to accessory proteins designated actin-
binding proteins (ABPs). These include gelsolin, profilin, cofilin and villin and mediate a 
dynamic process known as treadmilling in which actin monomers continually undergo a 
series of polymerization and depolymerization reactions to form F-actin filaments 
(reviewed in Revenu et al., 2004). A balance between these antagonistic reactions results 
in a dynamic state of equilibrium and stabilization of filament lengths. Perturbation of this 
steady state in response to upstream activating signals allow the cells to modify the 
composition and architecture of the actin cytoskeleton network for cell motility, migration 
or other cellular events like organogenesis and wound repair. 
Generally, these filaments are organized into discrete structures that are divided 
into three distinct classes. Actin stress fibers are actin filament bundles that traverse the 
cell with its ends anchored to the extracellular matrix via distinct contact points known as 
focal adhesions. Lamellipodia or membrane ruffles are protrusive actin sheets found at the 
leading edge of migratory cells while filopodia are long, thin cellular processes that are 
organized by a bundle of polarized actin filaments found mainly in motile cells. Different 
structures can be generated by modulating the capping activity at the barbed ends of the 
actin filaments (Figure 1.19a). These structures are maintained by the underlying actin 
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cytoskeleton in concert with co-factors that regulate the activity of the ABPs via 
posttranslational modifications which cause conformational changes or compete with actin 
filaments for these actin binding proteins (reviewed in Wear and Cooper, 2004). In this 
respect, the Rho GTPases participate in regulation of these co-factors in a guanine 
nucleotide-dependent manner. Generally, Rho proteins induce stress fiber formation (Mura 
et al., 1993; Ridley and Hall, 1992), while Rac proteins regulate membrane ruffles and 
lamellipodia formation (Ridley et al., 1992), and Cdc42 mediates filopodia formation 
(Kozma et al., 1995; Nobes and Hall, 1995) (Figure 1.19b). 
 
1.2.6.1.1. Roles of Rho GTPases in cytoskeleton reorganization 
Rho GTPases act as transducers that relay extracellular stimuli to activate several 
downstream signaling pathways leading to cytoskeleton remodeling. In fibroblasts, Rac 
induces lamellipodia and membrane ruffles followed by subsequent stress fiber formation 
(Ridley et al., 1992) while Cdc42 induces filopodia at the cell periphery prior to 
lamellipodia and membrane ruffles formation (Kozma et al., 1995; Nobes and Hall, 1995). 
These reports are an indication that members of the Rho family modulate the dynamics of 
actin remodeling through a series of sequential and coordinated events. Figure 1.20 








Figure 1.19a. Generation of different actin filament architectures by modulating the 













Figure 1.19b. Rho GTPase proteins regulate the actin cytoskeleton organization through 
the induction of distinct actin structures. GTPase activity can be stimulated in the presence 
of different ligands bradykinin (Cdc42), PDGF or insulin (Rac) and LPA (Rho). LPA, 














Figure 1.20. Rho GTPase effector pathways in actin cytoskeleton remodeling. (Adapted 
from Raftopoulou and Hall, 2004). 
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Amongst the Rho effector families, the Rho-associated coiled-coil kinase (ROCKs) 
are ~160kDa protein serine/threonine kinases of that play important roles in induction of 
Rho-induced stress fibers and focal adhesions by regulating the phosphorylation states of 
different candidate proteins downstream (reviewed in Riento and Ridley, 2003). 
Phosphorylation of the myosin light chain promotes F-actin bundling, stress fiber and focal 
adhesion formation thus, enhancing cell contractility. This is regulated by the antagonistic 
activities of myosin light chain kinase (MLCK) and myosin light chain phosphatase 
(MLCP). Activated ROCK negatively regulates the activities of MLCP by phosphorylation 
of its myosin binding subunit (MBS) resulting in upregulated MLCK actvity which in turn 
promotes the cell contractility and stress fiber induction (Gong et al., 1996; Noda et al., 
1995). ROCK cooperates with mammalian Diaphanous (mDia), a member of the formin-
homology containing protein family in RhoA-induced stress fiber formation and actin 
cytoskeleton remodeling (Watanabe et al., 1999). mDia can bind to profilin, an actin-
binding protein via its FH1 domain to enhance actin polymerization (Watanabe et al., 
1997). Alternatively, it could directly stimulate actin polymerization (Pruyne and 
Bretscher, 2000) and stabilize microtubules assembly during cell migration (Palazzo et al., 
2001).  
ROCK can also function via an alternative cascade involving LIM (Lin11, Isl1 and 
Mec3) kinase, a serine/threonine kinase that participates in regulation of actin-filament 
assembly via a series of phosphorylation events initiated by Rho activation (reviewed in 
Riento and Ridley, 2003). The Rho-ROCK-LIM kinase pathway promotes actin filament 
assembly by negative regulation of cofilin, an actin-depolymerizing protein that regulates 
the turnover of actin filaments (Maekawa et al., 1999). Conversely, LIM kinase is also 
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targeted by PAK. This family of serine/threonine kinases serve as important regulators of 
cytoskeletal dynamics and cell motility downstream of Rac and Cdc42 activation 
(reviewed in Zhao and Manser, 2005). In addition to LIM kinase, PAKs also mediate the 
activities of myosin light chain in actin filament assembly. All PAKs contain an 18-amino 
acid Cdc42/Rac interactive binding (CRIB) motif that mediates its interactions with Rac 
and Cdc42 proteins while different regions designated the Rho-binding domain (RBD) on 
Rho effectors mediate their interactions with Rho. These effectors have been subdivided 
into three distinct classes based on their Rho-binding motifs (Fujisawa et al., 1998). Class I 
and III effectors bind to RhoA between residues 75-92 and 23-40, corresponding to the 
switch II and switch I regions, respectively. Class II effectors utilize both these regions for 
RhoA associations. 
The ERM (ezrin-radixin-moesin) proteins are adaptors that translocate between the 
cytosol and the plasma membrane. These proteins are common targets downstream of Rho, 
Rac and Cdc42 activation. ROCKs can phosphorylate ERM proteins resulting in 
translocation to cell protrusions (Shaw et al., 1998) while the Cdc42/Rac effector, 
myotonic-dystrophy-kinase-related Cdc42-binding subunit (MRCK) enhances Cdc42-
induced filopodia and activation of ERM proteins by serine/threonine phosphorylation 
(reviewed in Zhao and Manser, 2005).  
In addition to PAKs, several other Rac and Cdc42 effectors participate in actin 
cytoskeletal remodeling. This includes the partner of Rac (POR1) which interacts with Rac 
in a GTP-dependent manner and has been implicated in Rac-dependent membrane ruffles 
(van Aelst et al., 1996). Within the cell, the Arp2/3 complex functions as a major regulator 
of actin polymerization that nucleates actin filament assembly in a unidirectional manner 
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initiating the growth of protrusive actin filaments at the leading edge. Rac and Cdc42 
target the WASP family verprolin homologous (WAVE) and the neuronal Wiskott-Aldrich 
syndrome protein (N-WASP) complexes, respectively. These in turn direct the activation 
of the Arp2/3 complex in a spatio-temporal manner. Rac activation causes the recruitment 
of the WAVE multiprotein complex to the membrane. The subsequent dissociation of 
WAVE from the complex promotes the formation of a WAVE-Arp2/3 complex which 
positively regulates actin polymerization in lamellipodia. Conversely, active Cdc42 
recruits N-WASP to the membrane, subsequent PIP2 binding relieves autoinhibitory 
conformations exposing binding sites for actin and Arp2/3 complex which promotes 
filopodia induction. These events link actin polymerization to extracellullar stimuli 
received at the plasma membrane. The multidomain architecture of N-WASP includes a 
PH and CRIB domain that allows Cdc42 and PIP2 to coordinately activate N-WASP by 
stabilizing an active, open conformation (reviewed in Bompard and Caron, 2004).  
Both Rac and Cdc42 also participate in IQGAP activities at membrane ruffles and 
at cell-cell adhesions (Kuroda et al., 1998). This multidomain protein functions as a 
scaffold linking Cdc42 activation with various components of the cytoskeleton (reviewed 
in Briggs and Sacks, 2003). Several motifs such as the WW domain, a SH3-binding motif, 
a calmodulin-binding domain, and a Ras GAP-like motif help orchestrate diverse activities 
such as cytoskeleton reorganization, cell adhesion, polarity and motility (Kuroda et al., 
1998; Li et al., 1999; Watanabe et al., 2004). Interestingly, IQGAP does not function as a 
GAP but instead inhibits the intrinsic Cdc42 GTPase activity (Brill et al., 1996; Hart et al., 
1996; Ho et al., 1999) and the maintenance of active Cdc42 for filopodia induction (Swart-
Mataraza et al., 2002).  
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 Rho GTPases can also mediate actin cytoskeleton remodeling via influencing lipid 
signaling pathways mainly via activation of the lipid kinases, PI3K and phosphoinositol-4-
phosphate 5 kinase (PIP5K) (reviewed in Janmey and Lindberg, 2004). These enzymes 
catalyze the production of second messenger PIP2 which regulates actin cytoskeletal 
dynamics by modifying ABPs, influencing their activities in actin filament assembly. 
Increased cellular PIP2 levels usually correspond to increased actin assembly. Besides 
acting downstream of Rac and Cdc42 activation which contributes to actin polymerization 
via the activities of N-WASP, profilin and other actin-capping proteins, Rho-mediated 
activation of PIP5K influences downstream activation of ERM proteins via ROCK. Arf6 
has been implicated in Rac-mediated membrane ruffling downstream of PIP2.  Thus, 
phosphoinositide signaling integrates different upstream stimuli and allows for concerted 
regulation of growth factor and G protein signaling.  
 
1.2.6.1.2. Roles of Rho GTPases in microtubule regulation 
 In addition to actin cytoskeleton remodeling, the Rho family GTPases can utilize 
different subsets of these effectors to direct other cellular events. Microtubules (MTs) are a 
major component of the cytoskeleton essential for cell polarization, cell division, cell 
migration, and vesicular transport (reviewed in Watanabe et al., 2005). MTs are composed 
of 13 protofilaments made up of α- and β-tubulin dimers. Generally, MTs nucleate at their 
minus ends which are localized at the microtubule organizing center (MTOC) while their 
plus ends adopt a state of dynamic instability, continually growing and shrinking. Selective 
stabilization of these MTs at their growing ends enables the MTOC to maintain an 
asymmetrical polarized MT array important for cell shape maintenance. This is supported 
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by the activities of microtubule-associated proteins (MAPs) that bind to the plus ends of 
microtubules (reviewed in Revenu et al., 2004) 
Although Rho GTPases are known more as regulators of the actin cytoskeleton, 
some of those effectors also participate in the temporal regulation of MT dynamics in 
response to signals that induce cytoskeleton reorganization (Figure 1.21). A concerted 
model for MT organization involves Rac activation which induces the formation of 
microtubules at the leading edge while RhoA activation induces the assembly of 
posttranslationally modified tubulin subunits, Glu-tubulin (Glu-MT) into stable 
microtubule filaments. Cdc42 signaling reorients the MTOC towards direction of the 
stimuli. This is mediated by the Cdc42 effectors dynein and dynactin which form motor 
complexes that redirects the minus end of microtubules.  
Stable microtubules are the result of the polymerization of Glu-MT. RhoA and its 
downstream effector mDia have been implicated in the formation of Glu-MT. In addition, 
integrin-mediated activation of focal adhesion kinase (FAK) may enhance the formation of 
Glu-MT by targeting RhoA and mDia to lipid rafts localized in the leading edges 
effectively bringing about site specific RhoA activation of mDia.  Alternatively, Rho and 
mDia can also facilitate integrin-FAK signaling via interactions with the tumour 
suppressor adenomatous polyposis coli (APC) and the EB1 proteins which are MAPs that 
promote MT bundling and stabilization. In addition, ROCKs may target MAPs (MAP-2 
and tau) and work in concert with mDia in directing the dynamics of MT formation 













Figure 1.21. Signaling networks of Rho GTPases in microtubule organization. (Adapted 





 APC is a major regulator of MT organization and directs MT stability under the 
influence of various upstream activators. Besides Rho, Rac and Cdc42 also play crucial 
roles in MT organization via the activation of various downstream effectors at the leading 
edge of cells. Cdc42 promotes APC-mediated MT stability at the leading edge and 
influence the subsequent establishment of cell polarity by regulating the MTOC through 
Par6. Substratum adhesion results in integrin-FAK activation which promotes atypical 
protein kinase C (aPKC) activity via Cdc42 and Par6. This results in the phosphorylation 
and inactivation of glycogen synthase kinase-3β (GSK-3β) which relieves APC inhibition 
at the leading edges of cell.  
In addition, Cdc42 and Rac enhance IQGAP and CLIP-170 associations which 
form docking sites for MT plus ends at the cell cortex thereby, enhancing MT stability. 
Taken together, this suggests that the IQGAP-CLIP-170 complex functions in the 
recruitment and anchorage of APC-mediated microtubules plus ends to specific points at 
the cell cortex under the influence of Rac and Cdc42. APC association with the Rac-
specific GEF, Asef promotes Rac activation which influences both MT and actin filament 
assembly creating a positive feedback mechanism necessary for sustained cytoskeleton 
reorganization involving both the actin and microtubule components. 
Besides APC, Rho family effectors also regulate the functions of other MAPs. The 
MT destabilizing protein, stathmin (Op18) is downregulated by PAK phosphorylation 
downstream of Rac activation. The asymmetrical distribution of CLIP-115 and CLIP-170-
associating proteins (CLASPs) direct polarized growth of MT arrays toward the leading 
edge. These proteins are regulated by PI3K and GSK-3β allowing the regulation of 




1.2.6.2. Rho GTPases in cell dynamics and motility 
1.2.6.2.1. Roles of Rho GTPases in cell migration 
 Cell migration is essential for various physiological processes like wound repair, 
chemotaxis, angiogenesis and development. Cells may respond to various extra- or intra-
cellular cues that influence the cell shape, polarity and location. Migration requires the 
coordinated movement of different parts of the cell which is regulated by dynamic 
cytoskeleton remodeling within the cell involving both the actin and microtubule filament 
networks (reviewed in Raftopoulou and Hall, 2004). Polarized protrusions at the leading 
edge are stabilized by cell adhesions followed by cell body contraction and detachment of 
cell adhesions at the trailing end to produce a net forward movement (Figure 1.22).  
 Different members of the Rho GTPase family are spatially regulated with distinct 
sites of localized activation. Rac and Cdc42 may shuttle between the cytosol and different 
membrane sites while RhoA remains mainly cytosolic. During cell migration, Cdc42 
regulates the MTOC via activating the Par proteins and aPKC in determining cell polarity 
(Etienne-Manneville and Hall, 2003). In addition, Cdc42 also localizes to the Golgi 
apparatus to direct transport pathways to the leading edge for sustained migration. Recent 
work also indicates that Cdc42 mediates Arp2/3 complex and F-actin dynamics at the 
Golgi downstream of Arf1 activation (Dubois et al., 2005). At the forefront of the cell, 
both Rac and Cdc42 work in concert with their effectors to induce actin assembly leading 
to membrane ruffling and filopodia, respectively. Rac is localized immediately behind the 












Figure 1.22. Cell migration requires the concerted efforts controlled by distinct members 




leading edge. Rac may also promote microtubule stabilization through PAK-dependent 
inactivation of stathmin. Subsequent APC activation promotes microtubule assembly and 
stabilization at the leading edge. APC binding to Asef allows feedback up-regulation of 
Rac signaling and coordination of Cdc42-mediated microtubule organization and cell 
polarization with Rac-mediated actin polymerization at the leading edge. This allows for 
the actin cytoskeleton to assist in guiding microtubule assembly.  
The membrane protrusions are then stabilized by cell adhesions induced by integrin 
and FAK activation. This in turn activates Rac and Cdc42 in a positive feedback loop. In 
addition, PAK can act in concert with PAK-interactive exchange factor (PIX) and GRK 
interactor I (GIT1) to regulate focal adhesion turnover necessary for actin organization and 
recycling of components. This results in sustained protrusion at the front and retraction at 
the rear of the cell providing traction for cell movement (Manabe Ri et al., 2002; 
Obermeier et al., 1998). Rho could promote microtubule stability via mDia by targeting 
microtubules to focal adhesions (Ishizaki et al., 2001; Palazzo et al., 2001) and inducing 
the maturation of focal adhesions behind the leading edge while participating in the 


















Figure 1.23. The roles of Rho GTPases in cell migration. The Cdc42/Par/aPKC complex is 
involved in establishment of cell polarity. At the front of the cell, Rac1 and Cdc42 work in 
concert with their effectors to regulate membrane ruffles and filopodia induction, 
respectively. These protrusions are stabilized by the formation of focal adhesions which 
involves integrin activation and the recruitment of structural and signaling components to 
the nascent adhesions. This in turn, positively regulates Rac1 and Cdc42 activation. RhoA 
is thought to be involved in retraction at the rear of the cell through the regulation of actin–
myosin contractility. RhoA activation also induces the maturation of focal adhesions 
behind leading edges. (Adapted from Watanabe et al., 2005). 
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1.2.6.2.2. Roles of Rho GTPases in phagocytosis 
Rac is a regulator of the NADPH oxidase complex which participates in the killing 
internalized foreign bodies during phagocytosis. In neutrophils, Rac can directly associate 
with the phox protein complex (p67, p47 and p40) via direct binding to the cytosolic 
p67phox which results in the subsequent membrane recruitment of the complex. Activation 
of the NADPH oxidase results in the generation of reactive oxygen species (ROS). This 
mechanism has been proposed to act in concert with Rac-mediated lamellipodia formation 
to direct phagocytosis (reviewed in Ridley, 2001). Rac mediates actin polymerization via 
activation of the WAVE-Arp2/3 complex which results in engulfment of foreign particles 
into phagosomes. Subsequent Rac dissociation from the WAVE-Arp2/3 complex promotes 
its interaction with the phox protein complex, bringing the phox proteins in close 
proximity to NADPH oxidase in the vicinity of the membrane thereby generating free 
radical ions within the phagosome. This biochemical activity allows the degradation of the 











1.2.6.3. Rho GTPases in cell proliferation, transformation and cancer development 
1.2.6.3.1. Cell proliferation and cell cycle progression 
Cell proliferation is a tightly regulated event associated with cell cycle progression 
and is dependent on stimulation from mitogenic growth factors and integrin-extracellular 
matrix adhesion. Deregulation often leads to defective nuclear signaling resulting in 
anchorage and growth factor independent growth, one of the hallmarks of cellular 
transformation. Cell cycle progression is mediated by complexes of cyclins and cyclin-
dependent kinases (CDKs) which phosphorylate retinoblastoma (Rb) tumor suppressor 
proteins thereby relieving its inhibition on cell-cycle progression. The D- and E-type 
cyclins (D1, D2, D3, E1, E2) form active complexes with CDK4/CDK6 and CDK2, 
respectively. CDKs are in turn regulated by two groups of cyclin-dependent kinase 
inhibitors (CKIs).  These include the INK4 proteins (p16INK4a, p15INK4b, p18INK4c, 
and p19INK4d) which specifically inhibit CDK4/6 and the Cip/Kip family (p21cip1, p27kip1 
and p57kip2) which activate cyclin-D-CDK4 and cyclin-D-CDK6 but inactivate cyclin-E-
CDK2 complexes upon association. The relative balance of cyclin and CKIs determine 
CDK activity and G1 progression. Cells can remain in the quiescent G0 phase until growth 
factor stimulation which activates the cyclin-CDK complexes leading to G1 progression 
and transcription of E2F-regulated genes necessary for entry into S phase. G1 progression 
is considered the ‘restriction point’ beyond which the cell is committed to division and 
serves as a point for integration of growth factor stimulation with the integrin-extracellular 
matrix (ECM) signaling pathway (Assoian, 1997). This effectively coordinates events 
downstream of the RTK and integrin signaling leading to Ras/Raf/MAPK/ERK activation 
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(Assoian and Schwartz, 2001). Thus, normal cell proliferation involves cell adhesion in the 
presence of growth factors which then promote G1 progression by upregulating cyclin D1 
expression allowing the inhibition of Rb as well as the formation of cyclin-D1-CDK4/6 
complexes which compete with cyclin-E-CDK2 for p21/p27 resulting in concomitant 
activation of both cyclin-D1-CDK4/6 and cyclin-E-CDK2 complexes (reviewed in 
Coleman et al., 2004; Sherr and Roberts, 1999). 
 
1.2.6.3.2. Roles of Rho GTPases in gene expression  
Several studies have established roles of Rho family effectors in Ras signaling 
pathways linking them to gene expression control. PAK activation downstream of Rac 
signaling stimulates the phosphorylation of Raf-1 and MEK1 which are intermediates of 
the Ras/Raf/MAPK pathways leading to Erk activation. Furthermore, PAKs can also 
mediate the activation of the stress-activated kinases, Jun N-terminal kinase (JNK) and 
p38MAPK via the activation of the mixed lineage kinases (MLKs), thereby stimulating 
AP-1 dependent gene expression. Genetic analysis of dorsal closure in Drosophila 
indicates that Rac participates in JNK regulation (Glise and Noselli, 1997). Recent work 
has established a link between ROCK-dependent JNK activation via MEKK1 in induction 
of Rho-mediated stress fibers downstream of transforming growth factor (TGF)-β 
signaling (Zhang et al., 2005).  
The serum response factor (SRF) is a nuclear protein that binds to the serum 
response element (SRE) found upstream of immediate early genes in skeletal and smooth 
muscle. The Rho GTPases can activate gene transcription via the SRF in a temporal 
manner. In addition, RhoA and ROCK have been shown to provide spatial regulation of 
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gene transcription by influencing SRF subcellular localization (Hill et al., 1995; Liu et al., 
2003). The active N-WASP has been shown to translocate into the nucleus implicating it in 
the modulation of gene expression (reviewed in Bompard and Caron, 2004). 
 
1.2.6.3.3. Role of Rho GTPases in cellular transformation and cancer  
Dysfunctional regulation of signaling cascades often results in deregulated cell 
growth, proliferation and survival leading to cellular transformation and oncogenesis. 
Cancer development is usually associated with gene mutations that create dominant active 
oncogenes or defective tumour suppressor proteins. Alternatively, changes in protein 
expression and biochemical activity of regulatory and effector proteins also contributes to 
transformation (Ridley, 2004, Boettner and van Aelst, 2002). Unlike the Ras oncogenes, 
members of the Rho family do not exhibit gene mutations but instead show altered gene 
expression that influence protein signaling cascades (Lin and van Golen, 2004). Thus, 
Rho-dependent pathways are thought to contribute to oncogenic Ras transformation 
(Perona et al., 1993; van Leeuwen et al., 1995). In addition, mutations within GEFs often 
result in constitutive activation of their cognate Rho targets and contribute to cellular 
transformation (Ron et al., 1991). 
The ability of Rho GTPases to target components of the MAP kinase pathway 
allows Rho-mediated apoptosis to reduce survival of transformed cells. When deregulated, 
cells become resistant to apoptosis leading to transformation. Rho GTPases also serve as 
key regulators of cytoskeletal remodeling and cell adhesion, prerequisites for anchorage-
independent cell growth. Their participation in cell migration indicates further involvement 
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in cellular transformation and metastasis. As previously discussed, Rho GTPases can act 
downstream of integrin-FAK signaling leading to actin and microtubule reorganization. 
Rho GTPases can direct cell cycle progression through regulation of cyclins and 
CKIs (reviewed in Coleman et al., 2004). Rac activation stimulates ERK-dependent cyclin 
D1 expression (Westwick et al., 1997; Gille et al., 1999; Welsh et al., 2001), subsequent 
Rb phosphorylation and E2F promoter activity in a positive feedback loop (Gjoerup et al., 
1998). Interestingly, cyclin D1 upregulation may also be induced by Rac-dependent ROS 
generation via NADPH oxidase and the allosteric activation of the cyclin D1 promoter by 
nuclear factor-κB (NF-κB) (Joyce et al., 1999). In addition, PI3K may mediate Rac 
activation downstream of α5β1 integrin (fibronectin) receptor (Mettouchi et al., 2001). 
Conversely, Rho controls a parallel pathway that regulates the timing of ERK-dependent 
cyclin D1 expression through sustained ERK activation (Page et al., 1999).  
Rho GTPases have also been implicated in downregulating p21cip1 and p27kip1 
induction which contributes to cell cycle progression and oncogenic Ras-mediated 
transformation (reviewed in Welsh, 2004), the mechanisms of which require further 
clarifications. It has been proposed that Rho promotes G1 progression by downregulating 
p21cip1 expression during the mid- to late G1 phase. Upon growth factor stimulation, 
p21cip1 undergoes an initial ERK-dependent induction which activates the cyclin-D-
CDK4/6 complexes in early G1 phase. Cell adhesions subsequently activates RhoA which 
in turn downregulates p21cip1 expression through an ERK- and p53-independent 
mechanism (Bottazzi et al., 1999).  
In addition, Rho activation downstream of growth factor stimulation is proposed to 
stimulate cyclin-E-CDK2 activation which directs p27kip1 for degradation by 
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phosphorylation during the late G1,S,G2 phase (Sheaff et al., 1997). Alternatively, Rho 
may inhibit p27kip1 protein synthesis by regulating translation via a Rho-responsive 
element at the 3’ untranslated region (UTR) in the p27kip1 mRNA (Vidal et al., 2002). 
Recent work suggests that RhoA conveys cell shape-dependent control of the F-box 
protein, Skp2 and is required for ubiquitination-dependent degradation of p27kip1. This in 
turn promotes G1 progression and implicates ROCK and mDia in mediating cell growth by 
coupling cell shape with cell cycle progression (Mammoto et al., 2004). 
 
1.2.6.3.4. Convergence of Rho and Wnt signaling pathways during cancer 
development 
Mutations in components of Wnt signaling result in defective Wnt/β-catenin/T cell 
factor (TCF) signaling and have been implicated in tumourigenesis (reviewed in Malliri 
and Collard, 2003). The axin/APC/GSK-3β complex regulates the phopshorylation state of 
β-catenin downstream of Wnt signaling. β-catenin phosphorylation by GSK-3β targets it 
for ubiquitination and subsequent proteolytic degradation. Upon stimulation by Wnt 
factors, the Frizzled (Fz) receptors downregulate GSK-3β through an adaptor protein, 
Dishevelled (Dvl) resulting in the stabilization of β-catenin which translocates to the 
nucleus to direct transcription in concert with the TCF family of DNA-binding proteins. 
Subsequent constitutive transcriptional activation and overexpression of Wnt-responsive 
genes result in cell proliferation and oncogenic transformation. In addition, Dvl can also 
mediate Wnt-Fz activation of Rac and Rho signaling pathways to promote morphogenetic 
movements during vertebrate gastrulation (Habas et al., 2003).  Other components of the 
Wnt signaling can also participate in the Rho signaling pathways. Wnt/Fz can regulate the 
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expression of several components of Rho signaling like the Rac-specific GEF, Tiam1 and a 
Cdc42-like GTPase, Wrch-1 (Tao et al., 2001). As previously discussed, APC can bind 
and enhance the GEF activity of the Rac-specific Asef thus enhancing microtubule 
assembly while downregulating E-cadherin-mediated cell-cell adhesions. In addition, 
downregulation of GSK-3β through the Par6-aPKC complex promotes microtubule 
stability that aids the establishment of cell polarity downstream of Cdc42 activation. 
Collectively, the multiple activities of Dvl, APC and GSK-3β in the Wnt/Rho signaling 
pathways contribute to cell movements in development and deregulated cell proliferation 





































              











Figure 1.24. Convergence of Rho and Wnt signaling pathways. Dvl, APC and GSK-3β 
participate in multiple pathways which contribute to cell movements during development, 




1.3. The BNIP-2 and BPGAP protein families  
1.3.1. The BNIP-2 and Cdc42GAP Homology (BCH) domain 
The BCH domain is a novel protein module first identified and characterized in this 
laboratory (Low et al., 1999; Low et al., 2000a; Low et al., 2000b). This unique protein 
domain is about 145 amino acids in length and was initially known to be conserved in two 
proteins: BCL2/adenovirus E1B 19kDa interacting protein 2 (BNIP-2) and p50-RhoGAP. 
We reported that a region in the C-terminus of BNIP-2 shares a significant level of 
homology to the non-catalytic domain of p50-RhoGAP (Figure 1.25). Interestingly, this 
region of p50-RhoGAP could bind Cdc42 but did not possess any GAP activity unlike its 
counterpart in BNIP-2. This led to the hypothesis that the BCH domain may represent a 
novel protein interaction domain regulating the functions of p50-RhoGAP and BNIP-2 via 
recruitment of different candidate proteins. In line with these findings, bioinformatics 
analyses indicate that this protein domain is highly conserved throughout evolution with 
representatives from Saccharomyces cerevisiae, Plasmodium falciparum, Arabidopsis 
thaliana, Caenorhabditis elegans, and Homo sapiens (Low et al., 2000b). 
 
1.3.2. Functions and classification of the BCH domain-containing proteins  
 A previous survey of uncharacterized globular proteins including BNIP-2 and 
several GAPs and GEFs like the Neurofibromatosis type 1 (NF1) protein neurofibromin 
(White and O'Connell, 1991), Dbl’s big sister (Dbs), Duo/Kalirin (Alam et al., 1997; 
Colomar et al., 1997) and Trio (Debant et al., 1996) revealed that these proteins contained 









   





Figure 1.25. The BCH domain is involved in protein-protein interactions. Schematic 
diagram of homologous BCH domains in p50-RhoGAP and BNIP-2. (Adapted from Low 





lipid-binding domain of the S. cerevisiae phosphatidylinositol transfer protein, Sec14p 
(Aravind et al., 1999). Sequence analysis indicates that BNIP-2 shares ~17% sequence 
homology to Sec14p. These findings indicate possible lipid regulation of Ras and Rho 
GTPases. However, these properties have yet to be confirmed. 
The S. cerevisiae Sec14p mediates phospholipid transfer between 
phosphatidylinositol and phosphatidylcholine in membrane lipid bilayers (Bankaitis et al., 
1990). The Sec14p crystal structure was solved in a complex with n-octyl-β-D-
glucopyranoside, a detergent molecule that is a putative analogue of endogenous substrates 
phosphatidylcholine and phosphatidylinositol (Sha et al., 1998). The Sec14p structure 
consists of an amino-terminus α-helical domain and a carboxyl terminus lipid-interacting 
α/β domain. Attempts to derive a functional interpretation of the relationships between the 
different subsets of Sec14p-like domain containing sequences were based on multiple 
alignments of the carboxyl terminus which indicate that the conserved β sheet may 
constitute a lipid-binding surface by directing lipid interactions through several key 
hydrophobic residues. The prevalence of a highly divergent amino-terminal α-helical 
domain led the conclusion that these proteins may have retained their ability to bind lipids 
but may lack phospholipid-transfer properties (Aravind et al., 1999).  
Subsequent investigations have provided further insights into their biochemical 
functions. Genetic mapping of several neurofibromatosis-related mutations to a region 
corresponding to that of the NF1 gene (Upadhyaya et al., 1997; Tassabehji et al., 1993) 
underscores the functional importance of the Sec14p-like region in the manifestation of a 
clinical phenotype. Aberrant neurofibromin has been attributed to tumour development in 
the nervous system and associated learning disabilities (Ozonoff, 1999). In addition, the 
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presence of Sec14p-like domains in Rho specific GAPs (p50-RhoGAP) and GEFs (Dbl, 
Duo and Trio) indicate lipid-mediated regulation of their catalytic activities and subcellular 
localization.  
Consistent with this hypothesis, recent reports demonstrated that p50-RhoGAP 
undergoes an auto-inhibitory regulation of its activity through intra-molecular interactions 
involving its Sec14p-like/BCH domain (Moskwa et al., 2005). Furthermore, the Sec14p-
like domain has been implicated in regulating the cellular distribution and transforming 
activity of Dbs (Kostenko et al., 2005) in addition to directing the subcellular localization 
of Dbl and Ost isoforms and their substrate Cdc42 (Ueda et al., 2004). These findings 
provide insights into the role(s) of the Sec14p-like domain in directing RhoGEF-mediated 
spatial regulation of substrate activation. Taken together, it appears that the BCH domain is 
a lipid and/or protein interaction domain and represents a subset of the S. cerevisiae 
Sec14p lipid-binding domain whose function has diverged during evolution.  
Given the diversity of BCH domain-containing proteins and other subsets of 
Sec14p-like domains, understanding the domain organization of these protein repertoires 
will provide greater insights into the functions of their homologous Sec14p-like domains. 
PFAM analyses of the protein database revealed that the subset of BCH domain-containing 
proteins can be divided into two distinct groups based on the position and distribution of 
the BCH domain (Low et al., 2000b). We observed that Type I proteins contain a 
conserved C-terminus BCH domain while Type II proteins on the other hand contain a 
classical catalytic GAP domain distal to the N-terminus BCH domain (Figure 1.26). 
Systematic characterization of these proteins will provide greater insights into the function 
of the BCH domain in different contexts.  Currently, this laboratory has identified and  
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Figure 1.26. Domain organization of BCH domain-containing candidate genes and 
classification based on BCH domain location. The BCH and RhoGAP catalytic domains 
are indicated as green and red, respectively. Species abbreviations used are: Sc, S. 
cerevisiae; Pf, P. falciparum; Ce, C. elegans; At, A. thaliana; and Hs, H. sapiens. (Adapted 
from Low et al., 2000b). 
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characterized several Type I members including BNIP-2 and BNIP-S as well as a Type II 
member, BPGAP1 as described below. 
 
1.3.3. BNIP-2: the prototypical BCH-domain containing protein 
 The cellular roles of BCH-domain containing proteins have been extensively 
delineated in BNIP-2. First identified in a yeast two-hybrid screen as a cellular target of the 
adenoviral E1B 19kDa protein and the B-cell CLL/lymphoma 2 (Bcl-2) protein, BNIP-2 
was proposed to be involved in cell survival in line with the anti-apoptotic functions of 
E1B 19kDa and Bcl-2 (Boyd et al., 1994). Interestingly, BNIP-2 overexpression was found 
to induce cell death that could be rescued by Bcl-2 (Garnier et al., 1997) leading to 
speculations that BNIP-2 exerts its pro-apoptotic effects by functioning as a cysteine 
protease. Alternatively, changes to the equilibrium of BNIP-2 and Bcl-2 levels may trigger 
apoptosis (Belcredito et al., 2000; Meda et al., 2000).  In addition, BNIP-2 gene expression 
has been shown to be negatively regulated by estradiol stimulation in different cell types 
(Garnier et al., 1997; Vegeto et al., 1999; Belcredito et al., 2000; Meda et al., 2000) and 
during murine brain development and maturation (Belcredito et al., 2001). These studies 
indicate the involvement of BNIP-2 in neural cell apoptosis and its correlation to 
neurodegenerative diseases such as Alzheimer's disease. BNIP-2 has also been implicated 
in coxsackievirus B3 (CVB3)-induced myocarditis (Yang et al., 1999). Further 
investigations suggest that BNIP-2 induces caspase-dependent apoptosis which inhibits 
CVB3 replication (Zhang et al., 2001). More recently, a survey of gene expression profiles 
indicates that BNIP-2 is downregulated during mouse lung tumor progression (Bonner et 
al., 2004). 
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 BNIP-2 was identified by our group as a putative substrate of the fibroblast growth  
factor receptor (FGFR) and is tyrosine phosphorylated upon growth factor stimulation 
(Low et al., 1999). Furthermore, BNIP-2 could directly bind p50-RhoGAP and mutually 
compete for Cdc42 binding. Interestingly, we showed that BNIP-2 could function 
biochemically as a weak GAP, stimulating the intrinsic GTPase activity of Cdc42 albeit at 
a much lower level compared to conventional GAPs. These activities of BNIP-2 were 
found to be negatively regulated by tyrosine phosphorylation. Taken together, these results 
suggest that BNIP-2 may mediate novel mechanisms coordinating RTK signaling, small 
monomeric G proteins and cellular events like apoptosis.  
Further investigations to delineate the mechanisms underlying BNIP-2 GAP 
activity revealed that its BCH domain could function as a non-canonical GAP domain with 
a novel arginine finger motif, (235)RRLRK(239) and targeting Cdc42 through a separate 
motif, (288)EYV(290) found adjacent to the catalytic motif (Low et al., 2000a). In 
addition, we observed that BNIP-2 and p50-RhoGAP could form homo- and heterophilic 
interactions via their conserved BCH domains which negatively regulate the GAP activity 
of both proteins (Low et al., 2000b). Deletion studies revealed that a third motif, 
(217)RRKMP(221) was responsible for homodimer formation independent of its intrinsic 
GAP activity and ability to bind Cdc42. In line with these findings, an extended region 
flanking the Cdc42 binding motif within the BCH domain was recently identified to 
mediate both BNIP-2/Cdc42 interaction and elicit BNIP-2 induced cell morphological 
changes (Zhou et al., 2005a) (Figure 1.27). These results demonstrate that the BCH 
domain contains multiple recognition motifs. 
Transient expression of the BNIP-2 BCH domain was sufficient to elicit membrane  
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Figure 1.27. The BNIP-2 BCH domain contains multiple signalling motifs to mediate 
different cellular effects. (a) Schematic diagram of motifs important for homo- and 
heterodimer formation, Cdc42 binding. (b) The BNIP-2 BCH domain is sufficient to elicit 
membrane protrusions and cell elongation. (Adapted from Zhou et al., 2005a).  
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protrusions and cell elongation with BNIP-2 localized in punctate vesicles and 
concentrated at the protrusive ends of extensions (Figure 1.27). Interestingly, these 
morphological effects could be inhibited by the isolated PAK-CRIB domain suggesting 
that the recruitment of Cdc42 via the BCH domain is necessary for the activation of Cdc42 
effector pathways.  Taken together, these results indicate that BNIP-2 utilizes different 
motifs within its BCH domain to exert its roles in modulating and activating Cdc42 
signaling pathways. 
 
1.3.4. BNIP-S: a mediator of cell apoptosis 
Two alternatively spliced isoforms of BNIP-2-Similar (BNIP-S) was identified 
based on their homology to BNIP-2 (Zhou et al., 2002). The two protein isoforms were 
designated BNIP-Sα and BNIP-Sβ with the latter lacking an intact BCH domain at its C-
terminus (Figure 1.28). Genome analysis revealed that the abrupt loss of the C-terminus 
was due to the introduction of a nonsense intron during RNA splicing in BNIP-Sβ. Semi-
quantitative RT-PCR in established cell lines indicates that both BNIP-S isoforms have 
differential expression profiles where high expression of one is accompanied by the weak 
expression of the other. In addition, weak expression of BNIP-Sα and not BNIP-Sβ was 
detected in mouse organs with elevated levels in the penis. These findings are in contrast to 
that of BNIP-2 which is ubiquitously expressed and suggest that BNIP-S isoforms may 
have different cellular functions. Interestingly, when introduced into cells, BNIP-Sα but 
not BNIP-Sβ induced extensive cellular apoptosis, exhibiting the hallmark cell rounding 
phenotype. Further investigations include Hoeschst dye staining for nuclear condensation 








Figure 1.28. Differential cellular effects of BNIP-S isoforms. (a) Schematic diagram of 
BNIP-Sα, BNIP-Sβ and the BCH domain deletion mutants. (b) BNIP-Sα induces cell 
rounding phenotype in β-galactosidase marker assays via an apoptosis-inducing motif in its 
BCH domain. Deletion of this region (ΔS) aborogates BNIP-Sα-mediated apopotosis. 
(Adapted from Zhou et al., 2002). 
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indicators associate with events early in the apoptotic pathways, confirming the role of 
BNIP- Sα as a mediator of cellular apoptosis (Figure 1.29). Furthermore, these results also 
indicate that the lack of a complete, functional BCH domain in BNIP-Sβ abrogated the 
pro-apoptotic effects seen in BNIP-Sα.  
In addition, we demonstrated that the pro-apoptotic effects of BNIP-Sα can be 
attributed to its BCH domain alone and delineated an apoptosis-inducing motif within the 
BCH domain of BNIP-Sα (Figure 1.28). As expected, this motif lies in a region of the 
BCH domain that is absent in BNIP-Sβ. In addition, we demonstrated the involvement of 
this motif in BNIP-Sα homodimer formation. Taken together, these results indicate a 
requirement for BCH domain-mediated homo- and heterophilic interactions in pro-
apoptotic events. Interestingly, BNIP-Sα does not associate with or inhibit the effects of 
the pro-survival Bcl-2 and Bcl-xL indicating that BNIP-Sα promotes apoptosis through 
caspase-independent pathways. Furthermore, an alternatively spliced variant designated 
BNIPL-2 which differs from BNIP-Sα at its N-terminus has been speculated to mediate 
apoptosis via its interactions with Bcl-2 and p50-RhoGAP unlike BNIP-Sα (Qin et al., 
2003). In addition, overexpression of BNIPL-2 in Hep3B hepatocellular carcinoma cells 
was found to induce the differential expression of genes involved in cell growth, 
proliferation, differentiation and apoptosis (Xie et al., 2004). 
 In an attempt to elucidate the mechanisms underlying BNIP-Sα function, our group 
has recently delineated a region in the proximal part of the BCH domain that mediates 
exclusive binding to RhoA (Zhou et al., 2005b). Interestingly, this region also 
encompasses the p50-RhoGAP binding motif. Further investigations indicate that RhoA 
and p50-RhoGAP can mutually compete for BNIP-Sα binding. In line with these findings,           
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Figure 1.29. Pro-apoptotic effects of BNIP-Sα. (a) Hoeschst dye staining showing nuclear 
condensation and annexin V staining on cell membrane confirm BNIP- Sα expressing cells 
are undergoing apoptosis. (b) Deletion of S-region within the BCH domain abrogates the 
apoptotic effects of BNIP- Sα. (Adapted from Zhou et al., 2002). 
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BNIP-Sα mutants lacking motifs for RhoA and/or p50-RhoGAP binding failed to elicit the 
cell rounding phenotype suggesting that the pro-apoptotic effects of BNIP-S is mediated 
by RhoA activation. It was proposed that different pools of BNIP-S may work in concert 
for RhoA binding and p50-RhoGAP sequestration. Taken together, these results suggest 
that multiple motifs within the BNIP-Sα BCH domain act cooperatively to promote pro-
apoptotic events by activating RhoA pathway necessary for cell rounding. In addition, 
yeast-two hybrid library screening has identified the Macrophage Migration Inhibitory 
Factor (MIF) and the Augmenter of liver regeneration (GFER) as novel BNIP-Sα 
interacting partners (Shen et al., 2003) suggesting that BNIP-Sα may regulate cell 
proliferation through apoptosis in concert with these cytokines.  
  
1.3.5. BNIP-H: a tissue specific member of the BNIP-2 family  
 BNIP-2-Homology (BNIP-H) or Caytaxin is a tissue-specific member of the BNIP-
2 family first identified in this laboratory. Unlike currently known members, BNIP-
H/Caytaxin is exclusively expressed in the brain (Zhou and Low, unpublished results). 
Consistent with these findings, genetic studies indicate BNIP-H/Caytaxin expression is 
neuron-specific and mutations at the locus on 19p13.3 results in the development of a 
congenital form of ataxia found distinctively in the Grand Cayman Islands (Bomar et al., 
2003). Interestingly, the authors also suggest that the phenotype of Cayman ataxia 
correspond to that of the recessive ataxic mouse mutant, ‘jittery’. Work is currently in 
progress in our group to delineate the function of this novel protein and the roles of the 
BCH domain in neuronal development. Unlike BNIP-2 and BNIP-Sα which target Cdc42 
and RhoA, respectively, BNIP-H does not interact with Cdc42, RhoA or Rac1 and its 
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GTPase target currently remains elusive.  
 
1.3.6. BPGAP1: a multi-domain integrator of GTPase signaling 
 As its name suggests, this novel ubiquitously expressed RhoGAP protein, BCH 
domain-containing, Proline-rich and Cdc42GAP-like protein subtype-1 (BPGAP1) maps to 
the same locus as human ARHGAP8 on band 22q13.31 and harbors a BCH/Sec14p-like 
domain at its N-terminus. Besides this, it also possesses a classical catalytic GAP domain 
with a highly conserved ‘arginine finger’ motif and a proline-rich sequence that lies 
between these two domains (Shang et al., 2003). Co-workers in our group demonstrate that 
besides enhancing the GTPase activity of RhoA both in vivo and in vitro, BPGAP1 also 
targets Cdc42 and Rac1. The introduction of a mutation at R232A abrogates its ability to 
catalyse GTP hydrolysis, consistent with previous reports that the ‘arginine finger’ confers 
the catalytic activity of other functional GAPs (Nassar et al., 1998; Gamblin and Smerdon, 
1998; Fidyk and Cerione, 2002). More recently, alternatively spliced variants of 
ARHGAP8 which differ in their BCH domains have been shown to be differentially 
upregulated in colorectal tumors (Johnstone et al., 2004) suggesting a possible link 
between GAP activity and the regulation of cancer progression. 
The multidomain architecture of BPGAP1 suggests that it could coordinate 
multiple cellular events via selective interactions with target proteins through these 
domains. This raises the possibility that BPGAP1 could regulate the activities of Cdc42 
and Rac1 even though they are not its substrates. Consistent with this hypothesis, we 
provide evidence that dominant negative mutants of Cdc42 and Rac1 could inhibit 
BPGAP1-induced pseudopodia formation. Conversely, RhoA activation inhibits the 
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formation of long pseudopodia while Cdc42 and Rac1 activation potentiates the 
appearance of drastic neurite-like extensions consistent with morphological changes 
associated with BPGAP1. Interestingly, the isolated BCH and GAP domains initiated the 
formation of short and long pseudopodia, respectively (Figure 1.30). Further analysis 
revealed a requirement for the central proline-rich region for initiation of cell migration. In 
this regard, we raised the possibility that BPGAP1 could function in recruiting Cdc42, 
Rac1 and other signaling components necessary for the activation and propagation of 
Cdc42 and/or Rac1 mediated pathways.  
To elucidate the molecular mechanisms underlying BPGAP1 function, matrix-
assisted laser desertion/ionization mass spectrometry/time of flight (MALDI/IMS/TOF) 
identified cortactin as a novel BPGAP1 interacting partner (Lua and Low, 2004). Like 
BPGAP1, cortactin is a multi-domain protein and has been implicated as a key regulator of 
actin rearrangments especially through binding of multiple protein targets at its C-terminus 
SH3 domain (reviewed in Lua and Low, 2005a; Bershadsky, 2004; Daly, 2004). 
Progressive deletion studies demonstrate the involvement of the BPGAP1 proline-rich 
region for binding to the SH3 domain in cortactin. The authors also show that BPGAP1 
facilitates cortactin translocation to the periphery coupled with enhanced cell migration. 
Taken together, these results provide evidence that BPGAP1 promotes efficient cell 
migration through its interactions with protein components of the cytoskeletal network. 
Figure 1.31 is a schematic diagram of a model outlining the roles of BPGAP1 in cell 
dynamics. More recently, co-workers demonstrate that BPGAP1 also targets the SH3 
domain of EEN/endophilin-II through the same proline-rich region and collaborate with its 









Figure 1.30. BPGAP1 induces unique pseudopodia via its BCH and GAP domains. (a) 
Schematic diagram of the domain layout of BPGAP1. (b) MCF7 cells were transfected 
with different fragments of BPGAP1 and visualized by direct fluorescence microscopy 16 










Figure 1.31. BPGAP1 is a multi-domain integrator of Rho GTPase signaling. Proposed 
model of BPGAP1 function in cell dynamics regulation. (Adapted from Shang et al., 2003; 




enhanced EGF-stimulated receptor endocytosis and ERK1/2 activation (Lua and Low, 
2005b). These findings indicate that BPGAP1 plays multiple roles in regulating distinct 
GTPase signalling pathways linking the cytoskeletal network to endocytic trafficking and 

























1.4. Hypothesis and aims of study 
The current review indicates that BCH domain-containing proteins can mediate 
diverse effects on cell morphology, motility and cell survival in association with Rho 
GTPase-mediated actin cytoskeleton remodelling. These proteins have been divided into 
two groups on the basis of their domain architecture. The Type I family currently consists 
of three members closely related to the prototypic BNIP-2 at amino acid level while 
BPGAP1 and p50-RhoGAP are the main Type II members containing other domains and 
motifs in addition to the BCH domain. Interestingly, while the regions encompassing the 
BCH domain remain conserved during evolution, they appear to mediate different aspects 
of cell dynamics when present in different proteins. 
BNIP-2 targets Cdc42 producing characteristic protrusive phenotypes whilst BNIP-
S isoforms direct their pro-apoptotic effects via associations with RhoA.  Both however, 
mediate these cell morphological changes through the Rho family GTPases. Thus, we 
asked the question: what are the implicit differences amongst these BCH domains that 
allow specificity to GTPase binding and the implication of this relationship to actin 
cytoskeletal dynamics? Intriguingly, the BCH domain of BNIP-2 also functions as a non-
canonical GAP for downregulating Cdc42. Furthermore, deletion studies have mapped the 
GTPase binding and GAP activity to individual motifs within the BCH. Studies in 
BPGAP1 also indicate that the BCH domain can coordinate adjacent signaling domains to 
induce distinct cellular phenotypes which are prerequisites for cell motility. This is further 
supported by recent findings that the BCH domains of BPGAP1 (Shang et al., 2003) and 
p50-RhoGAP (Moskwa et al., 2005) can form intramolecular interactions that limit their 
activities Thus, it would seem possible that the BCH domain location directs the 
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recognition of different binding partners and exerts its effects in concert with flanking 
sequences.   
Identification of novel BCH-domain containing proteins is expected to provide 
further insights into the function and mechanisms that govern the activities of this protein 
module and the evolutionary implications of these functional differences in comparison to 
the Sec14p-lipid binding domain. Both share sequence similarity (~17%) and may have 
diverged from a common ancestor in response to cellular needs. Aberrant Rho GTPase 
signaling has been implicated in cancer development and neurological disorders.  The 
identification of BNIP-H gene mutations and its association with the onset of Cayman 
ataxia indicates the involvement of BCH domain-containing proteins in developmental 
events and disease progression.  
 Here, we hypothesize that novel BNIP-2 family members could confer certain 
aspects of cell morphogenesis by targeting selective GTPases. The mechanism of which 
will be elucidated here. Specifically, we aim to: 
 identify novel BCH domain-containing proteins in silico; 
 clone and express BNIPXL full length cDNA that codes for a novel BCH protein; 
 determine the mRNA expression profile of BNIPXL and the possible existence of 
splicing variants in various human cell lines and tissues; 
 investigate the nature of protein-protein interactions of BNIPXL with its target(s) in 
vitro and in vivo;  
 delineate regions responsible for such interactions;  
 examine the cellular effects of BNIPXL; and  









Materials and Methods 
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2. Material and Methods 
Reagents used were of analytical grade, and standard protocols for molecular manipulations 
and media preparation were as described previously (Sambrook and Russell, 2001).  
2.1. Bioinformatics analyses 
 Novel proteins that contain homologous BCH domains were identified by position-
specific iterative BLAST (PSI-BLAST) (Altschul et al., 1997) search against the current 
non-redundant sequence database and human expressed sequence tag (EST) database at the 
National Center for Biotechnology Information (http://www,ncbi.nlm.nih.gov/blast) as 
described previously (Low et al., 2000b). Multiple sequence alignments and phylogenetic 
analyses were generated using Vector NTI Suite while pairwise global alignments were 
generated using the Stretcher program from EMBOSS (available at mirror site: 
http://sbcr.bii.a-star.edu.sg/emboss/). Genome analysis was generated using the Human 
Genome BLAST (http://www.ncbi.nlm.nih.gov/genome/seq/HsBlast.html). 
 
2.2. DNA amplification and cloning of BNIPXL  
 Full length BNIPXL cDNA was amplified by polymerase chain reaction (PCR) 
using the Expand Long Template PCR System (Roche Molecular Biochemicals) from BD 
Marathon Ready adult human brain and kidney cDNA libraries (CLONTECH, Palo Alto, 
CA) using the forward primer (5’-ATGGCTTTGTTTGATGGTGATCC-3’) and reverse 
primer (5’ CTTCTTCCAGCATGGCCAACTAAGGC-3’) with XhoI (forward) and NotI 
(reverse) restriction sites to facilitate subsequent cloning. A 50µL reaction mix containing 
10X Expand Long Template Buffer 2, 10mM dNTP mix, 3.75U Expand Long Template 
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enzyme mix, 1μL cDNA library and 5mM forward and reverse primers were subjected to 
the following PCR conditions: initial denaturation at 94 °C, 4 min; annealing at 55°C, 30 s; 
extension at 68 °C, 4 min; subsequent cycling (30 cycles) at 94 °C, 40 s; annealing at 
55 °C, 30 s; extension at 68 °C, 4 min; and final extension at 68 °C, 10 min. BNIPXL 
fragments were generated from the full-length template using various combinations of 
PCR primers with XhoI (forward) and NotI (reverse) sites with the same cycling 
conditions. In addition, BNIPXL deletion mutants were generated by outward PCR using 
primers incorporating NheI sites flanking the region to be excluded. The PCR products 
were separated by gel electrophoresis.  
DNA gels were cast using regular ultra-pure electrophoresis-grade agarose 
(Invitrogen Corp., San Diego, CA). 1%-1.5% (w/v) agarose was dissolved in Tris acetate 
EDTA (TAE) buffer (0.04M Tris acetate, 1mM EDTA) supplemented with ethidium 
bromide (0.5µg/mL). Samples were mixed with a suitable amount of a 6X DNA gel 
loading dye (1X TAE, 30% (w/v) glycerol, 0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol FF) and loaded alongside GeneRuler™ 1kb DNA Ladder (Fermentas UAB, 
Vilnius, Lithuania). Routine DNA gel electrophoresis was performed in the same buffer 
and the gels were viewed using a ultraviolet transilluminator (UVItec Limited, Cambridge, 
UK) and documented using a thermal printer (Mitsubishi Corp., Tokyo, Japan). 
Fragments of the expected size were excised and purified using the QIAquick Gel 
Extraction Kit (QIAGEN GmbH, Germany) according to manufacturer instructions. The 
PCR products were cloned into the pXJ40-FLAG or pXJ40-HA and pXJ40-GFP 
mammalian expression vectors containing the cytomegalovirus (CMV) enhancer and 
promoter, the Kozak initiation and N-terminus FLAG or HA epitopes, respectively (Figure 
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2.1, courtesy of Dr. E. Manser, Glaxo-IMCB Laboratory, Institute of Molecular and Cell 
Biology, Singapore). A 10µL ligation mix containing 10X T4 ligase buffer, 1U of T4 
ligase (New England BioLabs, Beverly, MA), 20ng of insert DNA and 50ng of vector was 
incubated overnight at room temperature and transformed into competent Escherichia coli 
strains, XL1-blue or DH5α.  
Prior to transformation, competent cells were prepared according to Sambrook and 
Russell, 2001. A single colony was selected and cultured overnight at 37°C in 5mL Luria 
Bertani (LB) nutrient broth medium (5g/L NaCl, 10g/L tryptone, 5g/L yeast extract). The 
overnight culture was diluted (1:6000) in fresh LB medium and grown at 37°C until log 
phase (O.D.600 = 0.3-0.6). The bacterial pellet was collected by centrifugation at 3,500g for 
10 min at 4°C and reconstituted in 1:20 volume of ice-cold sterile TSS (LB broth [pH 6.5], 
10% (v/v) PEG 3,350, 5%(v/v) DMSO, 10mM MgCl2, 10mM MgSO4). Aliquots were 
stored at -70°C for subsequent use. For transformation, 5μL of the ligation mixture was 
incubated with 30µL each of KCM (100mM KCl, 30mM CaCl2, 50mM MgCl2) and 
competent cells on ice for 1 h and plated onto LB-agar supplemented with 100mg/L of 
ampicillin. Plates were incubated overnight at 37°C and single colonies selected for further 
analysis. 
 
2.3. Plasmid DNA isolation, restriction and sequencing analysis 
Plasmid DNA was isolated using the QIAprep Spin Miniprep Kit (QIAGEN) 
according to manufacturer instructions. The protocol is based on the alkaline lysis method 











        /EcoRI/   ……….....................HA epitope tag………………………./BamHI 
T7     GAATTC   ACC  ATG  GTC  CCA  TAC  GAC   GTG  CCA  GAC  TAC  GCA   GGA TCC 
                     Kozac   M     V      P      Y      D      V      P      D      Y     A       G     S 
 
 
/ HindIII /  XhoI   /       NotI      /   Sma I  /    PstI    /    SacI   /  KpnI    / Bgl II 
AAG CTT CTC GAG  GCG GCC GCC CCG GGC TGC AGG AGC TCG GTA CC  AGATCT               




ATG  GAC  TAC  AAG  GAC  GAC  GAT  GAT  AAG  GGC 
 M     D      Y       K     D      D      D      D     K      G 
 
 
Figure 2.1. (a) Schematic diagram of the pXJ40 vector map. Transcription is driven by 
CMV enhancer/promoter and Kozak initiation upstream of a non-coding β-globin intron 
followed by an epitope tag, multiple cloning site (MCS) and a SV40 polyadenylation 
signal sequence. (b) Multiple cloning sites of the pXJ40 vector series constructed from 
parent plasmid (Xiao et al., 1991). The SacI site is not unique to the polylinker (Manser et 
al., 1997). (c) The FLAG epitope tag sequence in the pXJ40-FLAG vector. 
>>>CMV enhancer/ Promoter/β-globin intron (non-coding)/T7/Epitope tag 
/Mulitple cloning sites/Polyadenylation signal sequence >>> 
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NaOH was used in denaturation of bacterial cell wall proteins, choromomal and plasmid 
DNA. Addition of potassium acetate results in neutralization and preferential annealing of 
covalently closed plasmid DNA whilst chromosomal DNA and bacterial proteins 
precipitate with SDS and potassium to form a complex which is removed by 
centrifugation. Plasmid DNA is then recovered through a cationic affinity chromatography 
column, purified and eluted. In brief, 5mL overnight cultures of recombinant colonies were 
pelleted by centrifugation and re-suspended in the cell resuspension solution (50mM Tris 
[pH 7.5], 10mM EDTA, 100μg/mL RNase A). The cell lysis solution (0.2M NaOH, 1% 
(w/v) SDS) was added and the suspension mixed by inversion. Neutralisation solution 
(1.32M KOAc) was added to the suspension, mixed gently and centrifuged at 13,000g to 
remove cell debris. The cleared lysate was applied to the QIAprep spin column and briefly 
centrifuged to aid passage of lysate through the column. The column was washed with PE 
buffer (80mM potassium acetate, 8.3mM Tris-Cl [pH 7.5], 40μM EDTA, 55% (v/v) 
ETOH). Excess PE buffer was removed by further centrifugation. The plasmid DNA was 
then eluted from the resin with 50µL of sterile water. Plasmid concentrations were 
calculated at O.D. 260 for use in subsequent experiments and the purified DNA was stored 
at -20° C.  
Putative clones were identified using restriction enzyme digestion and verified 
through bi-directional DNA sequencing using the ABI PRISM BigDye Terminators v 3.0 
(Applied Biosystems, Foster City, CA). A 5µL reaction mixture containing 70ng of 
plasmid DNA and 1.6mM of primer was subjected to the following PCR conditions (25 
cycles): denaturation at 96°C, 30 s; annealing at 50°C, 15 s and extension at 60°C, 4 min. 
The amplified products were precipitated for 15 min at room temperature with 80μL of 
  100
ethanol/sodium acetate solution (3µL of 3M NaOAc [pH 4.6], 75% (v/v) ETOH). The 
mixture was centrifuged for 10 min at 13,000g and the supernatant aspirated. The pellet 
was washed with 500μL of 75% (v/v) ETOH, centrifuged for 5 min, supernatant aspirated 
and the pellet was air dried. DNA samples were re-suspended in 11μL of HI DI 
formamide, denatured for 2 min at 95°C and cooled on ice before loading. Sequencing was 
performed using the ABI PRISM™ 3100 DNA Sequencer (Applied Biosystems). Positive 
clones were propagated in E. coli and plasmids were purified using HiSpeed Plasmid Midi 
Kit (QIAGEN) according to manufacturer instructions. 
 
2.4. Mammalian cell culture    
 HEK293T human embryonic kidney epithelial cells are a clonal derivative of the 
HEK293 adherent cell line stably expressing the SV40 large T antigen. This cell line is 
frequently used for production of recombinant proteins owing to its ease of transfection. 
HeLa is a human cervical cancer cell line. MCF-7, SK-BR3 and MDA-MB-231 are human 
epithelial breast cancer cell lines. All are mammary adenocarcinomas established from 
pleural effusions. MCF-7 are non-motile and exhibit morphologies resembling epithelial 
cells found in monolayers and are thus, excellent candidates for studying subcellular 
structures using fluorescence microscopy. SK-BR3 lacks E-cadherin expression while 
overexpressing the HER2/c-erb-2 gene product and are weakly invasive while the MDA-
MB-231 is highly metastatic. These cell lines have been used in expression profiling 
studies to determine the significance of gene expression with their metastatic potential 
(Zajchowski et al., 2004). 
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 HEK293T and MCF-7 (ATCC, Manassas, VA) and SK-BR3 human breast 
carcinoma cells (courtesy of  T.L. Lo, Institute of Molecular and Cell Biology, Singapore) 
were maintained in RPMI-1640 (Hyclone, Logan, UT) medium supplemented with 10% 
(v/v) fetal calf serum (FCS) (Invitrogen Corp., San Diego, CA), 2mM L-Glutamine, 
100U/ml penicillin and 100μg/ml streptomycin (Hyclone), and grown at 37°C in a 5% CO2 
atmosphere whereas HeLa was grown in high glucose Dulbecco’s modified Eagle’s 
medium (D-MEM) and  MDA-MB-231 was maintained in D-MEM supplemented with 
0.1mM non-essential amino acids (NEAA) and 1mM sodium pyruvate (Invitrogen Corp.). 
Cells were split to 80% confluence one day prior to subsequent manipulations.  
 
2.5. Total RNA isolation and first strand cDNA synthesis 
Cells were rinsed with cold phosphate-buffered saline (PBS) buffer (1.3M NaCl, 
70mM Na2HPO4, 30mM NaH2PO4 [pH 7.4]) and total RNA isolated using the RNeasy 
Mini Kit (QIAGEN) according to manufacturer instructions. Briefly, cells were lysed in 
600µL of buffer RLT supplemented with 1% (v/v) β-mercaptoethanol, aspirated several 
times through a sterile syringe and the total RNA was precipitated with 70% (v/v) ETOH 
before application to the RNeasy mini spin column. Column was centrifuged to aid 
passage of lysate followed by addition of buffer RWl and subsequent centrifugation. The 
bound RNA was washed twice with buffer RPE before elution in 30µL of RNase-free 
water. Total RNA (3µg) was denatured for 10 min at 80 °C and added to a reaction mix 
containing 32U avian myeloblastosis virus (AMV) reverse transcriptase, 5U RNAsin and 
10mM dNTPs (Promega Corp., Madison, WI). First strand cDNA synthesis was primed 
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with oligo(dT) (Operon Biotechnologies, Inc. Alameda, CA) for 1 h at 42 °C and the 
cDNA was stored at -20° C for subsequent use. 
 
2.6. Semi-quantitative reverse transcription PCR 
Equal amounts of single-stranded cDNA was then subjected to PCR amplification 
with high fidelity, long-template DyNAzyme (Finnzymes Oy, Espoo, Finland) using the 
respective primers indicated. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
housekeeping gene was used to normalize the level of loading. PCR products were 
separated by electrophoresis using 1.5% (w/v) agarose gels and results were verified in at 
least two independent experiments with varying numbers of PCR cycles to ensure near-
linear amplification. 
 
2.7. Mammalian cell transfection, lysis and immunoprecipitation 
 Transient transfection was performed using FuGENE 6 transfection reagent (Roche 
Molecular Biochemicals) or LIPOFECTAMINE™ 2000 transfection Reagent (Invitrogen 
Corp.) according to manufacturer instructions. In brief, FuGENE 6 was diluted (1:30) in 
serum-free growth medium, mixed well and incubated for 5 min at room temperature. 
DNA plasmids were added to the cationic lipid mixture in the ratio of 2:3 (µg: vol), mixed 
well and incubated at room temperature for 15 min. The DNA-lipid complex was 
incubated with cells in serum-free medium at 37°C for 3 h followed by supplementation 
with 10% (v/v) serum. The cells were then incubated for 48 h before lysis. For 
transfections with LIPOFECTAMINE™ 2000, 2 µg of DNA plasmid and 5 µL of 
transfection reagent was diluted separately with 125 µL each of Opti-MEM® I reduced 
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serum medium (Invitrogen Corp.) for 5 min at room temperature. The mixtures were then 
combined and incubated for 20 min before addition to cells maintained in antibiotic-free, 
10% (v/v) serum-containing growth medium for 48 h before lysis. Cells were lysed in cold 
lysis buffer (50 mM HEPES [pH 7.4], 150 mM sodium chloride, 1.5 mM magnesium 
chloride, 5 mM EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 5 mM sodium 
orthovanadate, and a mixture of protease inhibitors) (Roche Molecular Biochemicals) and 
centrifuged at 13,000g for 10 min at 4°C. The supernatant was retained and used for 
subsequent experiments. 
For immunoprecipitations, aliquots of cell extracts were analyzed as whole-cell 
lysates (25 µg) for protein expression or used in affinity precipitation experiments (500 µg) 
with anti-FLAG®M2 Affinity Gel (Sigma-Aldrich). 5µL of anti-FLAG antibody conjugate 
was added to each sample of cell extracts and incubated overnight at 4°C with rotation. 
The beads were spun down and washed three times with cold lysis buffer. The samples 
were then vortexed to release bound proteins and denatured at 95°C for 5 min in suitable 
amounts of 6X SDS-PAGE loading buffer (125mM Tris-HCL [pH 6.8], 15% (w/v) 
glycerol, 7.5% (v/v) β-mercapthoethanol, 0.15% (w/v) bromophenol blue) and separated 
by gel electrophoresis (Figure 2.2).  
 
2.8. SDS-polyacrylamide gel electrophoresis and transfer 
Polyacrylamide gels (10%-12.5%) were cast using 30% acrylamide/bis (37:5:1) 
solutions, N,N,N,N-tetramethyl-ethylenediamine (TEMED) as the accelerator (all from 
BioRad Laboratories, Hercules, CA) and 10% (w/v) ammonium persulphate (APS) 






Figure 2.2. Schematic diagram of immunoprecipitation. Cell lysates serve as a source of 
target protein complexes and may contain non-specific proteins (small triangles). The bait 
complexes are captured using a specific antibody and the antibody-bait-target assembly is 
immobilized onto Protein A/G covalently attached to Sepharose beads. The beads are then 
washed to remove non-specific proteins and the antibody-bait-target conjugate is eluted by 
boiling in SDS-PAGE loading buffer. (Adapted from Masters, 2004). 
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even by layering with butanol and left to polymerize at room temperature for 45 min. The 
butanol was discarded and the resolving gel rinsed with water before addition of the 
stacking gel.  The stacking gel with its large pore size has very little sieving effect, 
allowing the proteins to migrate and form a narrow band at the stacking/resolving gel 
interface (Johnstone and Thorpe, 1987; Hames, 1988). Samples were loaded alongside 
Precision Plus protein pre-stained standards (BioRad Laboratories) and gel electrophoresis 
performed using the Mini-PROTEAN 3 Electrophoresis System (Bio-Rad Laboratories) in 
Tris-glycine buffer (25mM Tris, 145mM glycine, 0.1% (v/v) SDS). A constant current of 
40 mA per gel was applied until the dye front reached the bottom of the gel. Following 
electrophoresis, the size-fractionated proteins were transferred onto nitrocellulose 
membranes using a Trans-Blot cell (all from Bio-Rad Laboratories) in transfer buffer 
(25mM Tris, 195mM glycine, 0.1% (w/v) SDS, 20% (v/v) methanol). The membranes 
were pre-soaked in methanol and then rinsed in transfer buffer. The gel was sandwiched 
between one pre-equilibrated membrane and Whatman 3MM filters (Whatman plc., 
Middlesex, UK), assembled in the Trans-Blot cell and transferred at 100V for 90 min in 4° 
C.  
 
2.9. Western blot analyses 
 
Membranes were equilibrated in PBS-T buffer (1XPBS, 0.1% (v/v) Tween-20) and 
incubated in blocking buffer (PBS-T, 1% (w/v) bovine serum albumin [BSA]) either 1 h at 
room temperature or overnight at 4° C on an orbital shaker. Primary antibodies were 
diluted in sterile blocking buffer and incubated with the membranes for 90 min at room 
temperature on an orbital shaker. Primary antibodies used were anti-FLAG (monoclonal 
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and polyclonal; Sigma-Aldrich), polyclonal anti-HA (Zymed Laboratories, Inc., South San 
Francisco, CA), monoclonal anti-MYC (Roche Molecular Biochemicals), polyclonal anti-
RhoA and monoclonal anti-Rac (Upstate Biotechnology, Inc., Lake Placid, NY), 
polyclonal anti-Cdc42 and polyclonal anti-GFP (both Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA). All were diluted 1:1000 except for the anti-FLAG polyclonal antibody 
(1:10,000). The antibody solution was then removed, filter-sterilized and stored at 4° C for 
re-use.  
The membranes were washed three times, 10 min each at room temperature with 
PBS-T buffer before incubation with the appropriate goat anti-mouse or anti-rabbit 
horseradish peroxidase-conjugated secondary antibodies (1:2000 dilution in PBS-T) 
(Sigma-Aldrich) for 1 h at room temperature with agitation. The membranes was then 
subjected to three additional, 10 min wash in PBS-T buffer. Membranes were incubated in 
enhanced chemiluminescence reagents (Pierce Biotechnology, Inc., Rockford, IL), 
according to manufacturer instructions and placed between transparency sheets. Signal 
detection was performed by exposure to X-ray film (Fuji Photo Film, Tokyo, Japan) and 
developed in a RP X-OMAT Processor (Eastman Kodak Co., Rochester, NY). 
 
2.10. Yeast two-hybrid protein interaction assays 
  Full length BNIPXLα and BNIPXLβ were subcloned into the yeast GAL4 
Activation Domain (AD) vector, pACT2 and the GAL4 DNA-binding domain (DNA-BD) 
vector, pAS2-1 (CLONTECH). The clones were verified by restriction analysis and 
sequencing for use in subsequent experiments. The Saccharomyces cerevisiae AH109 host 
stain (courtesy of S.Y. Chow, Institute of Molecular and Cell Biology, Singapore) was 
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obtained and working stocks were streaked on YPD agar medium supplemented with 
0.003% (w/v) adenine hemisulphate (YPDA). Phenotype testing was performed on 
minimal Synthetic Dropout (SD) agar base supplemented with the appropriate Dropout 
(DO) supplement shown in Table I. The AH109 strain contains three reporter genes 
(ADE2, HIS3 and lacZ) under tight control from GAL4 upstream activating sequences 
(UASs) and TATA boxes which help reduce false positives ADE2 and HIS3 reporters 
provide strong nutritional selection to adenine and histidine, respectively. lacZ reporter  
encodes for β-galactosidase allowing for assay for transcriptional activation of gene 
expression (Figure 2.3).  
 Yeast transformations were performed using the Yeastmaker™ Yeast 
Transformation System 2 (CLONTECH), according to manufacturer instructions. Prior to 
lithium acetate (LiAc)-mediated transformation, competent yeast cells were prepared 
according to manufacturer instructions. Fresh yeast colonies were dispersed in 50mL of 
YPDA liquid medium and cultured overnight at 30°C. The overnight culture was diluted 
(1:10) in fresh YPDA liquid medium and grown at 30°C until mid-log phase (O.D.600 = 
0.4-0.6). The yeast pellet was collected by centrifugation at 1,000g for 5 min at room 
temperature, washed once with sterile 1XTE (10mM Tris-HCl, 1mM EDTA [pH 7.5]) 
buffer and the pellet reconstituted in 1.5mL of sterile TE/LiAc (1XTE, 100mM lithium 
acetate [pH 7.5]) solution.  
 For simultaneous cotransformation, 0.1 µg of each plasmid DNA was incubated 
with 0.1 mg of pre-denatured herring testes carrier DNA, 100µL of competent yeast cells 
and 600µL of sterile PEG/LiAc (40% (v/v) PEG 4,000, TE/LiAc) solution. The mixture 







Table I. Combinations of minimal Synthetic Dropout (SD) agar base supplemented with 
the Dropout (DO) supplements. 
 
































Figure 2.3. Schematic diagram illustrating the modular nature of the yeast GAL4 
transcription factor and the regulation of downstream reporter genes for ADE2, HIS3 and 
lacZ. (Adapted from Miller and Stagljar, 2004). 
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and gentle inversion. The samples were then heat shocked for 15 min at 42°C, chilled on 
ice and centrifuged at 13,000g for 5 s at room temperature. The supernatant was discarded 
and the pellet resuspended in 100µL sterile 1X TE buffer. 20µL each of diluted samples 
was (1:10, 1:100) plated on each type of SD agar plate in Table I and incubated at 30 °C 
for 2 days. Transformation efficiency and potential lethality of constructs was determined 
by selection on -Trp, -Leu or -His agar plates while plating on -Trp/-His and -Leu/-His SD 
allows determination of spurious self-activation of HIS reporter by the individual 
constructs. Dual transformants were selected on Trp/Leu-free SD agar plates while plating 
on Trp/Leu/His-free SD agar gave indication of direct protein-protein interaction. Colonies 
that survived the HIS3 growth selection were re-streaked on fresh Trp/Leu/His-free agar, 
grown at 30 °C for 2 days and subjected to β-galactosidase colony lift filter assays 
according to the manufacturer's protocol (CLONTECH). A schematic diagram illustrates 
an overview of the assay (Figure 2.4).  
 To measure β-galactosidase activity, sterile Whatman filters were pre-soaked in Z 
buffer/X-gal solution (Z-buffer: Na2HPO4•7H2O, NaH2PO4•H2O, KCl, MgSO4•7H2O [pH 
7.0], 33.4% (w/v) X-gal, 0.27% (v/v) β-mercaptoethanol). The colonies were blotted onto 
dry sterile Whatman filters and submerged in liquid nitrogen for 10 s and left to thaw at 
room temperature for cell permeablization. The filter is then placed colony side up onto the 
pre-soaked filters and incubated at 30 °C. Positive interactions were scored for the 
appearance of blue colonies in less than 8 h according to the protocol. In all experiments, 
















2.11. GST-fusion protein production 
Glutathione S-transferase (GST) fusion proteins were produced in E. coli BL21 
strain carrying pGEX vectors (Amersham Pharmacia Biosciences, Piscataway, NJ). An 
overnight culture was diluted (1:200) in fresh LB medium and grown at 37°C until log 
phase (O.D.600 = 0.3-0.6). The bacterial pellet was collected by centrifugation at 3,500g for 
10 min at 4°C and stored at -70° C. Pellets were thawed and reconstituted in 5mL of GST 
lysis buffer (1XPBS, 1% (v/v) Triton X-100 and 1mM dithiothreitol [DTT]) and a mixture 
of protease inhibitors (Roche Molecular Biochemicals). The mixture was sonicated for 3 
min at 20% amplitude and centrifuged at 3,500g for 1 h (Vilber Lourmat, Marne la Vallée 
Cedex, France). The supernatant was incubated with 150µL of glutathione sepharose 4B 
beads (Amersham Pharmacia Biosciences) for 1 h at 4°C. Beads were washed five times in 
cold PBS buffer supplemented with 1% (v/v) Triton X-100 and stored at 4°C as a 50% 
slurry for up to 2 weeks. A second round of capture was performed with the supernantant 
overnight at 4°C, if necessary. 
 
2.12. GST-fusion protein binding assays 
For in vitro binding assays, aliquots of the suspensions (10ug) were washed twice 
with 500µL of cold pre-binding buffer (50mM Tris HCl [pH 7.4], 50mM NaCl, 5mM 
MgCl2, 1mM DTT, and a mixture of protease inhibitors). The beads were then loaded with 
water, GDP or guanosine 5'-O-3-thiotriphosphate (GTPγS) (Sigma) in 39µL of binding 
buffer (25 mM NaCl, 20 mM Tris HCl [pH 7.5], 0.1 mM dithiothreitol), 50 mM EDTA, 
and 10 mM GDP or GTPγS at 30°C for 10 min. The reaction with stopped by addition of 
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MgCl2 to final concentration of 20mM. The beads were subsequently incubated with whole 
cell lysates (500 µg) at 4°C in GAP lysis buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 
1.5 mM MgCl2, 5 mM EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100), 5 mM sodium 
orthovanadate and a mixture of protease inhibitors (Roche Molecular Biochemicals), 
collected by centrifugation, and washed three times with 1 ml of IP wash buffer (20 mM 
HEPES [pH 7.4], 150 mM NaCl, 10mM MgCl2, 10% (v/v) glycerol, 0.1% (v/v) Triton X-
100). Bound proteins were eluted and heat denatured in suitable amounts of 6X SDS-
PAGE loading buffer, separated by SDS-PAGE and analyzed by Western blot analyses 
(Figure 2.5). 
 
2.13. In vitro direct protein binding assays  
 For direct binding assays, in vitro transcribed and translated epitope-tagged 
proteins were synthesized using the TNT® Quick Coupled Transcription/Translation 
System (Promega Corp.), according to manufacturer’s instructions. Briefly, 1 µg of DNA 
plasmid template was incubated with 20 µL of TNT® Quick Master Mix and 1µL of the 
T7 TNT® PCR Enhancer in a 25 µL reaction volume at 30°C for 90 min. 2 µL of the TNT 
product was analyzed by SDS-PAGE while the remaining product was incubated with 10 
µg of GST fusion proteins immobilized on glutathione-sepharose beads overnight at 4°C. 
The mixture was then diluted with 100 µL of cold lysis buffer and allowed to incubate for 
1 h at 4°C. Beads were collected by centrifugation and washed three times with 200 µL of 
lysis buffer. Bound proteins were eluted and heat denatured in suitable amounts of 6X 








Figure 2.5. A schematic diagram illustrating a GST-fusion protein binding assay. Cell 
lysates are incubated with the bait, GST-fusion protein bound to gluthathione (GSH)-
agarose matrix. Only proteins that interact with the fusion protein in the X region will be 
‘pull-down’. (Adapted from Vikis and Guan, 2004). 
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2.14. In vitro Rho activity assays 
For GST-RBD pull-down assays, cells were lysed with ice-cold lysis buffer (50 
mM Tris-HCl [pH 7.4], 2 mM magnesium chloride, 1% (v/v) Triton X-100, 10% (v/v) 
glycerol, 100 mM sodium chloride, supplemented with 1 mM dithiothreitol and a mixture 
of protease inhibitors). Lysates were centrifuged at 14,000 rpm for 10 min at 4°C. The 
cleared lysates were diluted five times with lysis buffer and incubated for 45 min at 4°C 
with 20µL of GST fusion of Rhotekin-RBD bound to glutathione sepharose 4B beads 
(plasmid courtesy of Dr Simone Schoenwaelder, Monash University, Australia). The beads 
were subsequently collected by centrifugation and washed three times with 750µL of lysis 
buffer. Bound proteins were eluted and heat denatured in suitable amounts of 6X SDS-
PAGE loading buffer, separated by SDS-PAGE and analyzed by Western blot analyses. 
 
2.15. Confocal immunofluorescence microscopy 
MCF-7 and HeLa cells were seeded on glass coverslips in 6-well plates at 30% 
confluency and transfected with various constructs. 24 h post-transfection, the cells were 
washed with cold PBS buffer supplemented with 10mM CaCl2 and 10mM MgCl2 
(PBSCM) and fixed in 4% (w/v) paraformaldehyde for 30 min at 4°C. Fixed cells were 
washed twice with PBSCM, twice with PBSCM containing 50mM NH4Cl, and twice again 
with PBSCM, followed by permeabilization with 0.1% (w/v) saponin (Sigma-Aldrich) in 
PBSCM for 15 min at room temperature. Coverslips were incubated in fluorescence  
dilution buffer (FDB) (PBSCM, 7% (v/v) fetal bovine serum [FBS], 2% (w/v) BSA) for 30 
min and then with monoclonal FLAG and/or polyclonal HA antibodies diluted 
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(1µg:100µL) in FDB for 1 h at room temperature. The coverslips were washed three times, 
2 min each in PBSCM supplemented with 0.1% (w/v) saponin before incubation with 
secondary antibodies diluted (1:200) in FDB for 1 h at room temperature in the dark. 
Secondary antibodies used were fluorescein isothiocyanate-conjugated (FITC) goat anti-
rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) or Pacific Blue-
conjugated goat anti-rabbit IgG (Molecular Probes, Eugene, OR).  F-actin staining was 
performed using TRITC-conjugated phalloidin (Sigma-Aldrich) (Figure 2.6). Coverslips 
were washed five times in PBSCM supplemented with 0.1% (w/v) saponin and mounted 
with FluorSave (Calbiochem, San Diego, CA). Confocal microscopy was performed with 
an Olympus Fluoview confocal microscope (Olympus Corporation, Tokyo, Japan) attached 
to an Olympus 1 X 81 inverted fluorescent microscope equipped with a 60X oil immersion 

































Figure 2.6. The schematic diagram illustrates the multicolor detection of cellular proteins. 
Primary antibodies are used to detected individual proteins (shaded triangles and semi-
circle). Subsequent incubation with fluorophore-conjugated secondary antibody allows 


















3.1. Investigating the roles of the BCH domain in novel proteins 
 
3.1.1. In silico identification of a novel BCH domain-containing protein 
To investigate the functional diversity of the novel BNIP-2 family proteins and the 
possibility that homologous BCH domains may exert distinct roles in targeting specific 
GTPases for cell morphogenesis, we set out to identify novel BCH domain-containing 
proteins using a bioinformatics approach. BCH domain homologues were identified using 
the BLASTN and PSI-BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) programs as 
described in “Materials and Methods”. All BCH domains were identified without iteration 
using unfiltered query sequences. Using the full-length human BNIP-2 and its BCH 
domain (residues 167-303) with an E-value of 0.001, we identified in silico a partial coding 
sequence for a putative human mRNA (GenBank™ accession number AB002365) with an 
extensive 3’ untranslated region (UTR) encoding for the KIAA0367 gene (Nagase et al., 
1997). Several conserved primers were designed based on the predicted open reading frame 
and used in reverse-transcription-based PCR to isolate the full-length cDNA from human 
brain and kidney cDNA libraries. Following PCR, an expected 2500-bp DNA fragment 
was isolated (Figure 3.1) and cloned into epitope-tagged pXJ40 mammalian expression 
vectors for subsequent propagation in XL1-blue and DH5α Escherichia coli host strains. 
Antibiotic resistant colonies harboring DNA fragments of the expected size that was 
released by XhoI/NotI double restriction digest was selected for bi-directional DNA 






         
  
   
Figure 3.1. Cloning of full-length BNIPXL. PCR amplification from human brain and 
kidney libraries were performed using the cycling conditions described in ‘Materials and 
Methods’ (upper panel). From left to right, lanes 1, 6: 5’ untranslated region and full 
length (UTR_FL); lanes 2, 7: full length; lanes 3, 8: N-terminus lacking BCH domain 
(WBCH); lanes 4, 9: C-terminus. Different primer pairs were used for amplification of 
BNIPXL fragments as indicated (lower panel). The BNIPXL coding sequence is from 
nucleotides 163-2470. In addition to the BCH domain, the region with significant 
homology to BNIP-2 is shaded in gray. Numbers indicate nucleotide base pairs. 
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3.1.2. Sequence verification and bioinformatics analyses of BNIPXL  
Bi-directional sequencing using vector and gene specific primers repeatedly 
identified two unique cDNA sequences (Figure 3.2) in several clones that had 99% 
identity to the KIAA0367 gene (GenBank™ accession number AB002365). The 
KIAA0367 cDNA was originally isolated from size-fractionated human brain cDNA 
libraries (Nagase et. al., 1997). This cDNA generated a protein corresponding to an ORF 
of 716 amino acid residues in the in vitro transcription and translation system. The authors 
could not locate an in-frame termination codon in the 5’-untranslated region (5’UTR) 
suggesting that KIAA0367 could either be truncated at its N-terminal or that internal 
translation initiation sites within the existing cDNA clone could be induced.  
We observed that several nucleotide polymorphisms (Table 2) had resulted in 
silent mutations and amino acid substitutions when compared to the KIAA0367 gene.  
These single nucleotide polymorphisms were consistently found in several clones of the 
two cDNA sequenced. Similar observations were noted for nucleotide insertions 
corresponding to the three amino acids residues (588)GLR(590). The three residue 
insertion is likely to be the result of polymorphism as BLAST results of the cDNA 
sequences against the human EST database indicates the presence of several ESTs from 
lung (GenBank™ accession number DB229725), brain (GenBank™ accession numbers 
DA216136, DA194357 and DA406210) and liver (GenBank™ accession number 







 gctttgtttgatggtgatccacatttatccacagagaatcctgccttggttcctgatgct      60 
  
 ttgctagcctcagacacttgtctggatataagcgaagctgcctttgaccacagtttcagc      120 
  
 gatgcctcaggtctcaacacatccacgggaacaatagatgacatgagtaaactgacatta      180 
             M  S  K  L  T  L       6 
  
 tccgaaggccatccggaaacgccagttgatggggacctagggaagcaagatatctgctca      240 
  S  E  G  H  P  E  T  P  V  D  G  D  L  G  K  Q  D  I  C  S       26 
 
 tctgaagcctcgtggggtgattttgaatatgatgtaatgggccagaatatcgatgaagat      300 
  S  E  A  S  W  G  D  F  E  Y  D  V  M  G  Q  N  I  D  E  D       46 
  
 ttactgagagagcctgaacacttcctgtatggtggtgaccctcctttggaggaagattct      360 
  L  L  R  E  P  E  H  F  L  Y  G  G  D  P  P  L  E  E  D  S       66 
 
 ctgaagcagtcgctggcaccgtacacacctccctttgatttgtcttatatcacagaacct      420 
  L  K  Q  S  L  A  P  Y  T  P  P  F  D  L  S  Y  I  T  E  P       86 
 
 gcccagagtgctgaaacaatagaggaagctgggtctccagaggatgaatctctgggatgc      480 
  A  Q  S  A  E  T  I  E  E  A  G  S  P  E  D  E  S  L  G  C       106 
 
 agagcagcagagatagtgctttctgcacttcctgatcgaagaagtgagggaaaccaggct      540 
  R  A  A  E  I  V  L  S  A  L  P  D  R  R  S  E  G  N  Q  A       126 
 
 gagaccaaaaacagactgcctggatcccagctggctgtgctgcatattcgtgaagaccct      600 
  E  T  K  N  R  L  P  G  S  Q  L  A  V  L  H  I  R  E  D  P       146 
  
 gagtccgtttatttgccggtaggagcaggctccaacattttgtctccatcaaacgttgac      660 
  E  S  V  Y  L  P  V  G  A  G  S  N  I  L  S  P  S  N  V  D       166 
 
 tgggaagtagaaacagataattctgatttaccagcaggtggagacataggaccaccaaat      720 
  W  E  V  E  T  D  N  S  D  L  P  A  G  G  D  I  G  P  P  N       186 
 
 ggtgccagcaaggaaatatcagaattggaagaagaaaaaacaattcctaccaaagagcct      780 
  G  A  S  K  E  I  S  E  L  E  E  E  K  T  I  P  T  K  E  P       206 
 
 gagcagataaaatcagaatacaaggaagaaagatgtacagagaagaatgaagatcgtcat      840 
  E  Q  I  K  S  E  Y  K  E  E  R  C  T  E  K  N  E  D  R  H       226 
 
 gcactacacatggattacatacttgtaaaccgtgaagaaaattcacactcaaagccagag      900 
  A  L  H  M  D  Y  I  L  V  N  R  E  E  N  S  H  S  K  P  E       246 
 
 acctgtgaagaaagagaaagcatagctgaattagaattgtatgtaggttccaaagaaaca      960 
  T  C  E  E  R  E  S  I  A  E  L  E  L  Y  V  G  S  K  E  T       266 
 
 gggctgcagggaactcagttagcaagcttcccagacacatgtcagccagcctccttaaat      1020 
  G  L  Q  G  T  Q  L  A  S  F  P  D  T  C  Q  P  A  S  L  N       286 
  
 gaaagaaaaggtctctctgcagagaaaatgtcttctaaaagcgatacgagatcatctttt      1080 
  E  R  K  G  L  S  A  E  K  M  S  S  K  S  D  T  R  S  S  F       306 
 
 gaaagccctgcacaagaccagagttggatgttcttgggccatagtgaggttggtgatcca      1140 
  E  S  P  A  Q  D  Q  S  W  M  F  L  G  H  S  E  V  G  D  P       326 
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 tcactggatgccagggactcagggcctgggtggtccggcaagactgtggagccgttctct      1200 
  S  L  D  A  R  D  S  G  P  G  W  S  G  K  T  V  E  P  F  S       346 
 
 gaactcggcttgggtgagggtccccagctgcagattctggaagaaatgaagcctctagaa      1260       
  E  L  G  L  G  E  G  P  Q  L  Q  I  L  E  E  M  K  P  L  E       366 
  
 tctttagcactagaggaagcctctggtccagtcagccaatcacagaagagtaagagccga      1320 
  S  L  A  L  E  E  A  S  G  P  V  S  Q  S  Q  K  S  K  S  R       386 
 
 ggcagggctggcccggatgcagttacccatgacaatgaatgggaaatgctttcaccacag      1380 
  G  R  A  G  P  D  A  V  T  H  D  N  E  W  E  M  L  S  P  Q       406 
 
 cctgttcagaaaaacatgatccctgacacggaaatggaggaggagacagagttccttgag      1440 
  P  V  Q  K  N  M  I  P  D  T  E  M  E  E  E  T  E  F  L  E       426 
 
 ctcggaaccaggatatcaagaccaaatggactactgtcagaggatgtaggaatggacatc      1500 
  L  G  T  R  I  S  R  P  N  G  L  L  S  E  D  V  G  M  D  I       446 
 
 ccctttgaagagggcgtgctgagtcccagtgctgcagacatgaggcctgaacctcctaat      1560 
  P  F  E  E  G  V  L  S  P  S  A  A  D  M  R  P  E  P  P  N       466 
 
 tctctggatcttaatgacactcatcctcggagaatcaagctcacagccccaaatatcaat      1620 
  S  L  D  L  N  D  T  H  P  R  R  I  K  L  T  A  P  N  I  N       486 
 
 ctttctctggaccaaagtgaaggatctattctctctgatgataacttggacagcccagat      1680 
  L  S  L  D  Q  S  E  G  S  I  L  S  D  D  N  L  D  S  P  D       506 
 
 gaaattgacatcaatgtggatgaacttgatacccccgatgaagcagattcttttgagtac      1740 
  E  I  D  I  N  V  D  E  L  D  T  P  D  E  A  D  S  F  E  Y       526 
 
 actggccatgaagatcccacagccaccaaagattctggccaagagtcagagtctattcca      1800 
  T  G  H  E  D  P  T  A  T  K  D  S  G  Q  E  S  E  S  I  P       546 
 
 gaatatacggccgaagaggaacgggaggacaaccggctttggaggacagtggtcattgga      1860 
  E  Y  T  A  E  E  E  R  E  D  N  R  L  W  R  T  V  V  I  G       566 
 
 gaccaagagcagcgcattgacatgaaggtcatcgagccctacaggagagtcatttctcac      1920 
  D  Q  E  Q  R  I  D  M  K  V  I  E  P  Y  R  R  V  I  S  H       586 
                      
 ggaggacttagaggatactatggggacggtctaaatgccatcattgtgtttgccgcctgt      1980 
  G  G  L  R  G  Y  Y  G  D  G  L  N  A  I  I  V  F  A  A  C_      606 
 
 tttctgccagacagcagtcgggcggattaccactatgtcatggaaaatcttttcctatat      2040 
  F  L  P  D  S  S  R  A  D  Y  H  Y  V  M  E  N  L  F  L  Y       626 
 
 gtaataagtactttagagttgatggtagctgaagactatatgattgtgtacttgaatggt      2100 
  V  I  S  T  L  E  L  M  V  A  E  D  Y  M  I  V  Y  L  N  G       646 
 
 gcaaccccaagaaggaggatgccagggctaggctggatgaagaaatgctaccagatgatt      2160 
  A  T  P  R  R  R  M  P  G  L  G  W  M  K  K  C  Y  Q  M  I       666 
 
 gacagacggttgaggaagaatttgaaatcattcatcattgttcatccatcttggttcatc      2220 
  D  R  R  L  R  K  N  L  K  S  F  I  I  V  H  P  S  W  F  I       686 
 
 agaacaatccttgctgtgacacgaccttttataagttcaaaattcagcagtaaaattaaa      2280 
  R  T  I  L  A  V  T  R  P  F  I  S  S  K  F  S  S  K  I  K       706 
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 tatgtcaatagcttatcagaactcagtgggctgatcccaatggattgcatccacattcca      2340 
  Y  V  N  S  L  S  E  L  S  G  L  I  P  M  D  C  I  H  I  P       726    
 
 gagagcatcatcaaactggatgaagaactgagggaagcatcagaggcagctaaaactagc      2400               
  E  S  I  I  K  L  D  E  E  L  R  E  A  S  E  A  A  K  T  S       746               
      
 tgcctttacaatgatccagaaatgtcttctatggagaaggatattgacttgaagctgaaa      2460               
  C  L  Y  N  D  P  E  M  S  S  M  E  K  D  I  D  L  K  L  K       766                
  
 gaaaagccttagttggccatgctggaagaag                                   2491 










Figure 3.2. Nucleotide and deduced amino acid sequences of human BNIPXL gene. The 
human BNIPXLα and BNIPXLβ cDNAs encode for a 769- and 732 amino acid proteins, 
respectively. The BCH domain is underlined while the region excluded from the BNIPXLβ 
splice variant is in bold. Double lines indicate the Walker A motif (334)GPGWSGKT   
(341) identified by the NCBI Conserved Domain (CD) database search program 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) while the three amino acid 
insertion (588)GLR(590) is highlighted in red. The forward and reverse arrows define the 
region corresponding to the BCH domain amplified during diagnostic RT-PCR 
experiments (Figure 3.7). Residues highlighted in blue indicate primers used for BMCC1 




Table 2. List of nucleotide polymorphisms compared to the KIAA0367 gene and its effect 
at amino acid level in the BNIPXL gene.  
 
Nucleotide substitutions  Amino acid mutations 
C409A Leu83Ile 
C739T Pro193Ser 
C816T Cys218 (silent) 
G1059A Gly300Ser 
T1175C Ser338 (silent) 
G1355A  Ser398Asn 
T1402C Ser414Pro 












3.1.2.1. Genomic organization of BNIPXL  
Genome analysis using the Human Genome BLAST 
(http://www.ncbi.nlm.nih.gov/genome/seq/HsBlast.html) mapped both cDNAs to the 
human chromosome band 9q21.2 (Figure 3.3) indicating that they are products of 
alternative RNA splicing. Further analyses indicate that this gene spans 13 exons over a 
distance of ~86 kbp. The exclusion of two exons (exons 11 and 12) during exon skipping 
resulted in the introduction of an in-frame stop codon corresponding to a deletion of 86 
nucleotides at the C-terminus of the shorter splice variant resulting in the lost of 28 amino 
acids (Figure 3.4).  
 
3.1.2.2. BNIPXLα and BNIPXLβ are novel members of the BNIP-2 family 
The predicted open reading frame of the novel cDNAs encode for a 769- and 732 
amino acid proteins which had 25% amino acid identity to full-length human BNIP-2 and 
shares 68% identity at the C-terminus to the BNIP-2 BCH domain. Thus, we named them 
BNIPXLα and BNIPXLβ, extra-long members of the BNIP-2 family, with BNIPXLβ 
being the shorter splice variant. The complete sequences of human BNIPXLα and 
BNIPXLβ have been deposited in the GenBank™ under the accession numbers AY439213 
and AY439214, respectively. Pairwise sequence alignments of full length BNIPXL with 
BNIP-2 family members indicate that BNIPXL shares ~18-25% amino acid identity over 
the entire cDNA sequence (Table 3) while pairwise alignments of the BCH domains 
demonstrates that BNIPXL and the BNIP-2 family share ~50-70% amino acid identity at 
their BCH domains. The BNIP-H BCH domain being the most similar (72% identity)  
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Figure 3.3. The genomic organization of the human BNIPXL gene. Both BNIPXLα and BNIPXLβ map onto the human 
chromosome 9q21.2, spanning a distance of ~86 kbp and are products of alternative RNA splicing with BNIPXLβ being shorter 
by 86 bp. Dotted lines indicate exons included in BNIPXLα (upper) and BNIPXLβ (lower) isoforms, respectively. Nucleotide 























Figure 3.4. BNIPXLα spans 13 exons (upper panel) while exon skipping (exons 11 and 
12, highlighted in red) results in the deletion of 86 nucleotides from BNIPXLβ with the 
introduction of an in-frame stop codon (lower panel). (*) indicates the stop codon. The 
boundaries of the exons are denoted by arrows.  
     
       2340        2349        2358        2367        2376        2385 
          
                (exon 11)                             
    ATT CCA GAG AGC ATC ATC AAA CTG GAT GAA GAA CTG AGG GAA GCA TCA GAG GCA 
    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
     I   P   E   S   I   I   K   L   D   E   E   L   R   E   A   S   E   A  
   
       2394        2403        2412        2421        2430        2439    
         
 
(exon 12)                                            (exon 13)
     
    GCT AAA ACT AGC TGC CTT TAC AAT GAT CCA GAA ATG TCT TCT ATG GAG AAG GAT 
    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
     A   K   T   S   C   L   Y   N   D   P   E   M   S   S   M   E   K   D  
    
       2448        2457        2466        2475        2484        2493         
                                                                ATT GAC TTG AAG CTG AAA GAA AAG CCT TAG TTG GCC ATG CTG GAA GAA GAG GAT 
    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
     I   D   L   K   L   K   E   K   P   *   L   A   M   L   E   E   E   D  
     
      
 
 
2340      2349    
          
 
                 
 
(exon 11)    
   ATT CCA GAG AGC ATC ATC AAA CTG GAT GAA GAA CTG AGG GAA GCA TCA GAG GCA 
    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
     I   P   E   S   I   I   K   L   D   E   E   L   R   E   A   S   E   A  
 
        
 
(exon 12)                                           (exon 13)
 
 
    GCT AAA ACT AGC TGC CTT TAC AAT GAT CCA GAA ATG TCT TCT ATG GAG AAG GA 
    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
     A   K___T   S   C   L   Y   N   D   P   E   M   S   S   M   E   K     
     
   2358        2367        2376        2385        2394        2403      
                                                                 
 
      TAT TGA CTT GAA GCT GAA AGA AAA GCC TTA GTT GGC CAT GCT GGA AGA AGA GGA 
    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
    Y   *   L   E   A   E   R   K   P   L   V   G   H   A   G   R   R   G  
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Table 3. Pairwise global alignments of full-length BNIP-2 family members. Values are represented as percentage amino acid identity 
obtained using the Stretcher program at (http://sbcr.bii.a-star.edu.sg/emboss/). 
 
 
 BNIPXLα   BNIPXLβ BNIP-2 BNIP-H BNIP-Sα 
BNIPXLα 100 95.1 24.2 26.3 18.5 
BNIPXLβ 95.1 100 24.9 25.3 18.7 
BNIP-2 24.2 24.9 100 48.3 41.1 
BNIP-H 26.3 25.3 48.3 100 32.8 
BNIP-Sα 18.5 18.7 41.1 32.8 100 
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while BNIP-S the least similar (47% identity) (Table 4). In addition, the flanking regions 
of BNIP-H and BNIP-2 also share ~45% amino acid identity with BNIPXL (Figure 3.5).  
 
3.1.2.3. Multiple sequence alignments of BCH domains  
Conserved Domain Architecture Retrieval Tool (CDART) analyses using the full-
length polypeptides as query sequence and multiple sequence alignments of the BCH 
domains of BNIPXLα and BNIPXLβ with other BNIP-2 family members revealed that the 
distal region of BNIPXL and the BCH domains of BNIP-2 family members were highly 
conserved. This confirms the presence of a BCH domain (Figure 3.6). Based on the 
classification derived from our previous survey of the GenBank (Low et al., 2000b), 
BNIPXLα and BNIPXLβ are now classified as novel Type I members where the BCH 
domain is present at the C-terminus. 
 
3.1.2.4. Phylogenetic analyses of the BNIP-2 family 
Phylogenetic trees were generated using the BCH domains and full length amino 
acid sequences of Type I family members. Tree topologies indicate that BNIPXL and 
BNIP-H share the closest relative ancestry followed by BNIP-2, with BNIP-S being more 





Table 4. Pairwise global alignments of the BCH domains of BNIP-2 family. Values are represented as percentage amino acid identity 
obtained using the Stretcher program at (http://sbcr.bii.a-star.edu.sg/emboss/). 
 
 
 BNIPXLα_BCH  BNIPXLβ_BCH BNIP-2_BCH BNIP-H_BCH BNIP-Sα_BCH 
BNIPXLα_BCH 100 90.4 66.9 72.1 47.9 
BNIPXLβ_BCH 90.4 100 64.2 72.7 50.0 
BNIP-2_BCH 66.9 64.2 100 64.4 48.6 
BNIP-H_BCH 72.1 72.7 64.4 100 47.6 









Figure 3.5. Schematic diagram showing pairwise alignments between the different regions 







                       1                                                          60 
      BNIP2_BCH  (167) IVVFPAVCFMPESS-PNYRYLMDNLFKYVIGTLELLVAENYMIVYLNGATTRRKMPSLGW 
     BNIPSα_BCH  (133) -VILFASCYLPRSSIPNYTYVMEHLFRYMVGTLELLVAENYLLVHLSGGTSRAQVPPLSW 
      BNIPH_BCH  (190) AIIVFAACFLPDSSLPDYHYIMENLFLYVISSLELLVAEDYMIVYLNGATPRRRMPGIGW 
    BNIPXLα_BCH  (600) -IIVFAACFLPDSSRADYHYVMENLFLYVISTLELMVAEDYMIVYLNGATPRRRMPGLGW 
    BNIPXLβ_BCH  (600) -IIVFAACFLPDSSRADYHYVMENLFLYVISTLELMVAEDYMIVYLNGATPRRRMPGLGW 
 
                       61                                                       120 
      BNIP2_BCH  (226) LRKCYQQIDRRLRKNLKSLIIVHPSWFIRTLLAVTRPFISSKFSQKIRYVFNLAELAELV 
     BNIPSα_BCH  (192) IRQCYRTLDRRLRKNLRALVVVHATWYVKAFLALLRPFISSKFTRKIRFLDSLGELAQLI 
      BNIPH_BCH  (250) LKKCYQMIDRRLRKNLKSLIIVHPSWFIRTVLAISRPFISVKFINKIQYVHSLEDLEQLI 
    BNIPXLα_BCH  (659) MKKCYQMIDRRLRKNLKSFIIVHPSWFIRTILAVTRPFISSKFSSKIKYVNSLSELSGLI 
    BNIPXLβ_BCH  (659) MK-CYQMIDRRLRKNLKSFIIVHPSWFIRTILAVTRPFISSKFSSKIKYVNSLSELSGLI 
 
                       121                        150                              183 
      BNIP2_BCH  (286) PMEYVGIPECIKQVDQELNGKQDEPKNEQ--------------------------------- 
     BNIPSα_BCH  (252) SLDQVHIPEAVRQLDRDLHGSGGT--------------------------------------  
      BNIPH_BCH  (310) PMEHVQIPDCVLQYEEERLKARRESARPQPEFVLPRSEEKPEVAPVENRSALVSEDQETSMS 
    BNIPXLα_BCH  (719) PMDCIHIPESIIKLDEELREASEAAKTSCLYNDPEMSSMEKDIDLKLKEKP----------- 
    BNIPXLβ_BCH  (719) PMDCIHIPESIIKY------------------------------------------------ 
       
 
B                         
                                     
 
Figure 3.6. (a) Multiple sequence alignments of BCH domains of the BNIP-2 family using 
Vector NTI suite. Residues that are identical in all members are shaded black, those that 
are conserved in most of the members are in dark gray while the significant but least 
conserved ones are in light gray shading. (b) Average distance trees generated using the 
Vector NTI Suite showing the relative evolutionary relationships of the BCH domain from 
different BNIP-2 family members. 
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3.2. Investigating the biochemical and cellular functions of BNIPXL    
 
3.2.1 Expression profile of BNIPXL 
3.2.1.1. Expression profile of BNIPXL in human tissues and cell lines 
 To determine the expression profile of BNIPXL in human tissues and cell lines, we 
employed semi-quantitative RT-PCR instead of Northern analyses. This will allow 
different isoforms to be distinguished using diagnostic primers. In addition, their 
significant homology to BNIP-2 and other BCH domain-containing proteins could 
potentially result in cross-hybridization in Northern analyses. To ensure greater specificity, 
we utilized an RT-PCR strategy with specific primers for amplification of both full-length 
and the BCH domain cDNA. The latter would effectively allow unambiguous distinction 
of BNIPXLα and BNIPXLβ mRNA transcripts. Amplification of BNIPXL plasmid 
controls were used for size comparision while a conserved fragment of the glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) housekeeping gene was included for normalization 
of samples. Results are representative of at least two separate determinations.  
 Human brain, kidney and liver cDNA libraries and total RNA isolated from a panel 
of transformed human epithelial cell lines grown in appropriate serum-containing medium 
were used in semi-quantitative RT-PCR as described in ‘Material and Methods’. MCF-7, 
SK-BR3 and MDA-MB-231 are human mammary adenocarcinomas established from 
pleural effusions. The HER2/c-erb-2 gene product is highly expressed in the weakly 
invasive SK-BR3 while MDA-MB-231 is an aggressive and highly metastatic breast 
cancer cell line which overexpresses RhoA and RhoC and exhibits constitutive activation 
of Ras (Kozma et al., 1987) and RhoA (Fritz et al., 1999). MCF-7 is a non-motile cell line 
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that exhibits morphologies resembling that of epithelial cells found in monolayers while 
HeLa is a human cervical carcinoma cell line that adopts a regular cuboidal shape. Both 
are excellent candidates for studying subcellular structures using fluorescence microscopy. 
The human embryonic kidney epithelial cell line HEK293T, is a clonal derivative of 
HEK293 stably expressing the SV40 large T antigen and was used in subsequent 
experiments for expression of epitope-tagged recombinant proteins. These studies were 
carried out to provide insights into the distinct characteristics of these cell lines in relation 
to BNIPXL expression. In all tissues and cell lines examined, both transcripts were present 
with the exception of the human embryonic kidney epithelial cells, HEK293T where only 
the BNIPXLβ isoform was expressed (Figure 3.7).  
 
3.2.1.2. Expression profile of BNIPXL in murine tissues and cell lines 
To better understand the spatial and temporal expression of BNIPXL, we examined 
a series of murine tissues and cell lines (Figure 3.8). Neuro2a is a mouse neuroblastoma 
cell line while PC12 is a well-characterized rat adrenal pheochromocytoma cell line that 
differentiates into neuron-like cells in response to nerve growth factor stimulation. Our 
earlier attempts to amplify murine BNIPXL using the human-specific forward and reverse 
primers were unsuccessful, suggesting that the murine BNIPXL sequence may have 
diverged from its human ortholog at its N-terminus and/or C-terminus end. Mouse and rat-
specific BNIPXL primers were then designed based on partial nucleotide sequences from 
overlapping cosmid clones of the mouse and rat genome. Semi-quantitative RT-PCR 
produced a band of the expected size in the various mouse organs and indicates that murine 









Figure 3.7. (a) The distribution of BNIPXL isoforms in adult human brain, kidney and 
liver cDNA libraries and (b) various human cell lines was examined by semi-quantitative 
PCR using primers pairs to amplify full-length (first panel) and BCH domain (second 
panel), as indicated by the forward (F) and reverse (R) arrows in Figure 3.2. BNIPXL 
plasmid controls and GAPDH expression was analyzed for size comparison and sample 
normalization, respectively. M, markers. 
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Figure 3.8. (a) The distribution of BNIPXL in (a) mouse organs and (b) various murine or 
rat cell lines was examined by semi-quantitative PCR using mouse- and rat specific 
primers pairs for full-length BNIPXL amplification. PC12 cells were maintained in serum, 
starved for 16 h in 0.5% serum-containing growth media or stimulated for 4 h with 
50ng/ml NGF following starvation. BNIPXL plasmid controls and GAPDH expression 
was analyzed for size comparison and sample normalization, respectively. M, markers.  
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intestines where a weak band was detected (Figure 3.8a). The mouse brain fragment were 
cloned into pGEMT-Easy vector and partial sequencing performed in both directions to 
confirm its identity. Sequence analyses confirm that the N- and C-terminus of murine 
BNIPXL are significantly different from human BNIPXL while pairwise alignments of 
mouse and rat BNIPXL indicate sequence homology at their C-terminus but not at the N-
terminus.   
 The expression profile of mouse BNIPXL is unlike that of human BNIPXL which 
is detected in various tissues. Similarly, the RT-PCR expression profile of KIAA0367 in 
various human tissues (http://www.kazusa.or.jp/huge/gfimage/rt-
pcr/html/KIAA0367.html) using primers corresponding to the 3’UTR region indicates that 
KIAA0367 is expressed in most of the human tissues examined except the heart, pancreas, 
spleen and thymus which show low or no detectable levels of expression. This suggests 
that expression of this gene locus in mouse may be differentially regulated in contrast to its 
human orthologs. An indication that mouse BNIPXL may be subjected to alternative RNA 
splicing comes from the observation of doublet bands in the mouse brain sample (Figure 
3.8b). BNIPXL was highly expressed in Neuro2a and PC12 cells and to a lesser extent, in 
the mouse fibroblast cell line, NIH3T3. We note BNIPXL expression in PC12 is highest 
when maintained in serum as compared to starved cells whilst nerve growth factor (NGF) 
induction alone is not sufficient to restore its expression to comparative levels.   
 During the course of thesis amendments, an article reporting the isolation and 
characterization of another novel BCH domain-containing protein designated BCH motif-
containing molecule at the carboxyl terminal region 1 (BMCC1) was published (Machida 
et al., 2005). Intriguingly, real-time RT-PCR indicates that favorable primary 
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neuroblastomas (NBL) exhibit increased expression of BMCC1. In addition, the authors 
observe increased apoptosis in the superior cervical (SCG) neurons derived from BMCC1 
transgenic mice upon the withdrawal of nerve growth factor (NGF) stimulation. 
Collectively, these findings led the authors to conclude that increased expression of the 
pro-apoptotic BMCC1 correlates to favorable prognosis in childhood NBLs.  
 Interestingly, full-length BNIPXL shares 98.6% amino acid identity to BMCC1 at 
its C-terminus suggesting that BMCC1 may be an extended isoform of BNIPXL and a 
product of alternative RNA splicing (Figure 3.9). Alternatively, this also suggests that 
BNIPXL may be a severely truncated form of BMCC1 since we are unable to identify an 
in-frame stop codon upstream of the BNIPXL translation initiation start site. Furthermore, 
Northern blot analysis indicates the expression of a 12kb mRNA transcript in human fetal 
brain which correlates to an expected size of 350kDa for BMCC1 (Machida et al., 2005).  
 However, the authors have not addressed if this 12kb species is also the only 
transcript present in other human organs. We note that the BMCC1-specific antibodies 
used in the paper failed to detect endogenous BMCC1 in the human embryonic kidney 
epithelial (HEK293) cell line while expression profiling of BMCC1 in multiple human 
tissues indicates that it is expressed in almost all the tissues surveyed including the kidney. 
Closer examination revealed that the primers used for amplification lie in the N-terminal 
region of the BNIPXL nucleotide sequence suggesting that different tissues may express 
various splicing isoforms of this gene that may or may not be recognized by the BMCC1-
specific peptide antibodies (Figure 3.2). Furthermore, the in vitro assembly of individual 
PCR- amplified exons into a full-length BMCC1 cDNA construct masks any potential 
alternative RNA splicing mechanisms that may regulate endogenous expression. In order  
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Figure 3.9.  Schematic diagram showing pairwise alignments between BNIPXL, BMCC1 





to address these questions, we sought to determine if BNIPXL is indeed an independent 
isoform using antibodies raised against BMCC1 in endogenous western blot analyses. 
However, the N- and C-terminus BMCC1 antibodies used in the paper correspond to 
residues 993-1022 and 1378-1402, respectively and are absent in BNIPXL. At the time of 
thesis re-submission, we are still waiting for the distal C-terminus BMCC1 antibodies 
corresponding to residues 2180-2209 and 2693-2714. In the absence of appropriate 
BMCC1 antibodies, we have utilized the designated primers for diagnostic RT-PCR in an 
attempt to clarify these discrepancies at the cDNA level (Figure 3.10). We were able to 
amplify the overlapping ~2.4kb fragments flanked by the XFL-1/XR (lanes 9, 14) and 
BMCCHF2/BMCC1R1 primers (lanes 10, 15) in HEK293T and HeLa cDNA but failed to 
amplify the ~4kb fragment flanked by the BMCCHF2/XR primers in HeLa (lane 16). 
Interestingly, we did not detect the ~4kb fragment in the BMCC1 plasmid control (lane 3). 
In addition, we observed a faint ~4kb fragment amplified in the HEK293T sample. We are 
currently sequencing the BMCC1 plasmid and cloning the ~4kb fragment for further 
clarification. Our results suggest that different splicing isoforms may be present in the two 
cDNA samples used. 
 
3.2.2. Domain architecture of BNIPXL constructs  
 To characterize the well-conserved BCH domain of this novel BNIP-2 family 
member, a series of BNIPXL fragments comprising the full-length, N-terminus and C-
terminus protein fragments (Figure 3.11) was FLAG epitope-tagged and transiently 
expressed in HEK293T cells. The C-terminus fragments starting from residue 440 
encompass most of the BNIP-2 sequence having ~67% amino acid identity. Western blot  
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Figure 3.10. (a) Location of various primers used for diagnostic RT-PCR on BNIPXL and 
BMCC1. (b) Diagnostic RT-PCR using primers pairs as indicated. Plasmid controls and 
GAPDH expression was analyzed for size comparison and sample normalization, 










Figure 3.11. Schematic diagram of BNIPXL fragments used in subsequent protein 
interaction studies. FLα and FLβ (full length, residues 1-769 and 1-732, respectively); 
WBCH (N-terminus without BCH, residues 1-599); NBCH (N-terminus without CBCH, 
residues 1-554); Cα and Cβ (C-terminus, residues 440-769 and 440-732, respectively); 
CBCHα and CBCHβ (C-terminus containing BCH, residues 555-769 and 555-732, 
respectively). The BCH domain is shaded black (66.9% identity with BNIP-2) while the 
region shaded gray is conserved in BNIP-2 (45.4% identity with BNIP-2). All numbers are 
inclusive. 
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analyses revealed that each construct was well-expressed as a fusion protein, but each was 
larger than the expected size with the size disparity more augmented in the N-terminal 
constructs (Figure 3.12). Full length BNIPXL is expected to yield a protein of ~ 80kDa. 
However, it co-migrates with the 120kDa band on the protein ladder indicating that 
BNIPXL may undergo post-translational modifications that contribute to this disparity in 
size or that this could be due to abnormal charge distribution. It was also noted that the 
larger full-length and N-terminus constructs were susceptible to proteolytic degradation in 
the course of sample processing as observed by the non-specific bands in Figure 3.12 
(lanes 1-4, red arrow). Since these bands (~45kDa) were detected by the FLAG antibody, 
this suggests that the region susceptible to cleavage lies near the N-terminus of BNIPXL. 
 
3.2.3. BNIPXL contains a functional protein-protein interaction domain  
In light of our previous reports that demonstrate the importance of the BCH domain 
in mediating protein-protein interactions in the BNIP-2 family, we investigated the 
functions of the BCH domain in BNIPXL in vivo and in vitro. 
 
3.2.3.1. BNIPXL isoforms form homophilic complexes via the BCH domain in vivo  
HEK293T cell lysates co-expressing various HA epitope-tagged BNIPXL 
fragments and FLAG epitope-tagged full-length BNIPXL were subjected to 
immunopreicitation with mouse anti-FLAG®M2 beads. Bound proteins were resolved in 
SDS-PAGE and subjected to western blot analyses as described under ‘Materials and 
Methods’. Both BNIPXL isoforms can form homophilic complexes requiring their 








Figure 3.12. Various FLAG epitope-tagged BNIPXL fragments were transfected into 
HEK293T cells and analyzed for their expression by anti-FLAG immunoblot (IB) analysis. 
The size of the protein fragments are indicated on the left. The larger BNIPXL fragments 
are susceptible to degradation (lanes 1-4, red arrow). A series of HA epitope-tagged 









Figure 3.13. BNIPXLα forms homophilic associations with itself via the BCH domain. 
HEK293T cell lysates expressing both FLAG-tagged full-length BNIPXLα and HA-tagged 
BNIPXL fragments were immunoprecipitated (IP) with anti-FLAG antibody beads 
conjugate. Bound proteins were detected with anti-HA immunoblot (IB) (lanes 5-8; first 
and third panels). Expression of transfected proteins was verified by anti-HA (lanes 1-4; 
first and third panels) or anti-FLAG (lanes 1-4; second and fourth panels) western analyses 
of whole cell lysates (WCL), respectively. Blots was stripped and re-probed with anti-
FLAG antibody to show amounts of precipitated proteins (lanes 5-8; second and fourth 
panels). Arrows indicate non-specific bands. 
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Figure 3.14. BNIPXLβ forms homophilic associations with itself via the BCH domain. 
Immunoprecipitation of HEK293T cell lysates expressing both FLAG-tagged full-length 
BNIPXLβ and HA-tagged BNIPXL fragments with anti-FLAG antibody beads conjugate. 
Bound proteins were detected with anti-HA immunoblot (lanes 5-8; first and third panels). 
Expression of transfected proteins was verified by anti-HA (lanes 1-4; first and third 
panels) or anti-FLAG (lanes 1-4; second and fourth panels) western analyses of whole cell 
lysates (WCL), respectively. Blots was stripped and re-probed with anti-FLAG antibody to 
show amounts of precipitated proteins (lanes 5-8; second and fourth panels). 
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containing the BCH domain could be detected in the IP lanes. Results from these initial 
binding experiments strongly indicate that BNIPXL may also bind other BCH domain-
containing proteins in a similar manner forming heterophilic complexes. 
 
3.2.3.2.BNIPXL associates with BNIP-2 and p50-RhoGAP in vivo  
 To test our hypothesis that BNIPXL may form heterophilic complexes with other 
BCH domain-containing proteins, FLAG epitope-tagged BNIP-2 or p50-RhoGAP was co-
expressed with HA epitope-tagged BNIPXL fragments in HEK293T cells and lysates were 
subjected to immunoprecipitation as previously described (Figures 3.15 and 3.16). We 
demonstrate that full-length BNIP-2 and p50-RhoGAP can precipitate full-length BNIPXL 
in vivo and this was primarily mediated by the C-terminus BCH domain of BNIPXL and 
not by the other regions of the protein. The apparent homophilic and heterophilic 
interactions between BNIPXL with itself, BNIP-2 or p50-RhoGAP was mediated by the 
BCH domain and is deemed specific because all other BNIPXL fragments without the 
BCH domain failed to bind to these protein targets under the experimental conditions. 
These findings are therefore consistent with previous observations that the BCH domain 
mediates target protein binding in other BCH domain-containing BNIP-2 family members 
(Low et al., 2000a; Zhou et al., 2002), and the BPGAP family proteins (Shang et al., 
2003).  
 
3.2.3.3.BNIPXL directly associates with its target proteins  
 For all binding experiments described previously, both BNIPXL and the candidate  




             
 
 
Figure 3.15. The BNIPXL BCH domain mediates protein-protein interaction with other 
BCH domain-containing proteins in vivo.  FLAG-tagged BNIP-2 and HA-tagged BNIPXL 
fragments were immunoprecipitated with anti-FLAG antibody beads conjugate. Bound 
proteins were detected with anti-HA immunoblot (lanes 5-8; first and third panels). 
Expression of transfected proteins was verified by anti-HA (lanes 1-4; first and third 
panels) or anti-FLAG (lanes 1-4; second and fourth panels) western analyses of whole cell 
lysates (WCL), respectively. Blots was stripped and re-probed with anti-FLAG antibody to 




        
 
 
Figure 3.16. BNIPXL forms heteromeric complexes with p50-RhoGAP via the BCH 
domain. HEK293T cell lysates expressing FLAG-tagged p50-RhoGAP and various HA 
epitope-tagged BNIPXL domains were immunoprecipitated with anti-FLAG antibody 
beads conjugate. Bound proteins were detected with anti-HA immunoblot (lanes 5-8; first 
and third panels). Expression of transfected proteins was verified by anti-HA (lanes 1-4; 
first and third panels) or anti-FLAG (lanes 1-4; second and fourth panels) western analyses 
of whole cell lysates (WCL), respectively. Blots was stripped and re-probed with anti-
FLAG antibody to show amounts of precipitated proteins (lanes 5-8; second and fourth 
panels). Arrows indicate non-specific bands. 
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present in great excess. Associations between these molecules are most likely to be direct 
since large protein amounts were precipitated indicating that there are no limiting third 
parties. To verify the direct involvement of BNIPXL in homo- and heterophilic complexes 
in vivo we employed the yeast-two hybrid system. BNIPXLα and BNIPXLβ were fused to 
the yeast GAL4 DNA-binding and activation domains and tested against itself, p50-
RhoGAP and BNIP-2 (Table 5). pAS- BNIP-2 and pACT-p50-RhoGAP binding was used 
as a positive control (Low et al., 2000a). Standard β-galactosidase assays confirmed that 
BNIPXL can directly form homo- and heterodimers in vivo (Figure 3.17). Collectively, 
these results demonstrate that BNIPXL can directly form homo- and heterophilic 
complexes that are mediated by its BCH domain in vivo confirming the notion that the 
BCH domain functions as a protein-protein interaction module within different protein 
contexts. 
 
3.2.4. BNIPXL induces morphological changes in HeLa cells via its BCH domain 
 BNIP-2 and other BCH domain-containing proteins have been shown to elicit cell 
morphological changes by targeting different members of the Rho GTPases. To investigate 
the cellular effects of BNIPXL, full length and various fragments of FLAG-epitope tagged 
BNIPXL were transiently expressed and examined in HeLa, a human cervical carcinoma 
cells using confocal fluorescence microscopy (Figure 3.18). Full-length and fragments 
containing the BCH domain exhibited phenotypes distinct from the surrounding non-
transfected cells and were localized in cytosolic punctate structures; inducing varying cell 
morphological changes dependent on the level of protein expression (Figures 3.18a, 




Table 5. BNIPXL forms direct homophilic and heterophillic interactions with itself and other BCH-domain containing proteins. The 
AH109 yeast strain was transformed, growth/X-gal selection and β-galactosidase assays were performed as described under “Materials 
and Methods”. Gal4 activation domain fusion proteins in the pACT vector included: BNIPXLα, BNIPXLβ, and p50-RhoGAP. Gal4 
DNA-binding domain fusion proteins in the pAS vector included: BNIPXLα, BNIPXLβ, and BNIP-2. O denotes vector alone. A 
positive interaction (+) is scored by colonies that turned blue within 3 h; (-) indicates a negative interaction.  
 
        pACT 
         pAS 
O BNIPXL-FLα BNIPXL-FLβ p50-RhoGAP 
O - - - - 
BNIPXL-FLα - + + + 
BNIPXL-FLβ - + + + 
BNIP-2 - + + + 
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Figure 3.17. The S. cerevisiae AH109 strain was co-transformed with (a) pACT-FLα/pAS-
FLα, pACT-FLα/pAS-FLβ, pACT-FLβ/pAS-FLα and pACT    -FLβ/pAS-FLβ constructs; 
(b) pACT-FLα/pAS-BNIP-2 and pACT-FLβ/pAS-BNIP-2 constructs; (c) pAS-FLα/pACT-
p50-RhoGAP, pAS-FLβ/pACT-p50-RhoGAP and pAS-BNIP-2/pACT-p50-RhoGAP as 
positive control.  Selection was performed on –Leu/-Trp SD agar and five individual 
colonies were re-streaked on –Leu/-Trp/-His SD agar. The corresponding colony lifts for 





Figure 3.18. (a-e) BNIPXL induces cell morphological changes via its BCH domain. HeLa cells expressing FLAG-tagged BNIPXL 
fragments were fixed 24 h post-transfection, permeabilized and stained. FLAG-tagged constructs were detected with a mouse 
monoclonal anti-FLAG antibody followed by FITC-conjugated goat anti-mouse secondary antibody. F-actin was detected using 
TRITC-conjugated phalloidin and visualized by confocal fluorescence microscopy. Arrows indicate membrane protrusions and 




coupled with membrane protrusions with BNIPXL concentrated at the leading edge of 
these protrusions while CBCH fragments exhibited similar protrusions and localization to 
the tips of these protrusions but without marked cell elongation. Conversely, the WBCH 
fragment lacking the BCH domain presented a uniform cytosolic distribution with no 
obvious perturbations in cell morphology when compared to control cells (Figure 3.18c). 
This was confirmed by co-staining transfected cells with TRITC-conjugated phalloidin for 
F-actin which demarcates the intact cuboidal cell border. These phenotypes observed  is 
consistent with previous observations that transiently expressed full length BNIP-2 and 
BPGAP1 can induce similar cell morphological changes in MCF-7 cells (Zhou et al., 
2005a; Shang et al., 2003). In contrast, BNIP-Sα transfected cells exhibited cell rounding, 
a typical hallmark of apoptosis (Zhou et al., 2002). Taken together, these results suggest 
that the BCH domain is necessary for BNIPXL-induced cell morphological changes and 
that homologous BCH domains can cause distinct cell shape perturbations. 
  156
 
3.3. Delineating the molecular mechanisms of BNIPXL-induced morphological 
changes 
 
3.3.1. BNIPXL associates with RhoA in vivo  
To further delineate the molecular mechanisms underlying the BNIPXL-induced 
cell shape changes, we next sought to understand which other proteins it might associate 
with. Our recent reports demonstrate the involvement of BNIP-2 in the modulation of 
Cdc42 signaling pathways via its BCH domain (Zhou et al., 2005a). To this end, we 
attempted to verify the possible involvement of the Rho family small GTPases in the 
observed cell phenotype based on the hypothesis that perturbations in cell shape are likely 
to be the result of actin cytoskeletal remodeling in which Rho GTPases are known to play 
important regulatory roles. Thus, we first determined if BNIPXL could specifically 
associate with members of the Rho GTPase family and then verified if this interaction(s) 
could affect BNIPXL-induced cell shape changes and membrane protrusions in any 
manner. Cells were cotransfected with HA-tagged wild-type RhoA, Cdc42 or Rac1 
together with either FLAG-tagged-BNIPXLα or BNIPXLβ and immunoprecipitations 
performed as described in ‘Materials and Methods’ (Figure 3.19). Both isoforms of 
BNIPXL were found to interact specifically with RhoA but not to Cdc42 or Rac1 in vivo. 
However, we did not readily detect the presence of endogenous RhoA in the complex. This 
implies that their binding may be transient and/or weak. Due to the similar binding profiles 
of both isoforms to candidate proteins tested so far, we decided to utilize BNIPXLβ, the 
shorter variant in all our subsequent experiments. 
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Figure 3.19. BNIPXL interacts specifically with RhoA in vivo. Co-expression of FLAG-
tagged BNIPXL with vector control or HA-tagged RhoA, Cdc42 or Rac1 were subjected to 
immunoprecipitation and bound proteins detected in anti-HA westerns (lanes 5-8, upper 
panels). Expression of transfected proteins was verified by westerns using anti-HA for 
GTPases (lanes 1-4, upper panels) or anti-FLAG for BNIPXL (lanes 1-4, middle panels) 
Blots were stripped and re-probed with anti-Rho GTPase antibody (lanes 5-8,  lower 
panels) and  re-probed with anti-FLAG antibody to show the amounts of precipitated 
proteins (lanes 5-8, middle panel). Arrows indicate light chain from antibody. 
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3.3.2. The BNIPXL BCH domain directly interacts with RhoA  
 To verify that BNIPXL-RhoA associations in vivo are direct, we subjected in vitro 
transcribed and translated FLAG-tagged BNIPXL to in vitro GST-fusion pull down assays 
with GST-RhoA. FLAG-tagged BNIPXL fragments produced in vitro was incubated with 
equal amounts of bacterially-produced GST or GST-RhoA and the bound proteins were 
then subjected to western blot analyses. Our results indicate that the CBCH fragment forms 
direct and strong interactions with RhoA (Figure 3.20). The requirement for longer 
exposure times is indicative that full-length BNIPXL-RhoA interactions may occur at 
much lower relative affinities in vitro. However, this claim has yet to be substantiated by 
quantitative measurements. These observations suggest that the presence of the N-terminus 
in full-length BNIPXL interferes with BNIPXL-RhoA interactions mediated by the CBCH 
domain.  
 
3.3.3. Delineating the RhoA-binding region in BNIPXL  
 Our next question was whether RhoA binding had any influence on BNIPXL-
induced cell shape changes. To answer this, we had to define the region that was 
responsible for mediating RhoA binding. Our recent finding indicates that BNIP-Sα 
contains a RhoA Binding Region (RBR) from residues 133-177 which lie within its BCH 
domain (Zhou et al., 2005b). Consistent with these findings, multiple sequence alignments 
of class I Rho-binding motifs found in several RhoA effectors (Fujisawa et al., 1998) and 
the BNIP-S Rho binding domain (RBD) (residues 148-177) suggests that the proximal 






Figure 3.20. BNIPXL directly interacts with RhoA. In vitro transcribed and translated 
FLAG-tagged BNIPXL fragments (a) were incubated with equal amounts of bacterially-
produced GST or GST-RhoA and the bound proteins were then subjected to western blot 
analyses using anti-FLAG antibody (b). Membranes were subjected to short (30 secs) and 
longer exposure (1 hr) times. Blots were then stained with amido-black to ascertain equal 
loading of GST fusion proteins in the in vitro pull-down assay. The integrity of GST fusion 
proteins was previously affirmed by checking their migration profiles on Commassie-blue 




3.3.4. Domain architecture of BNIPXL deletion constructs    
 Having identified the potential region for RhoA binding in silico, a sequential 
series of internal deletions within the BCH domain was generated based on the predicted 
secondary structure of the BNIPXLβ BCH domain. Using Jpred 
(http://www.compbio.dundee.ac.uk/~www-jpred/), residues outside the putative α-helices 
were chosen to define the different deletion regions to minimize the possibility of 
disrupting the BNIPXL conformational folds (Figure 3.22). The FLAG-epitope tagged 
deletion mutants were designated: U0, U1, U2, U3 and U4 was used in subsequent 
experiments (Figure 3.23). 
 
3.3.5. A full composite BCH domain is necessary for RhoA association 
 Cells were co-transfected with the FLAG-tagged BNIPXLβ deletions and HA-
tagged wild-type RhoA and subjected to immunoprecipitation as described previously 
(Figure 3.24). Interestingly, all five deletions failed to interact with wild-type RhoA 
suggesting that multiple motifs within the BCH domain are required for RhoA binding. We 
argued that deleting these regions within the BCH domain could have potentially destroyed 
the structural integrity of the protein. To confirm the structural integrity of the BNIPXLβ 
deletion mutants, the FLAG-tagged constructs were subjected to similar 
immunoprecipitation experiments with wild-type HA-tagged BNIPXLα and BNIPXLβ 
(Figure 3.25). All constructs retained their ability to associate with both wild-type 
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Figure 3.21. Multiple sequence alignments of BNIPXLβ, the BNIP-Sα RBR and Class I 
Rho binding motifs from RhoA effectors proteins using the Vector NTI Suite. Residues 
that are identical in all members are shaded black, those that are conserved in most of the 





                     
 
 
Figure 3.22. Secondary structure prediction of the BNIPXLβ BCH domain using Jpred 
(http://www.compbio.dundee.ac.uk/~www-jpred/). Arrows indicate the boundaries of the 
deletions. 
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Figure 3.23. Schematic diagram of BNIPXLβ deletion mutants constructs: BNIPXLβU0 
(U600-616 amino acids), BNIPXLβU1 (U617-655 amino acids), BNIPXLβU2 (U656-
684 amino acids), BNIPXLβU3 (U685-717 amino acids) and BNIPXLβU4 (U718-
U732 amino acids); were all tagged with FLAG-epitope for subsequent experiments. All 











Figure 3.24. The full composite BCH domain is required for RhoA binding. HEK293T 
lysates expressing HA-tagged wild type RhoA and different FLAG-BNIPXL fragments 
were subjected to immunoprecipitation and processed as previously described.  Expression 
of transfected proteins was verified by anti-HA (third panel) or anti-FLAG (fourth panel) 
western analyses of whole cell lysates (WCL), respectively. Blots were probed with 
polyclonal anti-RhoA antibody (first panel); stripped and probed with anti-FLAG antibody 











Figure 3.25. The BNIPXL deletion mutants are structurally intact. HEK293T lysates 
expressing HA-tagged wild type BNIPXLα or BNIPXLβ and different FLAG-BNIPXL 
fragments were subjected to immunoprecipitation and processed as previously described. 
Expression of transfected proteins was verified by anti-HA (third panel) or anti-FLAG 
(fourth panel) western analyses of whole cell lysates (WCL), respectively. Blots were 
probed with polyclonal anti-HA antibody (first panel); stripped and probed with anti-
FLAG antibody to show amounts of precipitated proteins (second panel).   
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mutants possess an intact conformation and indicates that a full composite BCH domain is 
essential for RhoA association in vivo. The results also demonstrate that BNIPXL utilizes 
multiple regions within its BCH domain for homo- and heterophilic interactions unlike 
BNIP-2 and BNIP-S. 
 
3.3.6. BNIPXL interacts with RhoA in vitro in a conformation-dependent manner 
To investigate the nature of BNIPXL associations with RhoA, we employed an in 
vitro GST-fusion pull down assays. Our aim was to determine if BNIPXL had any binding 
preference to RhoA in a nucleotide-dependent manner. Cells were transiently transfected 
with various fragments of FLAG-tagged BNIPXLβ or Myc-tagged p160ROCK. The 
p160ROCK, first purified as a GTP-RhoA binding protein using a ligand overlay assay 
(Ishizaki et al., 1996), was used as the positive control for GST-RhoA nucleotide loading 
as previously described (Peck et al., 2002). Lysates were pooled and then divided into 
three equal portions and subjected to a pull-down experiment with equal amounts of GST-
RhoA that was either preloaded with GDP or GTPγS (a nonhydrolyzable analogue of GTP) 
or not loaded with either nucleotide. The bound proteins were then subjected to western 
blot analyses.  
 Our results indicate that GST-RhoA binds to the CBCH fragment but failed to 
precipitate full length BNIPXL and the WBCH fragments in vitro (Figure 3.26). This is 
similar to that observed in the direct binding assays. Comparatively, the CBCH fragment 
preferentially binds to nucleotide-free and GTPγS-RhoA but weakly to GDP-bound RhoA. 
These results indicate that BNIPXL can interact with RhoA regardless of its guanine 






         
 
            
 
 
Figure 3.26. BNIPXLβ interacts with RhoA independent of its nucleotide-binding status. 
HEK293T lysates expressing FLAG-tagged BNIPXL fragments were incubated with GST-
RhoA, RhoA preloaded with GDP or GTPγS as indicated. Bound proteins and whole cell 
lysate input were analyzed by immunoblotting with anti-FLAG polyclonal or anti-Myc 
monoclonal antibodies followed by Amido-black staining to ascertain equal loading of 
GST fusion proteins used for the in vitro pull-down assay. The integrity of GST fusion 




RhoA suggests that BNIPXL may exert a regulatory effect on RhoA. 
 
3.3.7. BNIPXL interacts with dominant negative RhoA in vivo 
 To understand the implications of the BNIPXL-RhoA interactions in vivo, we 
examined BNIPXL interactions with the RhoA(G14V) (constitutive active) and 
RhoA(T19N) (dominant negative) P-loop mutants. Interestingly, our results indicate that 
BNIPXL preferentially binds to wild-type RhoA compared to the RhoA(T19N) mutant 
while BNIPXL-RhoA interactions were completely abolished with the RhoA(G14V) 
mutant (Figure 3.27). This appears to contradict our previous in vitro results which 
indicate BNIPXL preferences for unloaded and GTP-bound RhoA. However, it could also 
be an indication that the glycine residue and the P-loop region of RhoA are important for 
its association with BNIPXL. A recent survey of the RhoA structural motifs indicate that 
the P-loop region (residues 12-19) may mediate effector binding in addition to GAP 
recognition (Dvorsky and Ahmadian, 2004). These results suggest that BNIPXL could 
regulate RhoA/effector interactions via its ability to discriminate conformational changes 
associated with nucleotide binding. 
 In addition, we note that RhoA(G14V) and RhoA(T19N) appear to have different 
migratory profiles compared to wild-type RhoA. To ensure that this migratory pattern is 
not the result of spontaneous nucleotide mutations, we have sequenced and confirmed the 
integrity of all three constructs. This indicates that the differential migratory profile is 
likely to be an intrinsic anomaly arising from post-translational modifications of these 
mutants. Similarly, such differential migratory patterns have been observed in other RhoA 




               
 
Figure 3.27. BNIPXL interacts with dominant negative RhoA (T19N) but not with 
constitutive active RhoA(G14V) in vivo. Co-expression of FLAG-tagged BNIPXL with 
vector control (lanes 1 and 5) or HA-tagged RhoA wild-type, dominant active (G14V) or 
negative (T19N) mutants were subjected to immunoprecipitation and bound proteins 
detected in anti-HA westerns (first panel). Blots were re-probed with anti-RhoA antibody 
(second panel) and re-probed with anti-FLAG antibody to show the amounts of 
precipitated proteins (third panel). Expression of transfected proteins was verified using 
anti-HA for RhoA (fourth panel) or anti-FLAG for BNIPXL (fifth panel). Arrows indicate 




3.3.8. BNIPXL interacts with specific constitutive active RhoA mutants in vivo 
  To further investigate the nature of BNIPXL-RhoA interactions in vivo, we 
examined BNIPXL interactions with other RhoA constitutive active mutants. The 
RhoA(F30L) and RhoA(Q63L) mutants have single amino acid substitutions in the switch 
I (residues 29-42) and switch II (residues 62-68) regions, respectively. Like the 
RhoA(G14V) mutant, these mutants result in a net increase of active RhoA when 
introduced into cells. However, these phenotypes are the result of distinct mechanisms. 
The RhoA(F30L) mutant is spontaneously activated and exhibits enhanced intrinsic 
guanine nucleotide exchange from GDP to GTP while retaining normal GTP hydrolysis 
rates catalyzed by GAP proteins (Lin et al., 1999). RhoA(G14V) and (Q63L) are mutants 
locked in the GTP-bound active conformation as the residues necessary for GAP 
recognition have been mutated (Khosravi-Far et al., 1995).  
 Interestingly, our results indicate that BNIPXL associates with the ‘fast-cycling’ 
RhoA(F30L) mutant but fails to bind RhoA(Q63L) (Figure 3.28a). The binding profile is 
similar when the CBCH fragment is utilized in co-immunoprecipitation studies (Figure 
3.29a). In contrast, the WBCH fragment of BNIPXL fails to associate with any RhoA 
constructs (Figure 3.29b). Collectively, these results demonstrate that BNIPXL exhibits 
selective preference for different RhoA mutants via its CBCH fragment and suggests that 
the RhoA glycine14 and glutamine63 residues may be important for BNIPXL-RhoA 
association. To clarify the apparent size difference between wild-type RhoA and 







Figure 3.28. BNIPXL interacts specifically with the RhoA(F30L) fast-cycling mutant but 
not with other constitutive active mutants in vivo. Lysates co-expressing FLAG-tagged 
full-length BNIPXL fragments (a) with vector control or HA-tagged RhoA wild-type, 
dominant active (G14V), (Q63L) and (F30L) and dominant negative (T19N) mutants were 
subjected to immunoprecipitation and bound proteins detected in anti-RhoA westerns (first 
panel). Blots were re-probed with anti-FLAG antibody to show the amounts of precipitated 
proteins (second panel). Expression of transfected proteins was verified using anti-RhoA 
for RhoA (third panel) or anti-FLAG for BNIPXL (fourth panel). Arrows indicate light 
chain from antibody. (b) same as (a) with the exception that HA-tagged dominant active 










Figure 3.29. The BNIPXL CBCH fragment is responsible for RhoA interactions observed 
with full-length BNIPXL in vivo. Lysates co-expressing FLAG-tagged BNIPXL (a) CBCH 
and (b) WBCH fragments with vector control or HA-tagged RhoA wild-type, dominant 
active (G14V), (Q63L) and (F30L) and dominant negative (T19N) mutants were subjected 
to immunoprecipitation and bound proteins detected in anti-RhoA westerns (first panel). 
Blots were re-probed with anti-FLAG antibody to show the amounts of precipitated 
proteins (second panel). Expression of transfected proteins was verified using anti-RhoA 
for RhoA (third panel) or anti-FLAG for BNIPXL (fourth panel). Arrows indicate light 
chain from antibody. 
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(T19N) mutants were used for immunoprecipitation with BNIPXL (Figure 3.28b). Our 
results indicate that these RhoA mutants exhibit a similar migratory and binding profile 
with BNIPXL.  
 
3.3.9. BNIPXL reduces active wild-type RhoA and RhoA(F30L) levels in vitro   
 To examine the effects of BNIPXL-RhoA interactions in vivo, we performed in 
vitro Rho activity assays with GST fusion of Rhotekin-RBD to determine the levels of 
active RhoA (Figure 3.30). Our results indicate that full-length BNIPXL could effectively 
reduce the levels of active wild-type RhoA in vitro whereas BNIPXL deletion mutants that 
fail to associate with RhoA has no apparent effect. A similar reduction was observed for 
cells co-expressing BNIPXL and RhoA(F30L) albeit to a lesser extent. This is in contrast 
to cells co-expressing BNIPXL and RhoA(Q63L) where wild-type or mutant BNIPXL had 
no apparent effect on active RhoA levels in vitro. Taken together, these results indicate that 
















Figure 3.30.  BNIPXL reduces active wild-type RhoA and RhoA(F30L) levels in vitro. 
Lysates expressing wildtype RhoA, RhoA(Q63L), RhoA(F30L) and RhoA(T19N) mutants 
were incubated with GST or GST-RBD (A) to confirm specificity of GST-RBD for active 
RhoA. Lysates co-expressing wildtype RhoA (B), RhoA(Q63L) (C) or RhoA(F30L) (D) 
with vector control or FLAG-tagged wildtype BNIPXL and deletions were incubated with 
GST-RBD as described in ‘Materials and Methods’. Bound proteins and whole cell lysate 
input was analyzed using anti-RhoA (first and third panel) or anti-FLAG for BNIPXL 
(fourth panel). Amido-black staining was used to ascertain equal loading of GST fusion 
proteins. The integrity of GST fusion proteins was previously affirmed by checking their 
migration profiles on Commassie-blue stained gels. 
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3.4. Investigating the effects of BNIPXL and RhoA in vivo 
3.4.1. Loss of individual motifs within the BCH domain affects cell phenotype  
We next asked whether the BNIPXL deletions had any visible effects on its ability 
to induce cell morphological changes. To determine this, FLAG-tagged BNIPXLβ 
deletions were transiently expressed in HeLa cells and observed using confocal fluroscence 
microscopy (Figure 3.31). These mutants did not induce any apparent cell shape change 
when compared to wild-type BNIPXL although they were expressed at a level comparable 
to wild type BNIPXL. However, the U2 deletion appears to induce subtle cell elongation 
when compared to untransfected cells in the vicnity. Generally, the cells presented a 
uniform cytosolic distribution similar to that exhibited by the WBCH construct (Figure 
3.18c) which correlates with their deficiency in RhoA binding. These observations suggest 
that a full composite of BCH domain is not only necessary for RhoA association but also 
for the induction of BNIPXL-induced morphological changes. In addition, these results 
also indicate that cell morphological changes elicited by BNIPXL are independent of 
protein dimerization.  
 
3.4.2. BNIPXL potentiates protrusive phenotype during RhoA downregulation but is    
inhibited by constitutive active RhoA pathway 
 To better understand the cellular effects of RhoA on BNIPXL, we examined MCF-
7 cells co-expressing BNIPXL and RhoA dominant active or negative mutants (Figure 
3.32). Confocal fluorescence microscopy revealed that cells expressing BNIPXLβ and 
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Figure 3.31. BNIPXL deletions do not induce any apparent cell shape change. (a-f) HeLa cells expressing FLAG-tagged BNIPXLβ 
deletion constructs was fixed, permeablized and stained with a mouse monoclonal anti-FLAG antibody followed by FITC-conjugated 
goat anti-mouse antibody. F-actin was detected using TRITC-conjugated phalloidin and visualized by confocal fluorescence 
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Figure 3.32. BNIPXL potentiates cell morphology associated with RhoA inactivation. (a-c) MCF-7 cells expressing FLAG-tagged 
BNIPXLβ and HA-tagged wild-type, dominant active (G14V) or negative (T19N) RhoA were fixed, permeabilized and stained using 
a mouse monoclonal anti-FLAG antibody and rabbit polyclonal anti-HA antibody followed by FITC-conjugated goat anti-mouse 
antibody and Pacific Blue-conjugated goat anti-rabbit antibody. F-actin was detected using TRITC-conjugated phalloidin and 
visualized by confocal fluorescent microscopy. Bottom right, merged image of overexpressed FLAG-tagged BNIPXLβ (green), HA-





cell rounding and accompanying reduction in cell area with increase in actin stress fibers, 
as detected by the distinct phalloidin staining (Figures 3.32a and 3.32b). This was also 
observed in control cells expressing wild-type RhoA and RhoA(G14V) alone (Figure 
3.33). Furthermore, when compared to singly transfected cells in the same field or RhoA 
controls, no extended protrusions or cell elongation was found although thin spikes were 
observed at their periphery (arrows). These observations are consistent with reports that 
constitutively active Rho induces a retracted cell shape (Buchsbaum et al., 1996; Shang et 
al., 2003). Furthermore, inactivation of Rho has been shown to be associated with the 
formation of protrusions at the cell periphery (Hirose et al., 1998; Tatsis et al., 1998; 
Shang et al., 2003). Interestingly, cells co-expressing BNIPXLβ and dominant negative 
RhoA exhibit protrusions from the main cell body accompanied by more extensive 
filopodia-like extensions branching from the periphery of the proximal protrusions (Figure 
3.32c, arrowheads). The drastic phenotype suggests that down-regulation of RhoA in vivo 
could enhance BNIPXL-induced cell morphological changes. Recent reports that siRNA-
mediated knockdown of RhoA in MCF-7 results in cells exhibiting an elongated phenotype 
with large lamellipodia, a drastic reduction of cell to cell contact coupled with an enhanced 
migratory ability in this relatively non-motile cell line (Simpson et al., 2004). These 








         
 
 
Figure 3.33. Expression of wild-type RhoA and mutants alone is not sufficient to induce 
drastic changes in cell morphology. MCF-7 cells expressing HA-tagged wild-type, 
dominant active (G14V) or negative (T19N) RhoA were fixed, permeabilized and stained 
using a rabbit polyclonal anti-HA antibody followed by Pacific Blue-conjugated goat anti-
rabbit antibody. F-actin was detected using TRITC-conjugated phalloidin and visualized 
by confocal fluorescent microscopy. Bottom panel; merged image of HA-tagged RhoA 
(blue) and actin (red). Thin spikes (arrows) are indicated. Scale bars, 50μm. 
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3.4.3. A requirement for active Cdc42/Rac1 signaling pathways in BNIPXL-induced 
morphological changes 
Our current observations coupled with the fact that Cdc42/Rac1 activation can 
induce cell protrusions led to the hypothesis that BNIPXL-induced cell shape changes may 
require the interplay of various Rho GTPase signaling. RhoA inactivation may require the 
concomitant activation of Cdc42/Rac1 signaling pathways or vice versa for coordination of 
cell dynamics required for cell shape changes (Sander et al., 1999; Zondag et al., 2000). 
To address the question if BNIPXL could indirectly cause the activation of Cdc42/Rac1 
pathways, we examined the effect of the PAK-CRIB domain on BNIPXLβ-induced cell 
phenotype (Figure 3.34). This domain alone serves as a dominant negative mutant by 
sequestering all endogenous active Cdc42 and Rac1. This prevents activation of their 
downstream effectors, including PAK which mediates Cdc42 effect on morphological 
changes (Price et al., 1998; Sells et al., 1997; Kazuhiro et al., 1997; Zhou et al,, 2005b). 
Interestingly, cells expressing both BNIPXLβ and the CRIB domain exhibited 
morphologies similar to that of the BNIPXL deletion mutants with well-defined cell 
borders and no cell elongation and membrane protrusions. This suggests that BNIPXL-







                                                    
 
 
Figure 3.34. BNIPXL-induced cell morphological changes require involvement of Cdc/Rac1 effector pathways. MCF-7 cells 
expressing HA-tagged BNIPXLβ and FLAG-tagged PAK-CRIB were fixed, permeabilized and stained using a rabbit polyclonal anti-
HA antibody and mouse monoclonal anti-FLAG antibody followed by FITC-conjugated goat anti-mouse antibody and Pacific Blue-
conjugated goat anti-rabbit antibody. F-actin was detected using TRITC-conjugated phalloidin and visualized by confocal fluorescent 
microscopy. Bottom right, merged image of overexpressed HA-tagged BNIPXLβ (blue), FLAG-tagged PAK-CRIB (green) and actin 








4. Discussion and Conclusions 
4.1. BNIPXL: a novel member of the BNIP-2 family in cell dynamics control 
BNIPXL is a novel member of the BNIP-2 family that plays distinct roles in cell 
dynamics. Our current study provides insights into the structural and biochemical features 
of BNIPXL and their implications in RhoA-mediated cell shape changes. These findings 
highlight the functional significance of homologous BCH domains and the roles of the 
BNIP-2 family in Rho GTPase signaling pathways. 
BNIPXL encompasses most of the prototypic BNIP-2 sequence at the C-terminus 
and based on bioinformatics analyses, the BNIPXL gene is encoded by 13 exons spanning 
~86kbp at the human chromosome 9q21.2. The BNIPXL pre-mRNA undergoes alternative 
RNA splicing to produce two isoforms designated BNIPXLα and BNIPXLβ, indicating 
that different sub-populations of BNIPXL may target different proteins to direct diverse 
cellular events in a spatio-temporal manner. This is consistent with our previous findings 
that BNIP-S isoforms are functionally diverse with the full complement BCH domain 
being required for its pro-apoptotic effects whereas an incomplete BCH domain generated 
during RNA splicing became inert (Zhou et al., 2002). Furthermore, several splice variants 
of the BPGAP family have also been identified and unlike the prototypic BPGAP1, co-
workers demonstrate that BPGAP2 does not appear to cause extensive cell protrusions 
(Shang and Low, unpublished data). Sequence analyses indicate that the β isoforms of both 
BNIP-S and BNIPXL have truncated BCH domains towards the extreme C-terminus. 
Unlike BNIP-Sβ which is generated during intron splicing, BNIPXLβ is the result of an in-
frame stop codon introduced after the exclusion of exons 11 and 12 at the C-terminus. 
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The expression profile of human and murine BNIPXL provides an indication of the 
diversity of BNIPXL function. Reverse-transcription PCR revealed that both BNIPXL 
isoforms were expressed in human brain, kidney and liver and in a panel of breast 
carcinoma cell lines. This indicates that both BNIPXL isoforms may participate in 
epithelial cell dynamics and tissue morphogenesis. This is consistent with our 
bioinformatics analysis which has identified an expressed sequence tag (EST) isolated 
from ovarian carcinoma encoding a putative BNIPXL splice variant lacking the C-terminal 
BCH domain (GenBank™ accession no. AU133997). In addition, the exclusive expression 
of the β isoform in the human embryonic epithelial cell line, HEK293T is intriguing. 
Perhaps, the differential BNIPXL expression may be due to the different cell type origins 
suggesting that BNIPXL may participate in embryonic development. This however, has yet 
to be determined.  
Intriguingly, two recent publications demonstrate that BMCC1 (which shares 
98.6% amino acid identity with BNIPXL at its C-terminus) is up-regulated in 
neuroblastoma patients with favourable prognoses (Machida et al., 2005; Ohira et al., 
2005). The authors attribute the lower mortality rate to increased apoptosis in relation to 
increased BMCC1 expression. We have not been able to determine if BNIPXL is an 
isoform or if it is part of the larger BMCC1 due to the lack of suitable antibodies. Although 
our diagnostic RT-PCR seems to suggest that the region upstream of BNIPXL (~2.4kb) is 
expressed in both HEK293T and HeLa cells, we have not successfully cloned out the entire 
coding region (~8.0kb) of BMCC1 from these cell lines. Thus, it is still likely that this 
gene locus may generate several protein isoforms when translated.  
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Furthermore, the expression profile of BNIPXL in the mouse tissues is similar to 
that of BNIP-H/Caytaxin (Chew and Low, unpublished data), a protein whose loss-of-
function is responsible for the Cayman ataxia, a form of neurological disorder (Bomar et 
al., 2003). Together with phylogenetic analysis which indicates that the BCH domain of 
BNIPXL more closely resembles that of BNIP-H/Caytaxin, these results collectively 
suggest that BNIPXL may play important roles in neuronal cell morphogenesis.  
 
4.1.1. Significance of the BNIPXL domain architecture and functional 
 characterizaton 
 The conserved BCH domain at the C-terminus of BNIPXL distinguishes it as a 
member of the type I family together with BNIP-2, BNIP-S and BNIP-H. Previous studies 
demonstrate that distinct motifs within the BNIP-2 BCH domain mediate Cdc42 
recruitment, catalytic activity and homo- and heterophilic interactions (Low et al., 1999; 
Low et al., 2000a; Low et al., 2000b; Zhou et al., 2005a). Multiple sequence alignments of 
the type I BCH domains indicate the (288)EYV(290) Cdc42 binding motif is unique to 
BNIP-2 while the novel arginine finger (235)RRLRK(239) motif is conserved in BNIPXL 
and other members of the BNIP-2 family. The BNIP-2 dimerization (217)RRKMP(221) 
motif is highly conserved in BNIPXL and BNIP-H except the lysine residue which has 
been substituted with arginine in BNIPXL and BNIP-H to (650)RRRMP(654) and 
(241)RRRMP(245), respectively; while the corresponding sequence in BNIP-S 
(183)RAQVP(187) is less conserved.  
 Protein-protein interaction studies indicate that both BNIPXLα and BNIPXLβ can 
form homo- and heterophilic complexes with the same protein targets in this study thus, 
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the 23 amino acid truncation in the C-terminus of the BNIPXLβ BCH domain does not 
appear to affect homo- or heterophilic complex formation. However, we cannot rule out 
the possibility that other protein targets may bind BNIPXL isoforms differently. In 
addition, these findings are in line with previous work which demonstrates a role for the 
BCH domain in directing complex formation (Low et al., 2000a; Low et al., 2000b; Zhou 
et al., 2002; Shang et al., 2003). Our deletion studies did not successfully map the region 
of the BCH domain responsible for homophilic binding unlike that of BNIP-2 which is 
located in the proximal region of its BCH domain while studies in BNIP-S indicate that the 
lost of the C-terminus region in the β isoform abrogates homo- and heterophilic 
interactions. This suggests that the BCH domain of BNIPXL utilizes multiple motifs to 
direct homophilic associations. 
 Our earlier observations that the N-terminal BNIPXL fragments are prone to 
degradation indicates that this region of BNIPXL may be structurally less stable. 
Furthermore, full length BNIPXL migrated as a ~120 kDa band even though its expected 
size is ~80 kDa (Figure 3.12). This size disparity is augmented in fragments containing the 
N-terminus indicating that this region in BNIPXL may undergo post-translational 
modifications which serve to stabilize its conformation in vivo. This is consistent with our 
findings that the RhoA recruitment to the BNIPXL heterophilic complex is conformation-
dependent and may involve post-translational modifications as discussed in section 4.2.1. 
This may also explain why several attempts to produce stable quantities of the full length 
GST-BNIPXL fusion proteins in E. coli were unsuccessful (data not shown). Thus, the 
yeast two-hybrid system was used to verify that BNIPXL mediates direct protein-protein 
interactions in vivo. Collectively, these findings indicate that the BNIPXL homophilic 
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motif may be employed in a manner dependent on its conformation or surrounding 
sequence. 
 Structurally, dimer formation may increase conformational stability by ensuring 
tighter interaction between the two subunits and the reduction of exposed hydrophobic 
surfaces. In addition, such complex formation may also exert allosteric influence on 
protein conformation thus regulating protein biochemical activity through structural 
adjustments of the active sites (Mei et al., 2005). Molecular modeling of the BNIP-2 BCH 
domain using the Breakpoint cluster region homology (BH) domain of the p85α regulatory 
subunit of PI3K as a structural template indicates that the BCH domain adopts a 
conformation similar to that of the BH domain dimer (Low et al., 2000a) while functional 
characterization demonstrates that the BNIP-2 BCH domain is a non-canonical GAP for 
Cdc42. This is consistent with recent findings which indicate that the BH domain functions 
as a GAP for Rab GTPases (Chamberlain et al., 2004).  
 Biochemically, homo- and heterophilic interactions may represent a mechanism for  
modulating biochemical activity and intensity of cell response. For example, the presence 
of BNIP-2 and p50-RhoGAP results in mutual competition for Cdc42 binding in vitro in a 
nucleotide-independent manner (Low et al., 1999). BNIP-Sα-induced pro-apoptotic events 
requires BCH domain-mediated homophilic interactions (Zhou et al., 2002) which is 
consistent with our recent findings which indicate that different pools of BNIP-S may work 
in concert to sequester p50-RhoGAP while promoting RhoA-mediated apoptosis (Zhou et 
al., 2005b). Collectively, these corresponding structure-function relationships may provide 
insights into the functional roles of BNIPXL given that their BCH domains share ~45%-
75% amino acid similarities (Table 4). 
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Previous studies indicate that BNIP-2, BNIP-S and BPGAP1 direct distinct cellular 
phenotypes that are directly attributed to the BCH domain (Zhou et al., 2005a; Shang et 
al., 2003; Zhou et al., 2002). We observed that BNIPXL expression induced cell 
elongation and was concentrated at the tips of these protrusions while the BCH domain 
was sufficient to elicit similar protrusions and distribution albeit without cell elongation. 
This suggests that BNIPXL-induced cell morphological changes in HeLa requires 
coordinate regulation and confirms the notion that homologous BCH domains can direct 
various aspects of cell dynamics.  
In addition, the BCH domain-containing fragments of BNIPXL were localized in 
cytosolic punctate structures reminiscent of those observed with BNIP-2 (Zhou et al., 
2005a). The BCH domain appears to direct such cytosolic localization of BNIPXL and 
BNIP-2 as fragments lacking this domain exhibited a uniform cytosolic distribution. Thus, 
it is possible that these punctate structures represent membrane vesicles which direct the 
transport of BNIPXL and BNIP-2 to their sites of action at the leading edges of the 
membrane protrusions. These observations are consistent with sequence analyses which 
indicate that BNIPXL encompass most of the BNIP-2 sequence at its C-terminus with 
66.9% amino acid identity between their BCH domains (Figure 3.5). However, unlike 
BNIP-2 which elicits drastic polarized cell elongation, with ‘beads on a string’ appearance 
along these extensions, BNIPXL exhibits more subtle cell elongation and protein 
distribution. Although, it is possible that the BNIPXL N-terminus may attenuate the drastic 
membrane protrusions observed with BNIP-2, this seems unlikely since removal of the N-
terminus did not result in a more drastic morphology.  
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Alternatively, the unique structural motifs in the BNIPXL BCH domain may target 
different small GTPases to confer distinct phenotypes in cell morphogenesis. This is in line 
with our observations that deleting the individual regions within the BNIPXL BCH domain 
completely abrogates cell elongation and protrusions except the U2 mutant which appears 
to induce subtle cell elongation when compared to un-transfected cells. Similarly, co-
workers have established that the full complement of the BCH domain of BNIP-Sα targets 
RhoA activation for cell rounding and apoptosis (Zhou et al., 2005b) whereas BNIP-2 
utilizes different motifs within its BCH domain to modulate the Cdc42 signaling pathway 
(Zhou et al., 2005a). In addition, sequence analyses indicate that the proximal region of the 
BNIPXL BCH domain (residues 615-644) resembles that of the Class I Rho-binding motif 
found in the RhoA effectors PKN, rhophilin and rhotekin (Figure 3.21). Co-workers have 
recently identified a similar motif in the BNIP-Sα BCH domain and its role in facilitating 
RhoA signaling pathways (Zhou et al., 2005b). Here, we report that BNIPXL targets and 
inactivates RhoA instead and provide insights into the functional significance of this motif 
and its immediate regions in conferring distinct cellular effects for cell morphogenesis, as 
discussed below. 
 
4.2. The role of BNIPXL in Rho GTPase signaling pathways 
4.2.1. Significance of BNIPXL-RhoA associations 
 The striking structural similarities and morphological effects of BNIPXL and 
BNIP-2 collectively indicate that BNIPXL may associate with different members of the 
Rho family in mediating its cellular effects. Interestingly, unlike BNIP-2 which targets 
Cdc42, BNIPXL associates with RhoA and not Rac1 or Cdc42. Conversely, this binding to 
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RhoA was similar to that of BNIP-Sα (Zhou et al., 2005b). Furthermore, both BNIPXLα 
and BNIPXLβ can associate with RhoA which may explain similar effects when expressed 
in HeLa cells. These findings are consistent with multiple sequence alignments (Figure 
3.6) which indicates that the BNIP-2 (285)VPMEYVG(291) motif responsible for Cdc42 
binding is absent from BNIPXL while both BNIPXL and BNIP-S appear to contain a Class 
I Rho-binding motif within their BCH domains. In line with these observations, the loss of 
RhoA binding to BNIPXL deletion mutants correlates with the attenuation of BNIPXL-
induced cell morphological changes and indicates a functional link between RhoA and 
BNIPXL. In addition, our studies demonstrate that BNIPXL dimerization does not directly 
participate in cell shape changes as these deletion mutants retain their homo- and 
heterophilic interactions. However, we cannot exclude the possibility that dimerization 
may be necessary but not sufficient for BNIPXL function and that such interactions may 
play secondary regulatory roles in mediating other functions of BNIPXL. 
 Co-expression of BNIPXL and RhoA(T19N) in MCF-7 cells enhanced the 
BNIPXL-induced morphological changes with an increase in the number of filopodia-like 
protrusions extending from the cell periphery. These observations are consistent with 
Cdc42/Rac-mediated cell morphological changes and indicate that the expression of 
dominant negative RhoA may influence Ccdc42/Rac activation in parallel pathways 
leading to actin cytoskeleton remodelling. These findings are consistent with siRNA-
mediated RhoA knockdown in MCF-7 cells which exhibit an elongated cell phenotype 
with large lamellipodia and an enhanced migratory ability (Simpson et al., 2004) while a 
similar inhibition of RhoA in MDA-MB-231 cells reduced cell proliferation and 
invasiveness both in vivo and in vitro (Pille et al., 2005). In contrast, cells co-expressing 
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BNIPXL and RhoA(G14V) exhibited cell retraction coupled with increased stress fiber 
formation suggesting that constitutive RhoA activation can override BNIPXL-induced cell 
elongation and membrane protrusions. 
 To investigate the functional significance of BNIPXL-RhoA interactions, in vitro 
GTP/GDP loading assays were performed to determine if this association was nucleotide-
dependent. Our findings that the BNIPXL BCH domain has higher affinity for GTPγS-
RhoA than GDP-RhoA, unlike the RhoA effector ROCK, which only associates with the 
active GTP-bound form (Ishizaki et al., 1997) indicates that the BCH domain can adopt 
conformations that aid the discrimination of subtle structural differences between the two 
nucleotide-bound states of the small GTPase. This binding profile is unique to BNIPXL 
and is unlike the BNIP-2 BCH domain which exhibits equal affinities for Cdc42 regardless 
of its nucleotide-binding status (Low et al., 1999). Interestingly, full length BNIPXL failed 
to interact with RhoA in vitro suggesting that in vivo BNIPXL-RhoA interactions may 
involve post-translational modifications and/or a third partner. This is consistent with our 
direct binding assays which indicate that the CBCH fragment forms direct and strong 
interactions with RhoA while full-length BNIPXL-RhoA interactions are not readily 
detected. This suggests that the presence of the N-terminus in full-length BNIPXL may 
have an inhibitory effect on BNIPXL-RhoA interactions. 
 Furthermore, our deletion studies demonstrate that the Rho-binding motif is 
necessary but not sufficient for stable BNIPXL-RhoA interactions. We find that regions 
flanking this motif in the BCH domain contribute to BNIPXL-RhoA interactions possibly 
via allosteric interactions. We have confirmed that the loss of RhoA binding is not the 
result of a general perturbation of protein structure in the BNIPXL mutants since they 
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retained their ability to dimerize with wild-type BNIPXL in vivo. In view of recent reports 
that Rho effectors may utilize multiple motifs including their GTPase-binding domains 
(GBDs) to form contact points with regions outside the classical switch domains 
(Blumenstein and Ahmadian, 2004), we hypothesize  that BNIPXL may utilize a similar 
strategy to ensure RhoA binding specificity. This is consistent with our current 
observations which suggest that allosteric sites in the BNIPXL BCH domain may act in 
concert with the Rho-binding motif to aid the discrimination of RhoA conformations 
associated with their respective nucleotide binding status. In addition, BNIPXL may 
undergo conformational changes in vivo that relieves restraints masking its RhoA 
recognition motif(s) in the BCH domain. 
 Disruption of autoinhibitory interactions is a common mechanism in Rho effector 
regulation as observed in ROCK (Amano et al., 1997), mDia (Watanabe et al., 1999) and 
Citron (Madaule et al., 1998). More recently, a mechanism involving lipid modification of 
small GTPases has been implicated in the relief of auto-inhibitory, intramolecular 
interactions involving the BCH and GAP domains in p50-RhoGAP (Moskwa et al., 2005). 
Similarly, BPGAP1 has been observed to adopt a similar conformation which regulates the 
functions of both its BCH and GAP domains (Shang and Low, unpublished data). We 
hypothesize that BNIPXL intermolecular interactions may instead play regulatory roles in 
other BNIPXL functions. To examine the functional significance of BNIPXL homo- 
and/or heterophilic complexes, it is necessary to first delineate the dimerization motif(s) 
responsible for these interactions and then examine their effects on BNIPXL-RhoA 
interactions. 
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 Interestingly, our in vivo binding studies indicate that BNIPXL retains preferential 
binding to wild-type RhoA over RhoA(T19N). However, the BNIPXL-RhoA interactions 
are completely abolished with the RhoA(G14V) mutant (Figure 3.27). Although this may 
appear to contradict our previous in vitro results which demonstrate that BNIPXL 
associates with GTP-bound RhoA, these findings indicate the importance of the glycine 
residue in the P-loop motif for mediating nucleotide-dependent BNIPXL-RhoA 
interactions. The in vitro nucleotide-bound forms of RhoA closely resemble the bona fide 
conformations of the small GTPase while the RhoA dominant active and negative mutants 
exert their functions by modulating RhoA interactions with its regulatory factors. These 
mutants have amino acid substitutions in the RhoA P-loop (12)GDGACGKT(19) motif 
which makes contact with a phosphate group of the bound nucleotide and coordinates a 
Mg2+ ion for stabilizing nucleotide binding. It is part of three distinct RhoA segments that 
border the nucleotide-binding site and participate in GTP/GDP discrimination (reviewed in 
Dvorsky and Ahmadian, 2004).  
 In addition, the P-loop region makes contact with the DH and GAP domains of 
RhoGEFs and RhoGAPs, respectively. Its interaction with the GAP domain facilitates 
RhoGAP recognition and discrimination of the RhoA nucleotide binding status while the 
insertion of DH domain residues in close proximity to the P-loop and the Mg2+-binding 
area has been shown to promote nucleotide exchange by disrupting Mg2+-ion coordination 
and favourable interactions for high affinity nucleotide binding (Worthylake et al., 2000; 
Buchwald et al., 2002; Rossman et al., 2002; Snyder et al., 2002). Thus, the substitution of 
glycine to valine at position 14 results in a GAP-insensistive RhoA mutant that abolishes 
its intrinsic and GAP-mediated GTPase activity (Lancaster et al., 1994; Ahmadian et al., 
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1997) and results in the maintenance of a constitutively active state. Conversely, the 
substitution of threonine to asparagine at position 19 results in increased affinity for 
RhoGEFs, corresponding to impaired nucleotide exchange and decreased affinity for GTP 
(Seasholtz et al., 1999). Thus, the dominant negative RhoA(T19N) mutant exerts its effects 
through RhoGEF sequestration and the subsequent inhibition of endogenous RhoA 
activation while the RhoA(G14V) mutant remains constitutively active as a result of 
impaired RhoGAP recognition.  
 In addition, we have also examined BNIPXL interactions with other constitutively 
active RhoA mutants to determine if the lack of binding with RhoA(G14V) is the result of 
the residue substitution or the active conformation of RhoA per se. The RhoA(F30L) and 
RhoA(Q63L) mutants have single amino acid substitutions in the switch I (residues 29-42) 
and switch II (residues 62-68) regions, respectively. While the RhoA(Q63L) is a RhoGAP 
insensitive mutant like RhoA(G14V), the RhoA(F30L) mutant is spontaneously activated 
independent of RhoGEF while retaining GAP-mediated GTPase activity. Interestingly, 
BNIPXL associates with RhoA(F30L) and not with RhoA(Q63L) suggesting that the 
RhoA glycine14 and/or glutamine63 residues may be important for BNIPXL-RhoA 
association (Figure 3.28). Alternatively, the BNIPXL BCH domain may function as a non-
canonical GAP domain as observed with BNIP-2 (Low et al., 2000a).  
Interestingly, these observations on RhoA binding to BNIPXL are analogous to that 
of BNIP-2 which exhibits diminished interaction with Cdc42(G12V) (Low et al., 2000a) 
and is consistent with reports that demonstrate reduced RasGAP binding to the Ras(G12V) 
mutant (Krengel et al., 1990; Al-Mulla et al., 1999). Structurally, the Ras(G12V) mutation 
does not affect the overall Ras conformation but instead reduces the localized flexibility of 
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a polypeptide loop which participates in conformational changes associated with 
nucleotide binding and catalytic activity (Krengel et al., 1990; Tong et al., 1991; Franken 
et al., 1993). Furthermore, structural data from Cdc42(G12V) supports the argument that a 
mutation at position 12 does not alter the conformation of the GTPase structure per se 
(Rudolph et al., 1999). In light of this, the requirement for a glycine14 and/or glutamine63 
for BNIPXL-RhoA association suggest that BNIPXL can discriminate localized RhoA 
conformational changes associated with nucleotide binding at its P-loop and Switch II 
regions in a manner similar to that of RhoGAPs.  
Furthermore, a recent survey of the RhoA structural motifs indicate that the P-loop 
(residues 14-19) and Switch II (residues 62-68) regions may contribute to effector binding 
in addition to GAP and GEF recognition (reviewed in Dvorsky and Ahmadian, 2004). 
Collectively, these biochemical and cellular observations suggest that nucleotide-
dependent BNIPXL-RhoA interactions may either interfere with RhoGEF-mediated 
guanine nucleotide exchange or hinder RhoA-effector recognition at different sites on the 
small GTPase thereby, downregulating RhoA pathways. In line with this hypothesis, in 
vitro Rho activity assays demonstrate that full-length BNIPXL could effectively reduce the 
levels of active wild-type RhoA in vitro whereas BNIPXL deletion mutants had no 
apparent effect. A similar reduction was observed for cells co-expressing BNIPXL and 







4.2.2. BNIPXL-induced cell shape changes require coordinate modulation of Rho  
          GTPase signaling pathways 
Our findings that the PAK-CRIB domain which sequesters endogenous active 
Cdc42 can inhibit BNIPXL-induced cell morphological changes indicate a requirement for 
PAK activation downstream of Cdc42/Rac (Figure 4.1). Rho signaling pathways may exist 
in a hierarchical network, where the activation of one member can lead to the inactivation 
of another (Sander et al., 1999; Zondag et al., 2000). Alternatively, the activation of one 
member may be necessary to activate another (Kozma et al., 1995; Nobes and Hall, 1995). 
Generally, actin cytoskeleton reorganization and cell motility are the result of coordinate 
Rac/Cdc42 and RhoA activities (Boshans et al., 2000; Nobes and Hall, 1999; Noren et al., 
2000). Rac/Cdc42 activation is mainly associated with induction of protrusions and 
lamellipodia consistent with increased migratory potential while RhoA tends to increase 
cell adhesion and cell shape retraction. Although BNIPXL associates only with RhoA, it is 
possible that it may indirectly modulate the Cdc42/Rac signaling pathways, perhaps by 
targeting proteins like BNIP-2 to heterophilic complexes. Thus, BNIPXL may directly 
sequester cellular populations of active RhoA to reduce effector binding and activation 
while facilitating the activation of Cdc42/Rac pathways via its BCH domain to induce cell 
morphological changes. This is in line with findings that several proteins participate in 
novel modes of GTPase regulation. IQGAP1 is an atypical GAP-domain containing 
protein which inhibits the intrinsic Cdc42 GTPase activity (Brill et al., 1996; Hart et al., 
1996; Ho et al., 1999) and positively regulates the Cdc42 pathway by stabilizing cellular 
populations of active Cdc42 to enhance filopodia induction and actin cytoskeleton  
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Figure 4.1. BNIPXL regulates cell shape determination through the Rho GTPase signaling 
pathways. The BNIPXL BCH domain directly facilitates RhoA downregulation resulting 
in membrane protrusions with filopodia induction. These morphological changes are 
enhanced with RhoA(T19N) and inhibited in the presence of RhoA(G14V) and the PAK-
CRIB domain indicating that these cellular effects are likely to involve concomitant 
activation of Cdc42/Rac signaling pathways through an as yet unidentified interacting 
partner. 
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remodeling (Swart-Mataraza et al., 2002). More recently, IQGAP has been linked to 
microtubule dynamics via its recruitment to a complex with APC and CLIP-70 for 
coordinated regulation of the cytoskeleton reorganization during cell polarization and 
movement (Watanabe et al., 2004). In addition, recent work implicates the CDK inhibitor, 
p27kip1 in modulating cell migration through Rac activation (McAllister et al., 2003) or by 
disrupting RhoGEF-mediated RhoA activation independent of its cell cycle functions 
(Besson et al., 2004). Furthermore, p27kip1 has been demonstrated to associate with 
stathmin in regulating microtubule dynamics necessary for cell migration and invasion 
(reviewed in Iancu-Rubin and Atweh, 2005; Baldassarre et al., 2005). 
 
4.3. Implications of BNIPXL-induced cell shape changes and its multi-motif BCH  
       domain 
 Our current study has provided greater insights into the role of BCH domain-
containing proteins in Rho signaling pathways and highlight the plasticity of the BCH 
domain in conferring distinct and novel mechanisms for cell morphogenesis by coupling 
different small GTPases to unique GTPase-binding motifs for actin cytoskeleton 
remodeling and cell shape changes. We demonstrate that BNIPXL functions differently 
from BNIP-2 and BNIP-S in mediating cell shape changes by directly promoting RhoA 
inactivation through its BCH domain. In light of this, BNIPXL might function as a scaffold 
which acts as a point of convergence for different Rho signaling pathways. Currently, there 
are several scaffold proteins that modulate Rho GTPase signaling pathways. For example, 
the class I RhoA effector Rhophilin-2, is a multi-domain protein that binds preferentially to 
GTP-bound RhoA but induces the loss of stress fibers through the concerted activities of 
  200
its resident domains. This indicates that Rhophilin-2 may promote F-actin turnover and 
limit stress fiber formation if RhoA activation intensity is below threshold levels (Peck et 
al., 2002). In contrast, the Small Protein Effector of Cdc42 (SPECs) family proteins can 
sequester Cdc42 via their CRIB domains. This results in the inhibition of Cdc42-induced 
JNK activation and morphological changes indicating that SPECs may compete with 
Cdc42 effectors to promote the downregulation of Cdc42 pathways. In addition, SPECs 
may also modulate Cdc42 signaling by recruitment of additional protein partners to the 
SPEC-Cdc42 complex to direct alterations of normal Cdc42 signaling pathways for 
cytoskeleton reorganization (Pirone et al., 2000). 
 Our most updated analyses indicate that in addition to the C-terminus BCH domain, 
BNIPXL contains a Walker A consensus (GXXXXGK (T/S) motif at its N-terminus 
(334)GPGWSGKT(341). This motif is characteristic of nucleotide binding proteins and is 
involved in positioning the triphosphate moiety of a bound nucleotide (Walker et al., 
1982). The P-loop is known to regulate the biochemical activities of several members of 
the Ras and Rab superfamily (Liang et al., 2000; Li and Liang, 2001; Ding et al., 2003; 
Zhu et al., 2003) and downstream effectors such as B-Raf in a conformation dependent 
manner (Wan et al., 2004). More recently, the P-loop motif has been implicated in 
coupling clathrin-mediated endocytosis with actin cytoskeleton organization (Guilherme et 
al., 2004). The role of this Walker A motif remains to be further investigated. We note that 
the degradation profile of the N-terminus BNIPXL fragments indicate that a region close to 
the P-loop motif may exist in a hinge conformation that makes it structurally labile or 
sensitive toward proteases. Collectively, the unique structural features of BNIPXL 
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contribute to its distinct functions in cell morphogenesis and highlight the emergence of 
the BNIP-2 family as novel regulators of cell dynamics. 
 The use of dominant active and negative mutants has enabled the dissection of 
RhoA function in BNIPXL-induced cell shape changes. Although they represent a useful 
tool in functional characterization of downstream pathways, it is noted that the dominant 
negative mutants sequester upstream GEFs that may interact with multiple members of the 
Rho family thus blocking all endogenous Rho protein activation. Recent studies 
demonstrate that dominant negative Rac and Cdc42 mutants had aberrant effects on 
oncogenic Dbl-induced RhoA activation (Debreceni et al., 2004). In view of this, a 
RhoGEF mutant that retained GTPase binding despite its impaired biochemical activity has 
enabled the specific inhibition of signaling pathways downstream of Rac activation 
(Debreceni et al., 2004). The use of similar RhoA-specific GEF mutants should provide 
greater insights into the specific roles of the small GTPase in regulating diverse cellular 
events. 
 
4.4. Conclusions and future work  
 In summary, we report the identification of a novel member of the BNIP-2 family, 
BNIPXL. BNIPXL is 769 amino-acid residues in length and encoded by a 13-exon gene 
mapped to human chromosome 9q21.2. It encompasses most of the prototypic BNIP-2 
sequence at its distal carboxyl terminus. Interestingly, the BCH domain of BNIPXL 
resembles most closely to that of BNIP-H/Caytaxin, a protein whose loss-of-function is 
responsible for the Cayman ataxia, a form of neurological disorder. More recently, 
increased expression of an extended form of BNIPXL correlates to favorable prognosis in 
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childhood NBLs. BNIPXL undergoes alternative mRNA splicing within the BCH domain 
where removal of exons 11 and 12 introduces a premature stop codon that results in 
deletion of the last 36 amino acid residues for the β-isoform. Both isoforms are 
ubiquitously expressed in most human tissues and cell lines examined, except for the 
HEK293T cells that showed exclusive expression of only the β-isoform. Furthermore, 
mouse BNIPXL is highly expressed in the murine brain and neuronal cell lines. Through 
the BCH domain, BNIPXL associates with itself and other BCH-domain containing 
proteins. However, unlike BNIP-2, the BCH domain of BNIPXL associates specifically 
with RhoA but not Cdc42 or Rac1. It is sufficient to elicit membrane protrusions, 
potentiated only by co-expression of the dominant negative RhoA (T19N) but inhibited by 
co-expression of the PAK-CRIB domain that sequesters endogenous active Cdc42/Rac. 
Removal of the proximal region of the its BCH domain (residues 615-644) which 
resembles the Class I Rho-binding motifs as well as other regions abolished both RhoA 
binding and cell protrusions. This suggests that, unlike BNIP-S, a full composite of the 
BCH domain, probably via a conformation-dependent manner, is required for both RhoA 
binding and cell morphological changes. These results indicate that BNIPXL functions 
differently from BNIP-2 and BNIP-S in mediating cell shape changes by promoting RhoA 
inactivation via its BCH domain. 
 Our observations that BNIPXL can mediate cellular events through the 
coordination of resident motifs come amidst increasing evidence supporting an emerging 
notion that the BCH domain is an important signaling module integrating diverse small 
GTPase pathways into coherent cellular response. To fully understand the molecular 
mechanisms underlying the cellular effects observed with BNIPXL, future work involves 
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the identification of novel BNIPXL interacting partners using an established mass-
spectrometry based proteomics approach. In addition, efforts to delineate the functions of 
the extended N-terminus will provide a better understanding of the roles of BNIPXL in 
modulating RhoA and Cdc42/Rac signaling pathways. Current structural data indicates that 
the RhoGAP domain adopts tertiary folds important for conformation-driven GTP 
hydrolysis. This raises the possibility that BNIPXL and other members of the BNIP-2 
family may represent a novel class of non-canonical GAPs since their BCH domains are 
highly conserved and may adopt structurally similar conformations. Further investigations 
into the catalytic abilities of homologous BCH domains should provide a better 
understanding of the biochemical roles of the BNIP-2 family in Rho signaling.  Future 
investigations will also determine if these BCH domains can modulate lipid signaling 
pathways based on their homology to the Sec14p lipid-binding domain (Zhou et al., 2002; 
Aravind et al., 1999). Recent work demonstrates the importance of the Sec14 homology 
domain in regulating cellular distribution and transforming activity of the Dbl family of 
exchange factors (Ueda et al., 2004; Kostenko et al., 2005) as well as conformation-
dependent p50-RhoGAP activity (Moskwa et al., 2005). This is in line with speculations 
that the Sec14 domain may bind PI-3,4,5-P3 to regulate GAP activity via membrane 
recruitment and/or conformational changes (Krugmann et al., 2002).  
. Our current work has addressed some of the biochemical and cellular aspects of 
BNIPXL functions. Membrane protrusions and cell shape changes are precursors of cell 
movement. Thus, investigating the effects of BNIPXL in in vitro wound healing or cell 
migration assays will help elucidate the physiological roles of BNIPXL in cell dynamics. 
The use of appropriate cell lines stably expressing BNIPXL will greatly facilitate these 
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functional assays. Genetic model systems such as transgenic and knockout mouse 
represent bona fide models to better understand the biological roles of gene function during 
development and in disease progression. For example, ablation of p190-RhoGAP in mice 
has provided insights into the roles of RhoGAPs in Src-mediated adhesion signaling in 
neuronal morphogenesis (Brouns et al., 2000, Brouns et al., 2001) and in cell size 
(Sordella et al., 2002) and cell fate (Sordella et al., 2003) determination downstream of 
insulin signaling during embryonic development. In addition, studies of transgenic mice 
overexpressing Ras and RhoA indicate their involvement in cell growth and cytoskeleton 
remodelling during cardiac myocyte development (Clerk and Sugden, 2000) while 
conditional Raf-1 gene knockouts have facilitated the dissection of its multiple roles in 
regulating cell movement and gene expression (Ehrenreiter et al., 2005). Collectively, 
these reports have provided clearer understanding of the interplay of Ras and Rho 
signaling pathways in vivo. 
 The emergence of RNA-mediated interference (RNAi) technologies has provided 
excellent alternatives to transgenic mouse models for the study of gene function both in 
vitro and in vivo. RNAi mediated knockdown of BNIPXL expression will enable further 
characterization of its roles in cellular events. In addition, the progressive use of RNAi 
technologies in generating transgenic animal models is expected to facilitate tissue specific 
gene inactivation, thus overcoming the requirements for conditional knockouts in mice. 
(reviewed in Ristevsk, 2005). Co-workers have recently delineated the roles of RhoA and 
its effectors in convergence and extension (CE) movements during embryonic 
development in the zebrafish (Zhu et al., 2005). Functional knockdown of RhoA using 
morpholinos provides evidence linking CE movements to RhoA activation downstream of 
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Wnt signalling and independent of Wnt-mediated cell fate determination. The use of this 
established platform will provide a better understanding of the roles of BNIPXL during 
development (Figure 4.2).  
 In this work, we report the identification, isolation, characterization and functional 
analyses of a novel BCH domain-containing protein, BNIPXL. Our findings indicate that 
BNIPXL participates in cell morphogenesis by distinctly targeting RhoA unlike other 
members of the BNIP-2 family. These findings also highlight the plasticity of the BCH 
domain in conferring distinct mechanisms for cell morphogenesis by coupling different 
small GTPases to its unique GTPase-binding motifs, and possibly by targeting their 

























Figure 4.2. Schematic diagram illustrating all possible future work that should provide 
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                     PDTCQPASLNERKGLSAEKMSSKSDTRSSFESPAQDQSWMFLGHSEVGDPSLDARDSG 
                     PGWSGKTVEPFSELGLGEGPQLQILEEMKPLESLALEEASGPVSQSQKSKSRGRAGPD 
                     AVTHDNEWEMLSPQPVQKNMIPDTEMEEETEFLELGTRISRPNGLLSEDVGMDIPFEE 
                     GVLSPSAADMRPEPPNSLDLNDTHPRRIKLTAPNINLSLDQSEGSILSDDNLDSPDEI 
                     DINVDELDTPDEADSFEYTGHEDPTATKDSGQESESIPEYTAEEEREDNRLWRTVVIG 
                     DQEQRIDMKVIEPYRRVISHGGLRGYYGDGLNAIIVFAACFLPDSSRADYHYVMENLF 
                     LYVISTLELMVAEDYMIVYLNGATPRRRMPGLGWMKKCYQMIDRRLRKNLKSFIIVHP 
                     SWFIRTILAVTRPFISSKFSSKIKYVNSLSELSGLIPMDCIHIPESIIKY" 
     misc_feature    1891..2340 
                     /gene="BNIPXL" 
                     /note="Region: sec14p-like lipid-binding domain" 
     misc_feature    1909..2334 
                     /gene="BNIPXL"
 
                     /note="Region: sec14p-like domain" 
     misc_feature    1960..2355 
                     /gene="BNIPXL" 
                     /note="Bnip2 and Cdc42GAP-like domain; Region: truncated 
                     BCH domain" 
ORIGIN       
        1 gctttgtttg atggtgatcc acatttatcc acagagaatc ctgccttggt tcctgatgct 
       61 ttgctagcct cagacacttg tctggatata agcgaagctg cctttgacca cagtttcagc 
      121 gatgcctcag gtctcaacac atccacggga acaatagatg acatgagtaa actgacatta 
      181 tccgaaggcc atccggaaac gccagttgat ggggacctag ggaagcaaga tatctgctca 
      241 tctgaagcct cgtggggtga ttttgaatat gatgtaatgg gccagaatat cgatgaagat 
      301 ttactgagag agcctgaaca cttcctgtat ggtggtgacc ctcctttgga ggaagattct 
      361 ctgaagcagt cgctggcacc gtacacacct ccctttgatt tgtcttatat cacagaacct 
      421 gcccagagtg ctgaaacaat agaggaagct gggtctccag aggatgaatc tctgggatgc 
      481 agagcagcag agatagtgct ttctgcactt cctgatcgaa gaagtgaggg aaaccaggct 
      541 gagaccaaaa acagactgcc tggatcccag ctggctgtgc tgcatattcg tgaagaccct 
      601 gagtccgttt atttgccggt aggagcaggc tccaacattt tgtctccatc aaacgttgac 
      661 tgggaagtag aaacagataa ttctgattta ccagcaggtg gagacatagg accaccaaat 
      721 ggtgccagca aggaaatatc agaattggaa gaagaaaaaa caattcctac caaagagcct 
      781 gagcagataa aatcagaata caaggaagaa agatgtacag agaagaatga agatcgtcat 
      841 gcactacaca tggattacat acttgtaaac cgtgaagaaa attcacactc aaagccagag 
      901 acctgtgaag aaagagaaag catagctgaa ttagaattgt atgtaggttc caaagaaaca 
      961 gggctgcagg gaactcagtt agcaagcttc ccagacacat gtcagccagc ctccttaaat 
     1021 gaaagaaaag gtctctctgc agagaaaatg tcttctaaaa gcgatacgag atcatctttt 
     1081 gaaagccctg cacaagacca gagttggatg ttcttgggcc atagtgaggt tggtgatcca 
     1141 tcactggatg ccagggactc agggcctggg tggtccggca agactgtgga gccgttctct 
     1201 gaactcggct tgggtgaggg tccccagctg cagattctgg aagaaatgaa gcctctagaa 
     1261 tctttagcac tagaggaagc ctctggtcca gtcagccaat cacagaagag taagagccga 
     1321 ggcagggctg gcccggatgc agttacccat gacaatgaat gggaaatgct ttcaccacag 
     1381 cctgttcaga aaaacatgat ccctgacacg gaaatggagg aggagacaga gttccttgag 
     1441 ctcggaacca ggatatcaag accaaatgga ctactgtcag aggatgtagg aatggacatc 
     1501 ccctttgaag agggcgtgct gagtcccagt gctgcagaca tgaggcctga acctcctaat 
     1561 tctctggatc ttaatgacac tcatcctcgg agaatcaagc tcacagcccc aaatatcaat 
     1621 ctttctctgg accaaagtga aggatctatt ctctctgatg ataacttgga cagcccagat 
     1681 gaaattgaca tcaatgtgga tgaacttgat acccccgatg aagcagattc ttttgagtac 
     1741 actggccatg aagatcccac agccaccaaa gattctggcc aagagtcaga gtctattcca 
     1801 gaatatacgg ccgaagagga acgggaggac aaccggcttt ggaggacagt ggtcattgga 
     1861 gaccaagagc agcgcattga catgaaggtc atcgagccct acaggagagt catttctcac 
     1921 ggaggactta gaggatacta tggggacggt ctaaatgcca tcattgtgtt tgccgcctgt 
     1981 tttctgccag acagcagtcg ggcggattac cactatgtca tggaaaatct tttcctatat 
     2041 gtaataagta ctttagagtt gatggtagct gaagactata tgattgtgta cttgaatggt 
     2101 gcaaccccaa gaaggaggat gccagggcta ggctggatga agaaatgcta ccagatgatt 
     2161 gacagacggt tgaggaagaa tttgaaatca ttcatcattg ttcatccatc ttggttcatc 
     2221 agaacaatcc ttgctgtgac acgacctttt ataagttcaa aattcagcag taaaattaaa 
     2281 tatgtcaata gcttatcaga actcagtggg ctgatcccaa tggattgcat ccacattcca 
     2341 gagagcatca tcaaatattg acttgaagct gaaagaaaag ccttagttgg ccatgctgga 













Appendix II: Primer pairs used in semi-quantitative RT PCR 
 
 Oligonucleotide sequence 
Forward: 5’-CCG CTC GAG ATG AGT AAA CTG ACA TTA TCC G-3’  
*Human BNIPXL 
(full length) Reverse: 5’-ATA AGA ATG CGG CCG CCT TCT TCC AGC ATG GCC    
AAC TAA GGC-3’ 
Forward: 5’-CCG CTC GAG ATC ATT GTG TTT GCC GCC TG-3’ *Human BNIPXL 
(BCH domain) 
Reverse: 5’-ATA AGA ATG CGG CCG CTC ATT TAG CTG CCT CTG 
ATG CTT CCC TCA G-3’ 
Forward: 5’-ATG AGT AAG CTG ACT CTA TCG-3’ Mouse BNIPXL 
(full length) 
Reverse: 5’-CCT CCT CCA GCA GGC CAG CTA CGG CTT-3’ 
Forward: 5’-ATG AGT AAG TTG ACT CTA TCG-3’ Rat BNIPXL 
(full length) 
Reverse: 5'-TCC TCC CGC AGG CCA TTA GGG CTT-3' 
 
*Human BNIPXL primers have XhoI (forward) and NotI (reverse) restriction sites 
incorporated at the respective 5’ ends. 
 
